Human Cytochrome P450 Enzymes in Drug Metabolism and Chemical Activation by Bart, Aaron




Aaron G. Bart 
A dissertation submitted in partial fulfillment 
 of the requirements for the degree of  
Doctor of Philosophy 
(Biophysics) 




Professor Emily E. Scott, Chair  
Professor Richard J. Auchus  
Assistant Professor Aaron T. Frank  



































I would like to thank everyone that has supported me throughout my graduate career.  I am 
grateful to Dr. Fernando Estrada, Dr. Klaus Pors, Dr. Aggi Walsh, Dr. Ryan Takahashi, Dr. 
Xiaojing Wang, Dr. Elizabeth Gillam, Dr. Kurt Harris, Sarah Burris, Cara Loomis, and Nicholas 
Martinez for direct contributions in at least one of the projects described in this dissertation.  
Additionally, I would like to thank the many Scott Lab members for their various support through 
the years: Dr. Simone Brixius-Anderko, Dr. Elyse Petrunak, Dr. Natasha DeVore, Dr. Linda Blake, 
Dr. Malika Godamudunage, Dr. Rahul Yadav, Dr. Kathy Meneely, and many others. 
I am also very grateful to Dr. Richard Auchus, Dr. Sarah Keane, and Dr. Aaron Frank for 
serving as committee members throughout my career as a graduate student at the University of 
Michigan.  I would also specifically like to thank Dr. Victor Day, whom I first met as an 
undergraduate student.  Victor taught me some of the fundamentals of crystallography and has 
continued to support me through the years as a graduate student.  Additional thanks to Dr. Audrey 
Lamb, Dr. Mario Rivera, Dr. Roberto De Guzman, Dr. Yoshiaki Azuma, and Dr. Susan Egan for 
being on my committee when I started graduate school at the University of Kansas. 
Most importantly, I am extremely grateful to my advisor Dr. Emily Scott who was willing 
to first take me into her lab as a biochemistry undergraduate student with little to no lab experience.  
I cannot thank her enough for her trust, mentorship, and support through the ups and downs.  Dr. 
Scott has been on my side throughout the years and I feel so fortunate in being in her lab, she is 
quite possibly the best mentor any student could ask for. 
 iii 
The work in this dissertation was funded by NIH Grant F37 GM076343 and in part by an 
NIH Graduate Training Program in the Dynamic Aspects of Chemical Biology at the University 
of Kansas (T32 GM008545).  Additional funding was provided by the Rackham Graduate School 
as a pre-doctoral fellowship.  Data for the many crystal structures described in this dissertation 
were collected at both the Stanford Synchrotron Radiation Lightsource and Advanced Photon 
Source.  I would like to thank the members of the University of Michigan Center for Structural 
Biology for lab space and instrumentation for crystallization.  I am also appreciative for the support 
from UM Biophysics, especially to Sara Grosky, who has continuously helped answer questions 
and made everything work logistically during my transition from KU to UM and through my UM 
graduate career. 
I own gratitude to the American Society for Pharmacology and Experimental Therapeutics 
(ASPET) for providing funding to attend Experimental Biology meetings throughout my graduate 
career, and for giving me the opportunity to serve as a member on the Drug Metabolism and 
Disposition Executive Committee.  I also want to extend my thanks to Genentech, for both inviting 
me to talk at the graduate student symposium in DMPK, and in providing the opportunity to 
explore industry through a summer internship, in particular thank you Dr. Ryan Takahashi and Dr. 
Cameron Noland!  Additionally, I would like to thank various individuals at OSU for access to 
NMR instrumentation (CCIC) and lab space (Coss Lab) to prep my samples these include: Dr. 
Alex Hanson, Dr. Rafael Brüschweiler, Dr. Christopher Coss, and Anees Dauki. 
Finally, I would like to thank all my friends and family for their support and encouragement 
throughout my graduate education.  In particular I want to thank my fiancé Elyse, whose love and 








TABLE OF CONTENTS 
 
Acknowledgements .................................................................................................................. ii 
List of Tables ......................................................................................................................... viii 
List of Figures .......................................................................................................................... ix 
Abstract ...................................................................................................................................xii 
CHAPTER 1 Introduction ........................................................................................................ 1 
1.1 Cytochrome P450 Spectroscopic Features ...................................................................................... 2 
1.2 Cytochrome P450 Catalytic Cycle .................................................................................................. 5 
1.3 Structure of Cytochrome P450 ....................................................................................................... 7 
1.4 Interactions of P450 with P450 Reductase and Cytochrome b5 ........................................................ 9 
1.5 P450 Modulation by Cytochrome b5 : Proposed Mechanisms ....................................................... 12 
1.6 Cytochrome P450 Enzymes Involved in Pro-carcinogenic and Toxin Activation .......................... 13 
1.7 CYP1A1 Role in Metabolic Activation of Tyrosine Kinase Inhibitors........................................... 16 
1.8 P450 Prodrug Strategy for Engineered Duocarmycins in Cancer Therapy ..................................... 18 
1.9 Ancestral Reconstructed P450 Enzymes with Higher Thermostabilities for Industrial Applications
 .......................................................................................................................................................... 20 
1.10 Conclusions ............................................................................................................................... 21 
1.11 References ................................................................................................................................. 23 
CHAPTER 2 Structural and Functional Effects of Cytochrome b5 Interactions with Human 
Cytochrome P450 Enzymes .................................................................................................... 29 
2.1 Summary ..................................................................................................................................... 29 
2.2 Introduction ................................................................................................................................. 29 
2.3 Experimental Procedures .............................................................................................................. 33 
2.3.1 Generation of the soluble domain of human cytochrome b5 with 15N-labeling for NMR 
experiments ................................................................................................................................... 33 
2.3.2 Generation of full length human cytochrome b5 for catalytic assays ................................... 35 
2.3.3 Generation of full length human NADPH-cytochrome P450 reductase for catalytic assays 36 
2.3.4 Generation of P450 enzymes for NMR and catalytic assays............................................... 36 
2.3.5 Mutagenesis...................................................................................................................... 37 
2.3.6 NMR Spectroscopy ........................................................................................................... 37 
 v 
2.3.7 Cytochrome P450 catalytic assays ..................................................................................... 38 
2.3.8 Measurement of NADPH Consumption ............................................................................ 39 
2.4 Results/Discussion ....................................................................................................................... 40 
2.4.1 Rationale for experimental scope ...................................................................................... 40 
2.4.2 Interactions and catalytic effects of b5 on CYP2A6 ........................................................... 43 
2.4.3 Interaction and catalytic effects of b5 on CYP2E1 ............................................................. 48 
2.4.4 Interaction and catalytic effects of b5 on CYP3A4 ............................................................. 51 
2.4.5 Interaction and catalytic effects of b5 on CYP2D6 ............................................................. 55 
2.4.6 Interactions and catalytic effects of b5 on CYP2A6 saturated with p-nitrophenol................ 59 
2.4.7 Comparison of P450/b5 interactions across P450 enzymes and substrates .......................... 63 
2.5 Conclusions ................................................................................................................................. 64 
2.6 References ................................................................................................................................... 65 
CHAPTER 3 Structures of Human Cytochrome P450 1A1 with Bergamottin and Erlotinib 
Reveal Active-Site Modifications for Binding of Diverse Ligands ........................................ 68 
3.1 Summary ..................................................................................................................................... 68 
3.2 Introduction ................................................................................................................................. 69 
3.3 Experimental Procedures .............................................................................................................. 70 
3.3.1 Protein Expression and Purification .................................................................................. 70 
3.3.2 CYP1A1 Inhibition Assays ............................................................................................... 73 
3.3.3 Ligand Binding Assays ..................................................................................................... 74 
3.3.4 Co-Crystallization, Data Collection, Structure Determination ............................................ 74 
3.4 Results and Discussion ................................................................................................................. 77 
3.4.1 Inhibition of CYP1A1 by Structurally Diverse Ligands ..................................................... 77 
3.4.2 Characterization of Bergamottin and Erlotinib Binding to CYP1A1 .................................. 82 
3.4.3 Overall CYP1A1 X-Ray Structures ................................................................................... 83 
3.4.4 Bergamottin Binding to CYP1A1 ...................................................................................... 85 
3.4.5 CYP1A1 Bergamottin Metabolism .................................................................................... 87 
3.4.6 Erlotinib Binding to CYP1A1 ........................................................................................... 88 
3.4.7 Comparison of all Three CYP1A1 Structures Yields Insights into Residues Involved in 
Accommodating Diverse Ligand Structures.................................................................................... 91 
3.5 Conclusions ................................................................................................................................. 93 
3.6 References ................................................................................................................................... 95 
CHAPTER 4 Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar 
Substrate ................................................................................................................................. 99 
4.1 Summary ..................................................................................................................................... 99 
 vi 
4.2 Introduction ................................................................................................................................. 99 
4.3 Experimental Procedures ............................................................................................................ 102 
4.3.1 Materials ........................................................................................................................ 102 
4.3.2 Protein Expression and Purification ................................................................................ 102 
4.3.3 Ligand Binding Assays ................................................................................................... 103 
4.3.4 Crystallization, Data Collection, and Structure Determination ......................................... 103 
4.4 Results ....................................................................................................................................... 106 
4.4.1 Binding of GDC-0339 and analogs to CYP1A1............................................................... 106 
4.4.2 CYP1A1 Structure with GDC-0339 ................................................................................ 109 
4.5 Discussion ................................................................................................................................. 111 
4.5.1 Binding of GDC-0339 and analogs to CYP1A1............................................................... 112 
4.5.2 CYP1A1 Structure with GDC-0339 ................................................................................ 113 
4.6 Conclusions ............................................................................................................................... 116 
4.7 References ................................................................................................................................. 118 
CHAPTER 5 Metabolism and Structural Interactions of Pro-Duocarmycins with 
Cytochrome P450 Enzymes 1A1 and 2W1 ........................................................................... 120 
5.1 Introduction ............................................................................................................................... 120 
5.2 Experimental Procedures ............................................................................................................ 124 
5.2.1 Isolation of Pro-duocarmycin Stereoisomers ................................................................... 124 
5.2.2 Protein Expression and Purification ................................................................................ 124 
5.2.3 Ligand Binding Assays ................................................................................................... 126 
5.2.4 Crystallization, Data Collection, and Structure Determination ......................................... 126 
5.3 Results and Discussion ............................................................................................................... 129 
5.3.1 Seco-Duocarmycin Binding Modes and Affinities for Human CYP1A1 and CYP2W1 .... 129 
5.3.2 Co-Crystal Structures of CYP1A1 with (S)-ICT2700 and (S)-ICT2726 ........................... 133 
5.3.3 Comparisons and Applications of CYP1A1/CYP2W1 Interactions with Seco-
duocarmycins…. .......................................................................................................................... 137 
5.4 References ................................................................................................................................. 140 
CHAPTER 6 Structure of an Ancestral Mammalian Family 1B1 Cytochrome P450 with 
Increased Thermostability .................................................................................................... 143 
6.1 Summary ................................................................................................................................... 143 
6.2 Introduction ............................................................................................................................... 144 
6.3 Experimental Procedures ............................................................................................................ 146 
6.3.1 Materials ........................................................................................................................ 146 
6.3.2 Preparation of Bacterial Membranes for Activity Assays ................................................. 147 
 vii 
6.3.3 Metabolic Assays ............................................................................................................ 147 
6.3.4 Protein Expression and Purification for Ligand Binding Assays and Crystallization ........ 149 
6.3.5 Ligand Binding Assays ................................................................................................... 150 
6.3.6 Crystallization, Data Collection, Structure Determination, and Analysis .......................... 151 
6.4 Results and Discussion ............................................................................................................... 155 
6.4.1 Comparison of Overall Structures:  Ancestral CYP1B1 vs. Extant Human CYP1B1 ........ 155 
6.4.2 Ancestral CYP1B1 Structure with a-Naphthoflavone...................................................... 157 
6.4.3 Ancestral CYP1B1 Titrations with a-Naphthoflavone ..................................................... 162 
6.4.4 Ancestral CYP1B1 Metabolism of a-Naphthoflavone ..................................................... 163 
6.4.5 Ancestral CYP1B1 Structure with 17b-Estradiol ............................................................. 164 
6.4.6 Ancestral CYP1B1 Titrations with 17β-Estradiol ............................................................ 165 
6.4.7 Ancestral CYP1B1 Metabolism of 17β-Estradiol ............................................................ 166 
6.4.8 Structural Changes to the Redox Partner Binding Surface ............................................... 167 
6.4.9 Structural Elements and Interactions Proposed to Confer Thermostability ....................... 168 
6.5 Conclusions ............................................................................................................................... 173 
CHAPTER 7 Conclusions and Future Directions................................................................ 185 
7.1 References ................................................................................................................................. 193 
 viii 
List of Tables 
Table 1.1  Major substrate classes for human cytochrome P450 enzymes ................................... 2 
Table 3.1  Data collection and refinement statistics for CYP1A1 crystal structures with 
bergamottin and erlotinib. ......................................................................................................... 76 
Table 3.2  Inhibition of CYP1A1 given as IC50 ± standard error. .............................................. 81 
Table 4.1  Data collection and refinement statistics for CYP1A1 crystal structure with GDC-0339
 ............................................................................................................................................... 105 
Table 5.1  Data collection and refinement statistics for CYP1A1 crystal structures with seco-
duocarmycin analogs............................................................................................................... 128 
Table 6.1  Data collection and refinement statistics for ancestral CYP1B1 with α-naphthoflavone 
and 17β-estradiol..................................................................................................................... 153 
Table 6.2  Comparison of salt bridge interactions in extant human CYP1B1 vs. the ancestral 
CYP1B1 enzyme..................................................................................................................... 175 
Table 6.3  Comparison of aromatic and pi-cation stacking interactions in extant human CYP1B1 
vs. the ancestral CYP1B1 enzyme. .......................................................................................... 176 
Table 6.4  MRM transitions used for quantification of a-naphthoflavone, metabolites and internal 
standard. ................................................................................................................................. 177 
 ix 
List of Figures 
Figure 1.1  Ligand-induced spectral alterations in P450 enzymes.. ............................................. 4 
Figure 1.2  P450 CO-difference spectrum. .................................................................................. 5 
Figure 1.3  General cytochrome P450 catalytic cycle.................................................................. 6 
Figure 1.4  Global structure of a human cytochrome P450 enzyme located in the ER. ................ 8 
Figure 1.5  The eukaryotic, ER-bound cytochrome P450 protein system. ................................. 11 
Figure 1.6  Contribution of human P450 isoforms in the activation of known carcinogens........ 14 
Figure 1.7  Bioactivation of a primary environmental pollutant, benzo[a]pyrene (B[a]P). ......... 16 
Figure 1.8  General scaffold and previous modifications on designed seco-duocarmycin prodrugs.
 ................................................................................................................................................. 20 
Figure 2.1  General structures of b5 and P450 enzymes and overview of their interaction as 
monitored by NMR. .................................................................................................................. 31 
Figure 2.2  Interaction of CYP2A6(coumarin) with 15N-b5 by NMR and b5 modulation of CYP2A6 
catalysis .................................................................................................................................... 44 
Figure 2.3  Interaction of CYP2E1(chlorzoxazone) with 15N-b5 by NMR and b5 modulation of 
CYP2E1 catalysis ..................................................................................................................... 49 
Figure 2.4  Interaction of CYP3A4(nifedipine) with 15N-b5 as determined by NMR and catalytic 
modulation of b5 on CYP3A4 mediated metabolism of nifedipine. ............................................ 53 
Figure 2.5  Interaction of CYP2D6(dextromethorphan) with 15N-b5 as determined by NMR and 
catalytic modulation of b5 on CYP2D6 mediated metabolism of dextromethorphan .................. 57 
 x 
Figure 2.6  Interaction of CYP2A6(pNP) with 15N-b5 as determined by NMR and catalytic 
modulation of b5 on CYP2A6 mediated metabolism of para-nitrophenol. ................................. 60 
Figure 3.1  Representative IC50 Curves for CYP1A1 inhibition.. .............................................. 78 
Figure 3.2  Bergamottin and erlotinib binding to CYP1A1. ...................................................... 83 
Figure 3.3 CYP1A1 structures bound to bergamottin, erlotinib, and previously determined 𝛼-
napthoflavone, all superimposed by Ca atoms. ......................................................................... 85 
Figure 3.4  CYP1A1 active site interactions with bergamottin and erlotinib.............................. 86 
Figure 3.5  Bergamottin metabolism by CYP1A1 ..................................................................... 88 
Figure 3.6  Active site cavities for CYP1A1 structures with 𝛼-napthoflavone, bergamottin, and 
erlotinib. ................................................................................................................................... 91 
Figure 3.7  CYP1A1 structures with erlotinib, bergamottin, and ANF overlaid ......................... 93 
Figure 4.1  Pim kinase inhibitor GDC-0339, its metabolite G-1025, and analogs. ................... 102 
Figure 4.2  CYP1A1 spectral binding assays with GDC-0339, G-0546, and G-0194 result in 
atypical binding response. ....................................................................................................... 107 
Figure 4.3  CYP1A1 active site with GDC-0339 bound. ......................................................... 110 
Figure 4.4  Comparison of active-site cavities for CYP1A1 structures with a-naphthoflavone, 
erlotinib, and GDC-0339.. ....................................................................................................... 114 
Figure 4.5  Comparison of the GDC-0339 conformation when bound to CYP1A1.................. 116 
Figure 5.1  Duocarmycin analogs ICT2700 and ICT2726 ....................................................... 122 
Figure 5.2  Spectral binding experiments of CYP1A1 and CYP2W1 with the seco-duocarmycin 
enantiomers of ICT2726.......................................................................................................... 130 
Figure 5.3  Spectral binding experiments of CYP1A1 and CYP2W1 with the seco-duocarmycin 
enantiomers of ICT2700.......................................................................................................... 132 
 xi 
Figure 5.4  Co-crystallization structures of CYP1A1 bound to (S)-ICT2726 and (S)-ICT2700..
 ............................................................................................................................................... 135 
Figure 6.1  Comparisons of the mammalian ancestral and human CYP1B1 cytochrome P450 
enzymes. ................................................................................................................................. 156 
Figure 6.2  Comparison of mammalian ancestral and human CYP1B1/ligand interactions and 
spectral binding of ancestral CYP1B1 with crystallized ligands. ............................................. 158 
Figure 6.3  Comparison of ancestral CYP1B1 and extant human CYP1B1 enzymes highlighting 
structural differences in helices F through G, the β4 loop, and helix I. ..................................... 161 
Figure 6.4  Metabolism of a-naphthoflavone by ancestral and extant CYP1B1 forms. ............ 163 
Figure 6.5  Comparison of the proximal surface of extant human CYP1B1 and ancestral CYP1B1..
 ............................................................................................................................................... 168 
Figure 6.6  Analysis of unique salt bridges and aromatic interactions in human CYP1B1 and the 
ancestral CYP1B1 structures, both co-crystallized with a-naphthoflavone. ............................. 172 
Figure 6.7  Mass fragmentation of a-naphthoflavone metabolites. .......................................... 178 
Figure 6.8  The known metabolic pathways of a-naphthoflavone (ANF) catalyzed by liver 
microsomes and recombinant CYP1A forms.. ......................................................................... 179 




The cytochrome P450 superfamily are heme-containing monooxygenases found 
ubiquitously in living organisms.  In humans, P450 enzymes are essential in the metabolism of 
drugs, pollutants, and foods, as well as in endogenous biosynthetic pathways for steroids, fatty 
acids, and vitamins.  Thus, these enzymes can be sources of deleterious effects in humans, with 
issues relating to drug safety and efficacy, metabolism of compounds into carcinogens or toxins, 
and disruptions of signaling pathways.  Prediction of P450 metabolism and design of selective 
P450 inhibitors are of great importance for human health.  Furthermore, leveraging the diversity 
in P450 catalysis holds promise as biocatalysts for production of synthetically difficult chemicals 
and green chemistry.  In both health and as biocatalysts, limited understanding of P450 structure 
and conformational flexibility hinders the rational pursuit of these goals.  Understanding P450 
structure and flexibility is complicated by the diverse compounds P450 enzymes bind and 
metabolize, and by structural changes that may occur when P450 enzymes interact with 
modulatory protein partners.  This dissertation explores structural features allowing human P450 
enzymes to interact with a protein partner, bind and metabolize diverse substrates, and structural 
interactions which contribute to a thermostable P450 biocatalyst. 
To understand how the catalytic modulator protein cytochrome b5 exerts variable effects 
on P450 catalysis, b5 complexes with different human drug-metabolizing P450 enzymes were 
characterized using NMR.  These experiments revealed that P450 enzymes bind shared and distinct 
surfaces on b5 and have varied complex affinity.  Mutating key residues on b5 confirmed the 
importance of individual b5 amino acids and functional experiments helped link complex 
 xiii 
formation to b5 modulation of P450 function.  The aspect of P450 flexibility in response to diverse 
ligands they interact with was probed through X-ray structures of the human P450 1A1, which has 
prominent roles in carcinogen and toxin activation.  This work demonstrated that CYP1A1 
undergoes conformational changes in the active site roof when bound to structurally diverse 
ligands, and also revealed channels allowing CYP1A1 to bind larger and nonplanar ligands.  
Increased understanding of CYP1A1 structural conformations provides a valuable resource for 
computational prediction of the binding, metabolism, and activation of drugs and chemicals.  For 
utilization of mammalian P450 enzymes as efficient biocatalysts, obstacles such as poor 
thermostability and activity need to be resolved.  The discovery that reconstructed ancestors of 
mammalian P450 enzymes have significantly improved thermostability provides a promising route 
for using these enzymes as biocatalysts, but structural contributors to this enhanced thermostability 
are unknown.  Both structure and ligand binding of the mammalian ancestor of human CYP1B1 
were characterized to examine sources for increased thermostability.  The structures of the ancestor 
CYP1B1 display an open active site conformation deviating significantly in the roof elements in 
comparison to the closed structure of human CYP1B1.  Substrate binding and activity reveal 
similar substrate profiles but altered regioselectivity for the metabolites.  Comparison of the 
ancestral and human CYP1B1 structure suggest that gains in thermostability may occur through 
increased electrostatic and aromatic/cation stacking interactions between distinct secondary 
structure elements.  The combined results of this dissertation provide valuable insight into P450 
structure and conformational flexibility for improvements in drug design, predictions of metabolic 







Cytochrome P450 enzymes are a superfamily of monooxygenases found in the majority of 
living organisms.  P450 enzymes have evolved to accept a wide range of substrates.  In humans 
57 different cytochromes P450 provide many critical functions that range from generation of 
endogenous biomolecules such as hormones and fatty acids to roles in xenobiotic metabolism 
encompassing dietary, environmental, and pharmaceutical chemicals.  A large repertoire of P450 
transformations includes chemically difficult oxidation reactions.  These reactions are enabled by 
activating molecular oxygen using a heme prosthetic group.  There is considerable pharmaceutical 
interest in these enzymes because human P450 enzymes metabolize approximately 75% of the 
most commonly prescribed drugs (1).  This large P450 contribution to drug metabolism can result 
in issues related to altered drug bioavailability and adverse drug-drug interactions.  Moreover, 
from a toxicology perspective, P450 enzymes bioactivate toxins and chemical carcinogens that can 
be found in drugs, environmental pollutants, and dietary sources. 
The wide variety of substrates catalyzed by cytochromes P450 occur through a number of 
different enzyme isoforms, with one example of a human isoform being CYP3A4.  As a 
superfamily, P450 enzymes are arranged into families and subfamilies, classified by amino acid 
sequence identity.  Families share approximately 40% or greater percent identity and are 
represented with an Arabic number, the “3” in the preceding example.  P450 families are 
subdivided into subfamilies (55% amino acid identity), which are represented by capital letters, 
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such as “A” in CYP3A4.  Finally, the terminal Arabic number specifies individual isoforms within 
a subfamily.  In humans the 57 P450 enzymes fall into 18 families and 41 subfamilies, which 
typically share a major substrate type (Table 1.1).  The majority of human P450 enzymes are in 
the xenobiotic and steroid substrate classes and for the most part human P450 families 1-3 are 
considered to be the major contributors towards drug metabolism.  A significant number of P450 
enzymes are also considered “orphans”, in which their primary substrate class has not been 
established (2).  In this thesis, human P450 enzymes from the xenobiotic substrate class are the 
focus. 
 
Table 1.1  Major substrate classes for human cytochrome P450 enzymes. 
 
1.1 Cytochrome P450 Spectroscopic Features 
Central to cytochrome P450 catalysis is the iron-containing heme prosthetic group, which 
activates molecular oxygen.  The heme group is buried within the protein environment, with the 
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iron proximally coordinated to an absolutely conserved cysteine.  Unique spectral signals in the 
UV-visible range result from the P450 heme, and are sensitive to the chemical environment and 
redox state of the iron.  The most intense of these absorbance signals is the Soret band.  When the 
heme is in a resting state with distal water coordination, the Soret absorbance is ~418 nm (3).  Both 
substrates and inhibitors of P450 enzymes can perturb the spin-state of the heme iron.  Such an 
event typically results in at least three spectral modes, which are commonly viewed as optical 
difference spectra between the ligand-free and ligand-bound spectra (Figure 1.1).  Difference 
spectrum resulting in migration of the Soret to shorter wavelengths (blue-shift) with a maximum 
at ~393 nm and minima at ~420 nm are termed “Type I” (shown as a blue trace in Figure 1.1).  
This “Type I” mode has been commonly characterized as a ligand displacing the distal water, but 
not itself coordinating to the heme iron, causing the iron to be in a penta-coordinate, high-spin 
state (4).  Ligands that cause the Soret to shift to a longer wavelength (red shift) with a maximum 
at ~424 nm, and minimum at ~390 nm in the difference spectra are referred to as “Type II” (red 
trace in Figure 1.1).  The “Type II” mode, observed often with nitrogen-containing heterocycles, 
is generally accepted to represent distal coordination to the iron by the ligand, resulting in a hexa-
coordinate, low-spin state (4).  A third mode, known as “Reverse Type I”, is also observed, and is 
characterized by a difference spectrum with a maximum at 415-420 nm and minimum at ~393 nm 
(green trace Figure 1.1).  This “Reverse Type I” mode is not well characterized but it is thought to 
be through coordination of the heme iron by a non-nitrogen heteroatom, or through a water-bridged 
ligand-to-iron interaction (5).  These spectral characteristics are a useful way to determine how a 
ligand is oriented in the P450 active site.  Additionally, observing these progressive spectral 
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changes as a function of ligand concentration is a convenient way to determine the dissociation 
constant (Kd). 
 
Figure 1.1  Ligand-induced spectral alterations in P450 enzymes.  Ligands can perturb the heme iron coordination state resulting 
in unique changes to the UV-Vis spectral signal.  Ligands (denoted as R) can displace a water typically coordinated to the heme in 
the resting state to cause one of three main difference spectra (type I: blue, type II: red, reverse type I: green). 
In addition to the liganded state, the Soret band also provides a useful measurement of 
P450 concentration, purity, and stability.  The concentration of the enzyme can be assessed using 
the Soret absorbance, extinction coefficient, and Beer’s law.  The relative purity can be measured 
by the ratio of Soret to ~280 nm absorbance.  Additionally, both concentration and stability 
assessments can be performed using a reduced-carbon monoxide difference spectrum, in which 
the heme iron is chemically reduced from the ferric (Fe3+) to ferrous (Fe2+) state in the presence of 
carbon monoxide (6).  Under these conditions the Soret absorbance red-shifts to ~450 nm due to 
carbon monoxide ligation (Figure 1.2).  Generally, the presence of an absorbance peak at 450 nm 
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in this difference spectrum is consistent with active P450 enzyme and can be quantitated using an 
extinction coefficient.  Alternatively, the reduced CO-difference spectrum can also produce an 
absorbance peak with a wavelength of 420 nm, which indicates a disruption of the heme-thiolate 
interaction and has been considered to be an inactive form of these enzymes (7). 
 
Figure 1.2  P450 CO-difference spectrum.  Spectral changes of a P450 enzyme when reduced and bound to carbon monoxide 
gives characteristic Soret absorbance at ~450 nm for which the enzyme superfamily is named. 
1.2 Cytochrome P450 Catalytic Cycle  
P450 catalysis is represented in a cyclical reaction mechanism, involving multiple steps 
(Figure 1.3).  In general, the initial or resting state of the cycle is water coordination to the heme 
iron, serving as a distal ligand (a).  The next step is typically substrate (R-H) binding in close 
proximity to the heme iron, displacing the distally coordinated water (b).  Substrate binding 
induces an increase in redox potential, which makes the heme iron a more favorable electron 
acceptor.  For the endoplasmic reticulum (ER)-bound P450 enzymes discussed in this dissertation 
thesis the flavin-containing protein cytochrome P450 reductase (CPR) transfers one electron from 
NADPH to the P450, transitioning the heme iron from a ferric to ferrous state (b to c).  Molecular 
oxygen then rapidly binds to the ferrous iron (c to d).  In continuation of the cycle, a second electron 
 6 
can be delivered by CPR or in some cases a heme-containing protein termed cytochrome b5 (d to 
e), to generate a peroxo-ferric species (e).  Subsequently two protonation events occur, first 
forming a hydroperoxo intermediate (f), and then an oxyferryl complex (g) after oxygen cleavage.  
This oxyferryl iron state, termed “compound I”, is thought to be the main oxidizing species for 
P450 enzymes, first abstracting a hydrogen from the substrate and then rebounding to form the 
product metabolite (represented as R-OH, step h).  The resulting metabolite is released by the P450 
and water again coordinates to the heme iron (h to a) to regenerate the initial state (a). 
 
Figure 1.3  General cytochrome P450 catalytic cycle.  Main productive pathway steps are shown on the grey circle (labeled steps 
a-h).  Nonproductive shunt pathways are indicated with dashed lines (pathways I-III).  P450 substrate is denoted as RH, and 
metabolized product as R-OH.  Figure adapted from Denisov et al. (8). 
In addition to productive completion of the catalytic cycle as illustrated above, P450 
enzymes also have three nonproductive pathways or shunts.  These shunts ultimately regenerate 
the ferric P450, but depending on which part of the catalytic cycle they occur produce either 
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superoxide (I), hydrogen peroxide (II), or extra water (III) (Figure 1.3).  The efficiency with which 
a P450 enzyme uses NADPH reducing equivalents for product formation versus shunting 
pathways is the coupling efficiency.  Funneling of reducing equivalents into the nonproductive 
shunt pathways is observed in most xenobiotic metabolizing human P450 enzymes, which 
typically have very low coupling efficiency compared to the more efficient bacterial P450 
enzymes. 
1.3 Structure of Cytochrome P450 
The overall fold of the cytochrome P450 superfamily is highly conserved.  It consists of a 
single globular domain composed of 12 major alpha-helices (designated A-L), a beta-sheet region 
of 3-4 sheets, and a varied number of shorter helices (denoted with a prime) (Figure 1.4).  Despite 
conservation of the global fold, substantial diversity in the amino acid sequence, differential 
positioning of secondary structure components, and potentially varied conformational dynamics, 
permit the wide range of accommodated substrates and reactions that P450 enzymes perform.  The 
P450 fold forms around the heme prosthetic group, which is roughly located in the center of the 
enzyme and forms a “floor” in the active site cavity (Figure 1.4, black sticks).  Residing 
underneath, or proximal to the heme is the coordinated cysteine thiolate which is located in a loop 
region (Figure 1.4, shown in orange) just prior to the L helix.  The top or distal face of the heme 
is flanked by the I helix (Figure 1.4, yellow) which spans the breadth of the P450, and contains a 
generally conserved alcohol/acid residue pair implicated in P450 protonation steps.  Other 
structural elements such as the B-C loop (sometimes forming a short helix termed B′) (Figure 1.4, 
blue), and variable loop regions (Figure 1.4, red and magenta) form the remaining sides of the 
active site cavity.  The most distal portions of the active site cavity or roof are formed by helices 
F through G (Figure 1.4, green), which are perpendicular to the I helix, and have been implicated 
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in ligand entry and egress routes, particularly for many hydrophobic substrates which are thought 
to access the buried active site from the membrane-bound face of the catalytic domain. 
 
Figure 1.4  Global structure of a human cytochrome P450 enzyme located in the ER.  In addition to membrane anchoring 
through a N-terminal helix, ER-bound mammalian P450 enzymes have partial membrane insertion of the globular domain.  Major 
structural elements typically forming the enclosed active site cavity are colored and labeled.  The two halves of the globular heme 
containing domain are commonly referred to as distal and proximal sides, this separation is by the plane of the heme (shown as a 
bold dashed line).  Structure shown is human CYP1A1 bound to ANF (PDB code: 4I8V). 
While prokaryotic cytochromes P450 are soluble enzymes, the mammalian P450 enzymes 
are membrane-bound and those involved in xenobiotic metabolism are largely localized in the 
endoplasmic reticulum.  These ER-bound P450 enzymes possess an N-terminal transmembrane 
helix, which in part secures them to the cytosolic face of the ER membrane.  Additionally, the 
membrane-bound mammalian P450 enzymes have regions forming the distal protein surface, 
namely the F/G loop (sometimes forming short helices designated F′ and G′), the exterior of which 
are largely hydrophobic and partially embedded into the membrane.  Even with deletion of the N-
terminal anchoring helix, recombinantly-expressed mammalian P450 enzymes are retained in 
membrane fractions, and require high ionic strength and/or detergent to extract the protein from 
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the membrane.  Deletion of the N-terminal anchoring helix is a common modification used to 
generate higher recombinant P450 expression levels and greater solubility in mammalian P450 
enzymes (9).  Almost all of the crystal structures of mammalian cytochromes P450 have been 
solved without the anchoring membrane helix.  These truncated enzymes still retain catalytic 
function consistent with the idea that the membrane helix likely serves as a tether and does not 
influence the structure of the heme-containing catalytic domain. 
P450 structures have generally been solved in what is colloquially termed a closed state, 
where the cavity above the heme is isolated from the protein exterior (as shown in Figure 1.4).  In 
order for ligands to access the active site, P450 enzymes must make conformational adjustments 
to allow for ligand entrance, as well as for product egress.  Some isoforms have been solved in 
both open and closed states (8), and comparisons between these states have largely pointed towards 
conformational changes occurring primarily in the F/G region associated with the membrane (10).  
These conformational motions can lead to access channels for substrate entry.  Additionally, 
entrance of typically hydrophobic substrates through the F/G region logically makes sense since 
this region of the P450 would typically be embedded or in contact with the membrane, allowing 
for energetically more favorable partitioning of hydrophobic substrates into the P450. 
1.4 Interactions of P450 with P450 Reductase and Cytochrome b5 
To perform catalysis, P450 enzymes require electrons.  For the human ER-bound enzymes, 
these are primarily delivered by NADPH-cytochrome P450 oxidoreductase (CPR).  CPR is a 
diflavin protein containing the cofactors flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN).  These flavins are located on separate domains, named for the cofactor 
they respectively bind, joined by a short flexible hinge (Figure 1.5).  CPR, like P450 enzymes, are 
anchored onto the ER membrane.  For CPR this is through a N-terminal membrane binding domain 
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preceding the FMN domain.  A current proposal on how electron transfer occurs between CPR 
and P450 enzymes is as follows: 1) NADPH binds to the CPR FAD domain.  2) The FAD flavin 
is reduced.  3) An interflavin electron transfer from FAD to FMN cofactors occurs.  4) The FAD 
and FMN domains move apart.  5) The exposed FMN domain forms protein-protein contacts with 
the proximal surface of a P450 enzyme.  6) The reduced FMN cofactor transfers one electron to 
the P450 heme (11).  The interaction between CPR and P450 enzymes has been partially defined 
through site-directed mutagenesis and crosslinking studies (12-15) for some mammalian P450 
isoforms, and is thought to be governed through a combination of electrostatic and van der Waals 
interactions (11).  In general, the primary interaction surfaces are the negatively charged surface 
around the CPR FMN and the positively charged proximal surface of the P450. 
In addition to P450 reductase, some cytochrome P450 enzymes can also receive electrons 
from the heme-containing protein cytochrome b5 (16,17).  Cytochrome b5 is a relatively small 
protein with an approximate molecular weight of 15 kDa.  In terms of structural topology, b5 is 
partitioned into a globular heme-containing domain, a C-terminal membrane anchored helix, and 
a flexible linker connecting the two (Figure 1.5) (11).  The heme of b5 is in a partially solvent-
exposed cleft, with coordination by two histidine residues on the proximal and distal positions, 
and functions as a one-electron acceptor and donor.  This heme-exposed face of b5 is composed of 
four helical elements (a2-a5), which contain multiple negatively charged aspartates and 
glutamates, and possesses a convex shape.  No structures of the cytochrome b5/P450 complex are 
currently available, however much information has been gained for multiple P450 isoforms 
through a combination of mutagenesis, cross-linking, and some NMR studies (16,18-22).  Similar 
to CPR, b5 also binds the P450 proximal surface.  This interaction has been postulated to be driven 
through electrostatic pairing between the two proteins, however there appear to be some 
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differences in which b5 residues are important for interactions with individual P450 enzymes 
(18,22-24).  It is thought that b5 and CPR largely compete for the same binding surface on P450 
enzymes, because b5 can inhibit reduction of ferric P450 by CPR under certain conditions (25), 
and NMR shows direct displacement (26,27).  Although cytochrome b5 and CPR have been shown 
to have mutually exclusive binding behavior, the interaction area is thought to not be completely 
shared because certain proximal P450 mutations have differential effects on binding either b5 or 
CPR (12,26). 
 
Figure 1.5  The eukaryotic, ER-bound cytochrome P450 protein system.  Proteins P450 reductase (CPR) and cytochrome b5 
can act as electron donating partners and/or allosteric modulators of P450 enzymes.  Proteins are shown in electrostatic surface 
representation.  Both CPR and b5 have large anionic surfaces areas, while cytochrome P450 enzymes typically have a cationic-
charged proximal surface. 
A high-resolution complex between any mammalian P450 enzyme and partner protein (CPR 
or b5) remains to be solved.  Although important residues have been identified for some P450 
isoforms, residue information for many of the human P450 isoforms have not been reported.  In 
addition to specific residues on the P450 forming complexes with b5 or CPR, little is known if 
conformational changes in the proteins are induced by complex formation. 
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1.5 P450 Modulation by Cytochrome b5 : Proposed Mechanisms 
The exact roles that b5 plays in catalysis has long been quite enigmatic (25,28-30).  In 
general, b5 is not required for P450 catalysis.  Rather it functions as a modulator of P450 reactions.  
As a modulator, b5 has been reported to have diverse responses on P450 reactions ranging from 
increasing P450 productive turnover of substrates, to having no measurable effect on product 
formation, and even inhibiting P450 catalysis (17,25).  These varied effects appear to be dependent 
on both the P450 isoform and substrate under study, and in some cases the assay conditions.  Even 
with these different responses, cytochrome b5 has frequently displayed the ability to increase 
coupling of the P450 catalytic cycle, by reducing unproductive reducing equivalent consumption 
via shunt pathways (31,32). 
Numerous mechanisms for how cytochrome b5 alters P450 activity have been proposed.  A 
major mechanism has been through b5 functioning as a redox partner in P450 catalysis.  
Cytochrome b5 is capable of donating the second electron to P450 enzymes, but typically is not 
capable of supplying the first electron due to the high redox potential relative to ferric P450 (32).  
Delivery of the second electron is thought to be one of the rate-limiting steps in the catalytic cycle, 
and it has been hypothesized that b5 can donate this electron at a faster rate than CPR (33).  Faster 
delivery of the second electron would presumably prevent decomposition of the oxy-ferrous P450 
species through the superoxide shunting pathway, and allow for a greater percentage of NADPH 
to be utilized to support product formation. 
Experiments showing increases of P450 turnover with redox-silent b5, either through heme 
removal or substitution with Zn-protoporphyrin IX, have also prompted an alternative mechanism 
(17,19,34).  This has been proposed as an allosteric role, where the physical interaction between a 
P450 and cytochrome b5 causes conformational changes in the P450 (19,32)  This allosteric 
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mechanism is supported by the ability of b5 binding to influence the spectral spin state of some 
P450 enzymes (35).  This suggests that binding of b5 on the proximal P450 surface can transmit 
conformational changes into the heme active site.  Cytochrome b5 has also been proposed to 
modulate proton delivery to a P450 heme intermediate (36), which would likely occur through 
conformational alterations affecting the proton delivery network.  Recently NMR experiments on 
the steroidogenic P450 17A1, which is modulated by b5, displayed perturbations of resonances in 
distal areas of the P450 (I helix and F/G region) (37), approximately 25-35 Å away from the b5 
binding site.  These observations suggest b5 could modulate substrate positioning since residues in 
the F/G region can form direct and indirect interactions with substrates.  Alterations in substrate 
positioning may lead to more precise binding geometry during catalysis, and could be an avenue 
for increased coupling and product formation.  Lastly it is possible that b5 modulation occurs 
through multiple steps within the catalytic cycle, that the mechanisms employed are 
isoform/substrate dependent, or a combination of mechanisms are operative.  Regardless of the 
mechanisms employed, cytochrome b5 binding has significant implications for P450 catalysis.  
Chapter 2 of this dissertation explores the b5/P450 interaction by probing the complexes through 
solution NMR. 
1.6 Cytochrome P450 Enzymes Involved in Pro-carcinogenic and Toxin Activation 
P450 enzymes can generate a variety of products from substrates they metabolize.  These 
products or metabolites often possess differing chemical properties from the original substrate, 
thus having the potential for altered interactions with the body.  For xenobiotic human P450 
enzymes a common metabolic route is generating metabolites with increased water solubility, 
thereby leading to excretion or enabling further metabolism with eventual elimination from the 
body.  In some cases, P450-mediated drug metabolites can increase the pharmacological activity 
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towards the drug target.  One example is the breast cancer drug tamoxifen which has significantly 
increased anticancer activity once it is metabolically converted to the active metabolite endoxifen, 
which is predominately mediated by CYP2D6 (38).  Accordingly, poor response to this anticancer 
drug has been observed in patients possessing low CYP2D6 activity (39).  Besides forming 
metabolites destined for elimination or playing roles in prodrug activation, P450 enzymes can also 
bioactivate compounds, resulting in metabolites with carcinogenic and/or toxic properties (40-42).  
This has important implications since many chemical carcinogens require enzymatic bioactivation 
to be genotoxic and P450 enzymes are considered major contributors to this process (43).  Human 
P450 isoforms that generate carcinogenic metabolites, include those in Figure 1.6.  Almost half of 
this activation is by the family 1 (CYP1) human cytochrome P450 enzymes, which include three 
isoforms, CYP1A1, CYP1A2, and CYP1B1 (44). 
 
Figure 1.6  Contribution of human P450 isoforms in the activation of known carcinogens.  Figure adapted and data from 
Rendic and Guengerich (44). 
Within the human CYP1 family, the CYP1A2 isoform is considered one of the major 
xenobiotic metabolizing P450 enzymes, representing about 15% of the total P450 pool in the liver 
and contributing to the metabolism of many common drug substrates, including acetaminophen 
and caffeine (45).  In contrast, isoforms CYP1A1 and CYP1B1 are largely found in extrahepatic 
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tissues with relatively low constitutive expression levels (45).  Expression of CYP1A1 has been 
predominately found in the lungs (46,47), whereas CYP1B1 expression in normal tissues on a 
mRNA level is distributed into areas such as the kidney, prostate, uterus, and mammary gland to 
name a few (48).  High expression of CYP1B1 has been shown in a large variety of different tumor 
tissues on a protein level (49). 
Common substrates for the CYP1 enzymes include small molecule scaffolds such as 
polycyclic aromatic hydrocarbons (PAHs), and heterocyclic and aryl amines (48).  These substrate 
classes possess physical chemical features such as high planarity and aromaticity, and low 
molecular weight.  Crystal structures of the human enzymes CYP1A1, CYP1A2, and CYP1B1 
have been solved, all in complex with a small, aromatic hydrocarbon compound known as alpha-
naphthoflavone (ANF) (50-52).  The active site cavity for all three of the P450 enzymes are narrow, 
planar pockets, consistent with the common substrate classes observed for these enzymes. 
As discussed previously both CYP1A1 and CYP1B1 enzymes are not constitutively 
expressed at high levels, however these CYP1 family members are significantly induced by some 
xenobiotics, including combustion smoke constituents.  This occurs via the aryl hydrocarbon 
receptor (AhR), which is activated by binding agonist molecules, many of which are known CYP1 
substrates, resulting in AhR translocation into the nucleus (Figure 1.7).  Once in the nucleus, AhR 
binds specific xenobiotic response elements leading to transcriptional activation of family 1 P450 
genes (53).  This is reflected by both CYP1A1 and CYP1B1 upregulation in smokers and ex-




Figure 1.7  Bioactivation of a primary environmental pollutant, benzo[a]pyrene (B[a]P).  This bioactivation process of B[a]P 
into a potent carcinogen is mediated by CYP1A1 and CYP1B1.  The family 1 P450 enzymes are highly inducible.  Many CYP1 
substrates (including B[a]P) activate the aryl-hydrocarbon receptor (AhR) resulting in transcriptional upregulation of these P450 
enzymes, and thus increased production of carcinogenic compounds. 
1.7 CYP1A1 Role in Metabolic Activation of Tyrosine Kinase Inhibitors 
An area of rapid drug development has been targeted kinase inhibitors for the treatment of 
various cancer types, with more recent expansion into other disease areas (55).  In the span of just 
15 years, ~30 small molecule kinase inhibitors have been approved for clinical use, with many 
more currently in clinical trials (56).  One of the proposed advantages of these targeted therapies 
in oncology has been the potential of reduced toxicities in comparison to conventional 
chemotherapy.  However, a number of kinase inhibitors have received “black box warnings” from 
the FDA for life-threating issues due to various toxicities (56).  Although occurring only in a subset 
of patients, the toxicities associated with these drugs can limit the use of these potentially lifesaving 
therapeutics.  The underlaying mechanism of how hepatotoxicity is induced by some of these 
kinase inhibitors still is largely unknown.  However, insight into possible initiation mechanisms 
can be garnered from other drug classes that cause hepatotoxicity or drug-induced liver injury 
(DILI).  DILI generally stems from reactive metabolite generation, resulting in direct toxicity 
and/or immune responses (57).  Due to their abundance in the liver, cytochrome P450 enzymes 
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have been major sources of DILI for a number of different drugs.  Additionally, a number of studies 
have linked specific human P450 isoforms to the generation of reactive metabolites.  Currently 
these have included the clinically available tyrosine kinase inhibitors: dasitinib, gefitinib, erlotinib, 
lapatinib, imatinib, axitinib, ponatinib, and sunitinib, as well some investigational tyrosine kinase 
inhibitors (56). 
The human cytochrome P450 enzyme CYP1A1 has been associated with producing reactive 
metabolites for a number of these kinase inhibitors (58-60).  The role of CYP1A1 in this process 
is interesting since it is not expressed significantly in the liver.  However relatively few studies 
have measured CYP1A1 expression on a protein or activity level in the human liver, and of these 
studies CYP1A1 expression has varied widely between liver preparations and individuals (61-63).  
Furthermore, a number of clinical drugs, including some of the tyrosine kinase inhibitors, such as 
erlotinib and axitinib, have considerable interindividual variability in drug pharmacokinetics, and 
have shown associations with a history of smoking (64,65).  This could indicate CYP1A1 liver 
expression has wide interindividual variability and/or is induced through AhR ligands such as 
those found in cigarette or combustion smoke.  Other toxicities, such as interstitial lung disease, 
have also been reported for some of the tyrosine kinase inhibitors such as imatinib, gefitinib, and 
erlotinib, and generally correlated with smoking as a risk factor (59,66,67). 
The ability of CYP1A1 to accommodate and ultimately metabolize these larger and structurally 
diverse kinase inhibitors is difficult to rationalize from a structural perspective given the previously 
known CYP1A1 restrictive active site dimensions.  The inability of the initial CYP1A1 structure 
with ANF to predict how these larger classes of compounds are accommodated is not only a 
question specific to CYP1A1.  The scope of conformational malleability is an open question for 
many human P450 enzymes.  To date 24 of the 57 human P450 structures by X-ray crystallography 
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have been solved.  Of these roughly 20% only have a single crystal structure.  Are the current 
range of P450 structures sufficient to explain known substrate and inhibitor scopes?  Chapters 3 
and 4 of this dissertation focus on addressing this question of P450 structural malleability, 
specifically for the human CYP1A1 enzyme, by solving new structures complexed with ligands 
with increased structural diversity.  Ultimately the goal of these investigations is to generate the 
structural resources to predict the carcinogenic or toxic metabolite generation of new compounds. 
1.8 P450 Prodrug Strategy for Engineered Duocarmycins in Cancer Therapy 
P450 metabolism is known to activate numerous prodrug compounds.  In many cases this 
feature was not initially designed into the drug, but rather found to occur during characterization 
(68).  Due to the reaction diversity of cytochrome P450 enzymes and tissue selective sites of 
expression for some P450s, prodrugs designed for specific activation hold promise for targeting 
drug action to selective cells and tissues.  This is in contrast to enzymes common in prodrug 
activation that are expressed systemically such as esterases (69).  One attractive prodrug strategy 
has been to develop extremely potent chemotherapeutics that are activated only in specific tumor 
tissues.  Recently a scaffold based on the highly cytotoxic duocarmycins has been engineered for 
P450-mediated prodrug activation (Figure 1.8) (70).  The duocarmycins represent a family of 
natural product compounds, first isolated from Streptomyces (71).  These compounds are 
exceptionally potent cytotoxic agents which bind and alkylate DNA in a sequence-selective 
manner.  Clinically the duocarmycins, and derivatives of these compounds, were found to have 
extreme systemic toxicity profiles, due to nonspecific effects, which halted their development (71).  
Due to their potency and mechanisms of action, interest has still been maintained in using 
engineered duocarmycins clinically, with various approaches to target the drugs in tumors.  These 
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include antibody-drug conjugates or masking of a DNA-alkylating chloromethylindoline moiety 
with subsequent reduction or cleavage in tumor cells (72,73). 
 P450-mediated activation of pro-duocarmycins has been developed utilizing a seco-
duocarmycin scaffold (Figure 1.8).  This eliminates the DNA-alkylating cyclopropane and a key 
hydroxyl moiety (70).  These seco-duocarmycins are designed for P450 enzymes to selectively 
install a hydroxyl group at a key site, resulting in spontaneous regeneration of the alkylating 
cyclopropane (Figure 1.8, bioactivation pathway).  Previously this site-specific oxidation was 
found to be exclusively performed by two human P450 enzymes, CYP1A1 and CYP2W1, and not 
by the major hepatic P450 enzymes (74).  CYP1A1, as described previously, has variable 
expression levels in different tissues, with the most common site of expression in the lungs.  There 
are some indications of overexpression of CYP1A1 in tumor tissues, however numerous studies 
have found expression in normal tissues as well (75).  In contrast CYP2W1, considered an orphan 
P450, has been only found in select tumor tissues.  Significant mRNA and protein levels of 
CYP2W1 have been found in approximately a third of adult colon cancers (76).  Thus, selective 
bioactivation of seco-duocarmycins by CYP2W1 needs to be achieved over CYP1A1.  The crystal 
structure of CYP2W1 has not been solved yet, hindering precise structure-based drug design.  
However, the CYP2W1 active site structure has been predicted to be most similar to CYP1A1, 
based on both overlapping substrate profiles and high identity in specific substrate recognition site 
(SRS) regions (77).  Initial functionalization of the DNA binding subunit has so far only resulted 
in gaining selectivity of CYP1A1 over CYP2W1, the opposite of the desired selectivity (74). 
Recently, further engineering of the seco-duocarmycins has investigated the bioactivation 
and selectivity effects of chirality of the chloromethyl moiety (Figure 1.8).  The binding and 
structural orientations of the separated enantiomers of seco-duocarmycin derivatives in the 
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CYP1A1 active site are the basis of research presented in Chapter 5 of this dissertation.  Results 
of this research are aimed at furthering the selectivity of these potent cancer therapeutics for 
specific activation in tumor cells. 
 
Figure 1.8  General scaffold and previous modifications on designed seco-duocarmycin prodrugs.  
Substitution/functionalization to the scaffold and changes to bioactivation into cytotoxic species were reported by Sheldrake et al. 
(74). 
1.9 Ancestral Reconstructed P450 Enzymes with Higher Thermostabilities for Industrial 
Applications 
The use of enzymes as biocatalysts has been an attractive route towards generating 
synthetically difficult, expensive, or unsustainable chemicals compounds.  For enzymes to be 
useful biocatalysts, they often require high turnover rates and extended stability in reaction 
conditions.  Due to the diverse and often regio-specific functionalization P450 enzymes can 
perform, especially on inert C-H bonds, use of cytochromes P450 as has had immense interest (78-
81).  Largely, the soluble bacterial P450 enzymes have been used for this purpose due to their 
already high turnover, stability, and high expression yields.  However, the bacterial enzymes often 
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have restrictive substrate profiles, limiting the array of useful compounds that could be produced.  
In contrast, many mammalian P450 enzymes have broad substrate scopes, but are disadvantaged 
due to poor stability in terms of thermal and solvent tolerances and often low activity (82).  
Methods which have been used to improve the stability and activity of these enzymes have broadly 
been either through rational or semi-rational mutagenesis (if a structure is available or if structure-
function relationships are well established) or directed evolution approaches (83,84).  While these 
methods have been applied successfully, these approaches often require multiple rounds of time-
consuming screening and yield only incremental improvements (82).  An alternative approach has 
been through the reconstruction of ancestral P450 linages, which have shown a fairly robust 
correlation between evolutionary age and gains in the thermal stability (82,85).  Recent work 
utilizing this approach has shown that very large enhancements in thermostability can be gained 
with ancestors of the major drug metabolizing human enzyme 3A4 (82).  Reconstructed 
mammalian P450 ancestors as starting templates hold promise for the development of highly stable 
and efficient biocatalysts for producing medicines, industrial chemicals, and as mediators for green 
chemistry.  Chapter 6 reports on the first structure of an ancestral reconstructed P450 enzyme.  
This enzyme known as N98-1B1-mammal, is the ancestral CYP1B1 mammalian ancestor.  In this 
chapter, examination of structural and catalytic differences between the ancestral CYP1B1 and the 
extant human CYP1B1 are performed, with the goal of deciphering structural elements that may 
contribute to enhanced thermostability. 
1.10 Conclusions 
The catalysis performed by human cytochrome P450 enzymes has a wide range of 
importance in drug metabolism, prodrug activation, carcinogen/toxin formation, and as 
biocatalysts.  To understand, predict, as well as take advantage of P450 catalysis, we need a high-
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resolution understanding of P450 enzymes and their interactions with ligands and redox partners.  
The malleability of the P450 active sites upon binding different ligands and potentially partner 
proteins can make the development of selective inhibitors or sites of metabolism prediction for 
substrates challenging or impossible even if structures of the P450 are known.  These uncertainties 
impede the development of safer and more effective pharmaceutical agents, prevention of 
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The small heme-containing protein cytochrome b5 can facilitate, inhibit, or have no effect 
on cytochrome P450 catalysis, often in a P450-dependent and substrate-dependent manner that is 
not well understood.  Herein solution NMR was used to identify b5 residues interacting with 
different human drug-metabolizing P450 enzymes. NMR results revealed that P450 enzymes 
bound to either b5 a4-5 (CYP2A6 and CYP2E1) or this region and a2-3 (CYP2D6 and CYP3A4) 
and suggested variation in the affinity for b5.  Mutations of key b5 residues suggest that not only 
are different b5 surfaces responsible for binding different P450 enzymes, but that these different 
complexes are relevant to the observed effects on P450 catalysis. 
2.2 Introduction 
Cytochrome P450 (P450) monooxygenases have vital roles in both the metabolism of 
xenobiotics including drugs and in the biosynthesis of endogenous compounds such as steroids, 
vitamins, fatty acids, and eicosanoids.  While the ability of P450 enzymes to oxidize such 
substrates requires interaction with a redox partner protein, catalysis can additionally be modulated 
by interactions with the membrane-bound heme protein cytochrome b5 (b5).  Cytochrome b5 has a 
                                               
* The contents of this chapter have been published: Bart, A.G. & Scott, E.E. (2017) Structural and Functional Effects 
of Cytochrome b5 Interactions with Human Cytochrome P450 Enzymes. Journal of Biological Chemistry, 292:20818-
20833. 
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complex influence, such that P450 catalysis can be stimulated, not affected, or even inhibited, 
prompting numerous investigations into the mechanism(s) by which these varied responses are 
elicited (1,2).  Proposals have largely focused on 1) b5 functioning in a purely redox role of electron 
delivery or 2) as an allosteric modulator of P450 conformation.  Metal-substituted, redox-silent 
forms of b5 still stimulate certain P450 reactions (4,5), supporting a purely allosteric role for b5, at 
least in some cases.  Allosteric modulation of P450 conformation could result in alterations in 
substrate binding, electron or proton delivery, or coupling of NADPH consumption to metabolite 
formation (1,2,3). 
Regardless of the mechanism, the capability of b5 to modulate P450 catalysis relies on 
direct binding between b5 and a P450.  Insights into individual P450/b5 complexes gained from 
mutagenesis (3,4), chemical modification (5), and cross-linking studies (6,7) are consistent with 
the convex, negatively charged, heme-exposed face of b5 (Figure 2.1A) transiently interacting with 
the concave, largely positively charged, proximal face of P450 enzymes (Figure 2.1B).  This 
proximal P450 face is the same surface to which the required redox partners bind (NADPH-
cytochrome P450 reductase (CPR) for microsomal P450 enzymes), underscoring the necessity of 




Figure 2.1  General structures of proteins in this study and overview of their interaction as monitored by NMR.  A, structure 
of the human cytochrome b5 soluble domain (residues 1-107), as determined by NMR (PDB 2I96).  The heme and coordinating 
histidine residues are shown as sticks. Alpha helices labeled 1-5.  The locations of E49 and D65 in helices 3 and 4 are indicated.  
B, P450 structure (CYP2A6, PDB 1Z10) viewed from the proximal face proposed to interact with b5.  The heme is again shown as 
sticks.  As a reference, the I helix is highlighted (orange) on the distal side of the heme where the active site is located.  C, the 1H-
15N HSQC NMR spectra of the soluble domain of human cytochrome b5 titrated with increasing amounts of unlabeled CYP2A6 
saturated with coumarin is representative of the type of changes seen for all P450 enzymes examined herein.  Progressive signal 
loss or line-broadening of most b5 resonances occurs with increasing concentrations of P450, indicating progressive complex 
formation between the two proteins.  D, a selected region of the NMR spectra (the region indicated as dashed box in panel C) is 
shown with increasing P450 to demonstrate differential line broadening effects.  In this example with CYP2A6, some resonances 


































































Fundamental questions persist with regard to P450/b5 interactions:  How variable is the 
binding interface between b5 and different P450 enzymes?  Do the affinities vary?  Could 
differences in the b5/P450 interaction underlie the different effects b5 has on P450 catalysis?  To 
complicate matters, the effects that b5 has on catalysis can depend not only on the P450 enzyme, 
but also the P450 substrate being metabolized (9-11) and experimental parameters, including the 
ratio of P450 to b5 (10).  Differences in b5 effects with different substrates has fueled interest in 
whether conformational linking exists between the P450 active site cavity and the P450 proximal 
face interacting with b5 and CPR (8,12,13). 
Since there are no X-ray structures available of b5 interacting with any P450, solution NMR 
is an attractive high-resolution approach to decoding these transient binding interactions.  Previous 
studies of 15N-labeled b5 binding to increasing concentrations of unlabeled human steroidogenic 
CYP17A1 enzyme or rabbit CYP2B4 revealed only small chemical shift perturbations, but more 
pronounced decreases in the intensity of b5 resonances (4,15).  These line-broadening effects may 
result from a number of potential sources.  Binding of the smaller ~16 kDa b5 to a larger P450 
enzyme (~50-55 kDa) would enhance the transverse relaxation rate, but could also result in 
paramagnetic effects from the P450 heme, and/or alter the protein-protein interaction to fall within 
the intermediate exchange time-scale (8,14).  Thus, while progressive line broadening occurs upon 
formation of increasing amounts of the reversible P450/b5 complex, there is not necessarily a 1:1 
correspondence between signal loss and amount of complex formed, which prevents the 
determination of meaningful Kd values.  Regardless, the degree of broadening has varied between 
these two different P450 enzymes, the P450 ligands present, and experimental conditions such as 
the presence of lipid mimic systems (8,14,15), providing various insights into these P450/b5 
interactions.  Both CYP17A1 and CYP2B4 studies reported that certain b5 resonances are 
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broadened substantially more than the average.  Since most of the b5 amino acids have been 
assigned to specific resonances (16), such differential line broadening has been used to 
successfully map out specific b5 residues that transiently interact with CYP17A1 and CYP2B4 
(8,14). 
The current study employed such solution NMR experiments to identify and compare b5 
residues interacting with the human xenobiotic cytochrome P450 enzymes 2A6, 2D6, 2E1, and 
3A4.  Results indicate that both shared and distinct interaction surfaces on b5 are present in these 
respective complexes.  Additionally, substantial differences between CYP2D6 and the other P450 
enzymes examined are consistent with different relative affinities of the complex with b5.  Key b5 
residues identified using this approach were subsequently validated by performing mutagenesis 
and evaluating both complex formation and effects on catalysis.  This comparison of P450/b5 
complexes provides a physical basis to begin understanding the ability of b5 to differentially 
modulate P450 catalytic activities. 
2.3 Experimental Procedures 
2.3.1 Generation of the soluble domain of human cytochrome b5 with 15N-labeling for NMR 
experiments 
A synthetic, codon-optimized gene encoding the soluble domain (residues 1-107) of human 
microsomal cytochrome b5 with a C-terminal His6 tag (Genewiz) was cloned into the NcoI and 
BamHI restriction sites of pET15b and transformed into E. coli C41 (DE3) cells already containing 
the pGro7 plasmid (Takara Bio) for expression of GroEL/GroES chaperones.  Transformed cells 
were selected by growing cells for ~18 hours at 37 °C on a non-inducing minimal media plate 
(MDAG-11) (17) supplemented with carbenicillin (100 µg/mL) and chloramphenicol (20 µg/mL) 
to select for the b5 and chaperone plasmids, respectively.  All subsequent cultures contained these 
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antibiotics.  A single colony was picked and grown for ~16 hours at 37 °C with shaking (250 rpm) 
in a 50 mL liquid culture of non-inducing minimal media MDAG-135 (17).  Expression cultures 
consisted of 1 liter of a defined minimal media (48 mM Na2HPO4, 22 mM KH2PO4, 9 mM NaCl, 
19 mM 15N NH4Cl, 53 mM glucose, 4 mM MgSO4, and trace metals) inoculated with 5 mL of the 
liquid starter culture.  Cells were grown with shaking (250 rpm) at 37 °C, to an optical density at 
600 nm (O.D.600) of 0.3, at which point the heme precursor d-aminolevulinic acid (ALA, to 1 mM) 
and the chaperone inducer L-arabinose (to 13 mM) were added.  After O.D.600 reached 0.7-0.8, b5 
expression was induced by adding 0.4 mM IPTG and the temperature and shaking were reduced 
to 30 °C and 225 rpm, respectively.  Cultures were subsequently grown for 20 hours prior to 
harvesting and freezing the cell pellet at -80 °C.  Purification was initiated by resuspending cells 
in lysis buffer (500 mM KPi, 100 mM NaCl, 15% glycerol, 1 mM EDTA, pH 7.4) with the addition 
of 1 mM PMSF.  Resuspended cells were lysed by a French press and heme reconstitution 
performed as described (18).  Lysed cells were clarified by ultracentrifugation at 140,000 x g and 
loaded onto a pre-equilibrated 25 mL Ni-NTA column (Qiagen) with loading buffer (100 mM KPi, 
20% glycerol, 200 mM NaCl, 20 mM imidazole, pH 7.4), washed with an additional 8 CV of 
loading buffer, and eluted using a 6 CV of elution buffer (loading buffer with 200 mM imidazole).  
Eluted fractions with A413/A280 > 4.0 were pooled and concentrated prior to loading on a Superdex 
200 Increase 10/300 GL column (GE Healthcare) and run with gel filtration buffer (50 mM KPi, 
20% glycerol, 100 mM NaCl, pH 7.4).  The protein sample was then exchanged into a storage 
buffer (50 mM KPi, 10% glycerol, pH 7.4) using a HiTrap desalting column (GE Healthcare).  
Final protein preparation was evaluated by SDS-PAGE and UV-visible spectroscopy (A413/A280 > 
6.0) and quantified using an extinction coefficient of 117 mM-1 cm-1 at 413 nm (19).  Aliquots 
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were stored at -80 °C until use. Samples for NMR were created by exchanging labeled b5 into 
NMR buffer (50 mM KPi, 50 mM NaCl, 10% D2O, pH 6.5) through dilution and centrifugation. 
2.3.2 Generation of full length human cytochrome b5 for catalytic assays 
A synthetic, codon-optimized DNA sequence encoding full-length human cytochrome b5 
plus a C-terminal His6 tag was generated (GenScript) and cloned into pET-15b vector using 
restriction enzymes NcoI and BamHI.  Expression of full length b5 was similar to the soluble 
domain of b5 except 1) expression cultures were grown in Terrific broth, 2) induction was 
performed with 0.1 mM IPTG at an O.D.600 of 1.1, and 3) induced cultures were grown at 20 °C 
with 250 rpm shaking for 44 hours.  Purification of full length b5 was initiated by resuspending 
cells in resuspension buffer (100 mM KPi, 20% glycerol, 1 mM EDTA, pH 7.4) supplemented 
with 1X HALT protease inhibitor cocktail (Thermo Fisher) and 1 mM PMSF.  Cells were lysed 
and reconstituted with heme as described above for the soluble domain.  Membrane fractions were 
isolated by ultracentrifugation at 140,000 x g for 30 min. and b5 extracted using resuspension 
buffer with the addition of 0.2 M NaCl and 1% (w/v) CHAPS.  Extracted membranes were pelleted 
by a second ultracentrifuge step at 140,000 x g for 30 min. and the b5-containing supernatant loaded 
onto a Ni-NTA column (Qiagen) and washed as described for the soluble domain of b5 but with 
the addition of 0.5% (w/v) CHAPS.  Eluted fractions with A413/A280 > 2.0 were pooled, 
concentrated and loaded on a Sepharcryl S-200 HR column (GE Healthcare) equilibrated and run 
with gel filtration buffer (50 mM KPi, 20% glycerol, 100 mM NaCl, 0.05% (w/v) CHAPS, pH 
7.4), and exchanged into storage buffer as described above.  Protein purity was assessed on SDS-
PAGE, and UV-visible spectroscopy was used to confirm degree of heme incorporation (A413/A280 
= 3.0) and quantify dithionite-reduced b5 (18). 
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2.3.3 Generation of full length human NADPH-cytochrome P450 reductase for catalytic 
assays 
 A construct encoding full length human NADPH-cytochrome P450 reductase preceded by 
the ompA signal peptide and followed by a His6 tag was cloned into pET-29a(+) using NdeI and 
HindIII.  Expression of reductase was performed as previously described for a truncated CPR 
construct (20) with modifications.  Modifications to the expression included 1) transformation and 
generation of the starter culture as described for soluble b5, 2) supplementation of expression 
cultures with 2 mg/L riboflavin, and 3) shaking at 200 rpm after induction.  Full length CPR was 
also purified in a similar manner to a previously described method (20), with modifications: 1) 
membrane fractions after cell lysis were isolated by ultracentrifugation at 140,000 x g for 25 min. 
prior to detergent extraction, 2) omission of the ammonium sulfate precipitation step, and 3) 
addition of a second nickel affinity column after elution from Octyl-Sepharose 4 Fast Flow (GE 
Healthcare) resin in order to deplete detergent.  Final reductase samples were evaluated on SDS-
PAGE and by UV-visible spectroscopy. CPR was quantitated by flavin absorbance of the fully 
oxidized protein at 454 nm with an extinction coefficient of 21.4 mM-1cm-1 (21). 
2.3.4 Generation of P450 enzymes for NMR and catalytic assays 
All cytochrome P450 enzymes were the forms previously used to generate crystallographic 
structures and result in catalytically active protein omitting the N-terminal transmembrane helix 
and adding a C-terminal His tag.  Constructs and expression and purification of human CYP2A6 
(22) and CYP2E1 (23) were reported previously.  Synthetic, codon-optimized genes encoding 
CYP2D6 and CYP3A4 were generated (Genscript) to match the reported constructs (24,25), 
cloned into the pCWori vector, and expressed and purified as described in these same publications 
with some modifications.  Briefly E. coli DH5a containing the pGro7 plasmid (Takara Bio) was 
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used to express the P450 enzymes.  Transformation and starter cultures were performed as 
described for soluble b5.  Proteins were purified by isolating spheroplasts (26), lysis by French 
press, detergent extraction using 4.8 mM CYMAL-5 (CYP2A6 and CYP2E1) or 14 mM CHAPS 
(CYP2D6 and CYP3A4).  After extraction, lysate was clarified by ultracentrifugation at 104,000 
x g and purified through Ni-NTA, carboxymethyl cellulose ion-exchange, and size-exclusion 
chromatography.  All proteins were depleted of detergent during ion exchange chromatography, 
exchanged into storage buffer (50 mM KPi, 10% glycerol, pH 7.4), and frozen as aliquots at -80 
°C.  P450 samples were evaluated by SDS-PAGE and UV-visible spectroscopy.  The reduced-
carbon monoxide difference spectra revealed, at most, only trace amounts of P420. 
2.3.5 Mutagenesis 
Single amino acid mutants of cytochrome b5 E49Q and D65N were produced by the 
QuikChange Lightning site-directed mutagenesis kit (Stratagene) for the full-length construct and 
commercially (GENEWIZ) for the soluble-domain construct.  The complete genes were verified 
by sequencing and protein expressed and purified as described for the respective wild-type 
constructs. 
2.3.6 NMR Spectroscopy 
NMR experiments were acquired at 298 K using a Bruker Avance III HD 800 MHz with a 
QCI cryogenic probe.  Data were processed using NMRPipe (27) and visualized and analyzed 
using Sparky (T.D. Goddard and D. G. Kneller, Sparky 3, University of California, San Francisco). 
Assignments for the backbone amide signals for human soluble domain of b5 were transferred from 
the deposited chemical shifts in the Biological Magnetic Resonance Data Bank (accession number: 
6921) (16).  All of the 2D 15N-HSQC experiments were obtained on 15N-labeled, soluble domain 
b5 (0.1 mM) in NMR buffer (50 mM KPi, 50 mM NaCl, 10% D2O, pH 6.5) acquired with 64 scans 
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and 128 increments, which took about 2.5 hours.  The signal for each individual resonance was 
measured as peak height, with the value at 0:1 P450:b5 defined as 100% signal.  For each titration 
point within a series, a new sample of labeled b5 was prepared and a defined molar amount of an 
unlabeled P450 enzyme added to the sample.  For samples including P450 enzyme, the peak height 
for each resonance was expressed as a percentage of the resonance peak height in the absence of 
the P450.  Concentration of the P450 substrate was saturating and constant between samples (500 
µM coumarin for 2A6, 500 µM chlorzoxazone (CZN) for 2E1, 2 mM dextromethorphan (DXM) 
for 2D6, 5 mM p-nitrophenol (pNP) for 2A6, or 200 µM nifedipine (NFP) for 3A4).  NMR 
experiments were performed with both b5 and P450 in their oxidized states.  At the conclusion of 
each NMR experiment, samples were collected from the NMR tube, centrifuged to determine if 
any precipitation had occurred, and evaluated in terms of the reduced-carbon monoxide difference 
spectrum. 
2.3.7 Cytochrome P450 catalytic assays 
All catalytic assays were performed by incubating a P450 with full-length human P450 
reductase and full-length human b5 (when applicable) at a 1:2:0 ratio for minus b5 reactions or a 
1:2:2 ratio for b5 containing reactions for 20 minutes at room temperature.  The amounts of P450 
enzyme were 10 (coumarin assay) or 50 pmol (pNP assay) CYP2A6; 50 pmol CYP2D6 (DXM); 
50 pmol CYP2E1 (CZN assay); and 50 pmol CYP3A4 (NFP assay).  This protein mixture was 
added to the same buffer used for NMR experiments, except for the nifedipine assay which used 
an assay buffer consisting of 40 mM HEPES, 30 mM MgCl2, pH 7.4.  The reactions also contained 
the respective P450 substrate (0-128 µM coumarin, 0-600 µM CZN, 0-1600 µM pNP, 0-1000 µM 
DXM, 0-250 µM nifedipine).  For the nifedipine assay all reactions were performed in amber vials.  
The reactions were pre-incubated at 37 °C for 3 min, then initiated with 1 mM NADPH and 
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allowed to proceed at 37 °C for 10 min (coumarin, CZN, and pNP assays) or 15 min (DXM assay) 
or 20 min (nifedipine assay).  Reactions were terminated by addition of diluted perchloric acid 
(acetonitrile for the nifedipine assay), placed on ice, and centrifuged at 5,000 x g for 5 min prior 
to injection onto a Luna C18 (5 µm, 150 x 4.60 mm, Phenomenex) column at a flow rate of 1 
mL/min (0.75 mL/min for the nifedipine assay).  Separation on HPLC was obtained using the 
following mobile phase solutions for each of the respective assays.  For separation of coumarin 
and its 7-OH metabolite the mobile phase consisted of 50%/50% 20 mM KPi, pH 2.8/methanol.  
For CZN and its 6-OH metabolite the mobile phase consisted of 75%/25% 20 mM KPi, pH 
2.8/acetonitrile to elute product, then a sharp gradient to 40%/60% to elute substrate, followed by 
reequilibration to 75%/25%.  For pNP and its 4-nitrocatechol metabolite the mobile phase 
consisted of 73%/27% 10 mM KPi, pH 3.5/acetonitrile.  For DXM and its O-demethylated 
metabolite dextrorphan the mobile phase consisted of 50%/50% 10 mM KPi, pH 3.5/50% 
acetonitrile and 100% methanol (250/200 v/v).  For nifedipine and its metabolite 
dehydronifedipine the mobile phase consisted of 45%/55% water/methanol.  Metabolite detection 
occurred by fluorescence for coumarin (355 nm excitation, 460 nm emission) and DXM (280 nm 
excitation, 310 nm emission) assays, and by ultraviolet absorbance for CZN (287 nm), pNP (345 
nm), and NFP (270 nm) assays.  The amounts of the different metabolites produced were calculated 
using authentic standards prepared in the same method as samples.  Each reaction at each substrate 
concentration was performed at least in duplicate.  Data were fit to the Michaelis-Menten equation 
using Graphpad Prism. 
2.3.8 Measurement of NADPH Consumption 
NADPH consumption during the various P450 reactions was measured by creating reaction 
samples similar to the catalytic assays except for the following: 1) 100 pmol P450 was used to 
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increase signal/noise, 2) reactions were scaled up to 1 mL in the respective assay buffer containing 
the maximum substrate concentration used in turnover reactions, 3) NADPH concentration was 
reduced to 0.5 mM to reduce background, and 4) reactions were allowed to proceed for 10 min.  
CYP2A6(pNP) samples required the use of 2 mm path length cuvettes due to high substrate 
absorbance, so these reactions used 50 pmol P450 and a final volume of 500 µL. Rates of NADPH 
consumption were measured by monitoring linear decreases in absorbance at 340 nm.  The amount 
of NADPH consumed was calculated using an extinction coefficient of 6.22 mM-1 cm-1.  Control 
reactions omitting P450 provided the background NADPH consumption, which was subtracted.  
The amount of product at the end of each reaction was measured using the same methods described 
for each catalytic assay.  Coupling efficiencies were calculated by dividing metabolite product 
formation in these experiments by their respective NADPH consumption.  All measurements were 
performed in duplicate. 
2.4 Results/Discussion 
2.4.1 Rationale for experimental scope 
The specific human P450 enzymes included in this study were selected for their importance 
in clinical drug metabolism, diversity across the xenobiotic P450 subfamily, and the range of b5 
effects on metabolite production as reported in the literature.  Cytochrome b5 reportedly stimulates 
CYP2E1-mediated oxidation of a number of different substrates, including acetaminophen, 
aniline, N-nitrosodimethylamine, and chlorzoxazone (28,29), but may play a redox role, as apo-b5 
does not increase product formation (30,31).  The influence of b5 on the major drug-metabolizing 
P450 enzyme CYP3A4 has been widely documented, with numerous CYP3A4-mediated reactions 
showing stimulation in the presence of both holo and apo-b5 (32).  CYP2A6 coumarin 7-
hydroxylation has also been reported to be stimulated 1.5 to 2.5-fold by b5 (30,33-35).  CYP2D6 
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is a clinically significant P450 enzyme because of its ability to metabolize a wide array of 
pharmaceuticals and its high degree of polymorphism (36), but whose metabolite production is 
reportedly less influenced by b5, at least with in vitro experiments (30,31,37,38).  All of these 
human P450 enzymes in this study were the N-terminally truncated, C-terminally His-tagged 
forms used to determine X-ray crystallographic structures.  They are expressed recombinantly in 
the significant quantities required to make multiple NMR samples, are highly purified, and 
functionally active without lipid addition.  The latter aspect provides a common environment 
across NMR and catalytic assays and avoids variation due to variability in P450 incorporation into 
lipid. 
Each P450 enzyme was saturated with a substrate to additionally stabilize the P450 proteins 
under NMR-compatible conditions.  From significant previous experience with P450 enzymes 
produced for crystallographic studies, it is clear that high-affinity ligands often greatly improve 
the stability of these flexible, promiscuous enzymes.  They also did so under conditions where the 
NMR experiments could be collected:  10-100 µM P450 in glycerol-free, low ionic-strength buffer 
at 25 °C for several hours.  Additionally, previous reports on P450/b5 interactions have indicated 
a greater affinity of the complex between the two proteins when P450 substrate is present (5).  In 
this study, classical substrates with a single or at least one major metabolite were preferred, as this 
might be expected to simplify interaction modes by promoting a more homogenous P450 
conformation, as well as permitting quantification of a single product in catalytic assays.  Thus, 
CYP2E1 was saturated with the muscle relaxant chlorzoxazone (CZN), CYP3A4 with the 
hypotensive drug nifedipine (NFP), CYP2D6 with the cough suppressant dextromethorphan 
(DXM), and CYP2A6 with coumarin and p-nitrophenol (pNP).  Of these substrates, addition of 
coumarin, chlorzoxazone, and dextromethorphan to CYP2A6, CYP2E1, and CYP2D6, 
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respectively, yielded shifts in the difference spectra indicating a transition from low spin to high 
spin, facilitating the ability to monitor protein saturation. The intrinsic absorbance of nifedipine 
and p-nitrophenol impaired such observations for CYP3A4 and CYP2A6, respectively.  Under 
these conditions none of the samples resulted in visible precipitation and the reduced-carbon 
monoxide difference spectra were unchanged from the freshly purified P450 protein. 
While NMR-observed titrations necessarily involved various concentrations of P450, other 
experiments were designed to reflect ratios of P450:CPR:b5 often used in P450 functional assays 
in the literature.  This is important as thoroughly demonstrated in studies on the rabbit CYP2B4 
by Waskell and coworkers (10). Herein all catalytic assays used 1:2:2 ratios of P450 to CPR to b5, 
rather than optimizing these ratios for maximal turnover with individual P450/substrate 
combinations as is frequently done.  In NMR experiments this same ratio of P450 to b5 was used 
to evaluate the b5 mutants (0.5:1 P450:b5, which is the same as 1:2 in the assays).  To ensure that 
these ratios are accurate, special precautions were taken to avoid frequent problems with the 
quality and quantification of reductase and b5.  Cytochrome b5 was reconstituted with heme during 
purification to avoid large amounts of apo-b5 that can otherwise occur when polypeptide 
production exceeds heme production and which could also possibly bind P450.  Reductase was 
purified to remove as much as possible of the proteolyzed form that can reduce cytochrome c, 
might be able to bind P450, but is not able to reduce P450 and promote catalysis.  Thus, reductase 
was quantitated by flavin content instead of cytochrome c reduction.  Reductase was also 
quantitated by total protein from the bicinchoninic acid assay using bovine serum albumin as a 
standard and was no more than 30% higher than quantitation by flavin absorbance.  Both b5 and 
reductase were the human forms to match the human P450 enzymes, rather than the rat versions 
often employed.  Finally, because electrostatics are likely involved in both steering and binding 
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between b5 and P450 enzymes, to provide additional consistency the same buffer was used in NMR 
experiments and all catalytic assays, with the exception of the CYP3A4 nifedipine metabolism 
assay, which required slightly different conditions (vide infra). 
 Finally, although the effects of b5 on P450 catalysis are often simply evaluated by 
monitoring differences in metabolite formation in the presence and absence of b5, b5 may also have 
other effects not readily detected by this approach.  It has been reported that b5 can change the 
amount of NADPH consumed per amount of product formation (% coupling) (1), which wouldn’t 
necessarily alter the amount of product formed.  For this reason, NADPH consumption and its 
coupling to product formation was also evaluated in the absence and presence of wild type and 
mutant b5 proteins. 
2.4.2 Interactions and catalytic effects of b5 on CYP2A6 
When the 2D HSQC spectrum of 15N-labeled b5 alone is collected (e.g. Figure 2.1C, black), 
the intensity of each resonance is by definition 100%.  As reported previously for CYP17A1 and 
CYP2B4, titrations of 15N-b5 with increasing concentrations of 2A6(coumarin) result in few 
chemical shifts, but line broadening occurs and the intensity of most resonances decreases (Figure 
2.1C), with more marked reductions for specific residues (Figure 2.1D).  Because the dominant 
features are changes in intensity and because such overlaid spectra are difficult to comprehend 
visually, each resonance in each series of spectra was analyzed and the percentage of intensity 
remaining plotted graphically (e.g. Figure 2.2A). 
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Figure 2.2  Interaction of CYP2A6(coumarin) with 15N-b5 by NMR and b5 modulation of CYP2A6 catalysis.  A, a single 
NMR spectrum of 0.2:1 CYP2A6(coumarin):15N-b5 is shown graphically.  The intensity of each b5 resonance (circle) corresponding 
to an individual b5 residues (x axis) is plotted as a percentage of that resonance’s intensity in the absence of P450 (y axis).  Fine 
lines between circles indicate continuous assignments for sequential b5 amino acids.  Gaps in the line between circles indicate that 
one or more intervening b5 amino acids have not been assigned to an individual resonance in the spectrum (also shown in white in 
Figure 2B).  The average (µ) and average minus one standard deviation (1s) are indicated on the plot by black and red dashed lines, 
respectively, and constitute the selection criteria of b5 residues involved in P450 binding (red circles).  B, on the surface of the 
human soluble domain b5 structure (PDB: 2I96) residues displaying differential broadening effects colored red, while residues that 
have assigned NMR resonances that are not differentially affected by P450 addition are colored grey, and unassigned residues are 
colored white.  C, resonance intensity plots as in 2A, but comparing the effects of line broadening between WT b5 and b5 mutants 
D65N and E49Q at a fixed 0.5:1 CYP2A6(coumarin):15N-b5 ratio.  D, the effects of wild type and mutant b5 proteins on Michaelis-
Menten kinetic parameters of CYP2A6-mediated coumarin 7-hydroxylation.  Each sample was generated in duplicate with standard 
deviation illustrated by error bars.  Steady-state kinetic constants below are shown with standard deviation.  E, measurement of 
NADPH consumed (nmol NADPH/min/nmol CYP2A6) for the CYP2A6 coumarin reaction at a fixed coumarin concentration of 
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128 µM.  Samples were generated in duplicate with the standard deviation illustrated by error bars.  F, percent coupling of CYP2A6-
mediated coumarin 7-hydroxylation of coumarin.  Samples were generated in duplicate with the standard deviation illustrated by 
error bars.  ns, >0.05; **, P£0.01; ***, P£0.001; ****, P £ 0.0001. 
For CYP2A6(coumarin) reductions in the average b5 signal intensity occur even at very 
low P450:b5 ratios.  At a CYP2A6(coumarin):b5 ratio of 0.1:1 an average of ~68% of the original 
signal remained. As expected with increasing formation of the complex, the average intensities 
continued to decrease as more and more CYP2A6(coumarin) was added.  At 0.2:1 on average 
~41% of the original signal intensity remained (Figure 2.2A, black dashed line).  At 0.3:1, 0.4:1, 
and 0.5:1 approximately 35%, 26%, and 22% of the original signal remained. 
At titration points with ~40-60% reduction in intensity there is enough P450/b5 complex 
formed to clearly identify specific b5 amino acids whose resonances are differentially broadened 
compared to the average.  For CYP2A6(coumarin) this corresponds to the 0.2:1 ratio, which 
reveals a number of b5 resonances were broadened more than one standard deviation (Figure 2.2A, 
red dashed line) from the average (Figure 2.2A, black dashed line), consistent with the involvement 
of these b5 residues in binding CYP2A6(coumarin).  These b5 resonances correspond to residues 
T60, D65, H68, S69, T70, and R73, which cluster on b5 helices 4 and 5 and the loop connecting 
them (Figure 2.2B, red). 
In order to further examine the role of specific b5 residues interacting with 
CYP2A6(coumarin), a series of mutations were examined.  Residues D65 and E49 were selected 
based on 1) their location on the b5 surface, 2) previous evidence that electrostatic pairing is 
important in b5/P450 complex formation (4,8), 3) locations on distinct b5 faces (Figure 2.1A), and 
4) their location in or near binding interfaces identified herein (vide infra).  D65 is located in b5 
a4, while E49 is in b5 a3.  The effects of the charge-neutralizing E49Q and D65N mutations on 
P450 interactions with b5 were evaluated at a P450:b5 ratio of 0.5:1 for all P450 enzymes.  As 
indicated above, under these conditions with wild type b5, the intensity for the average b5 resonance 
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decreases to ~22% of the original signal (Figure 2.2C, left panel).  However, when the b5 mutant 
D65N was mixed with CYP2A6(coumarin) at the same ratio, the overall line broadening was much 
less—to only 76% of the original (Figure 2.2C, middle panel)—consistent with decreased complex 
formation between b5 D65N and CYP2A6(coumarin) compared to wild type b5.  Conversely, 
mixing the b5 mutant E49Q with CYP2A6(coumarin) yielded average line broadening (to ~25%, 
Figure 2.2C, right panel) similar to wild type b5 (22%, Figure 2.2C, left panel), suggesting that this 
mutation did not adversely affect formation of the b5/CYP2A6(courmarin) complex.  These results 
suggest that while the anionic charge on D65 in b5 helix 4 has a significant role in b5 binding to 
CYP2A6(coumarin), that E49 in b5 helix 3 has little to no effect on complex formation. 
In order to relate these structural observations to enzymatic function, coumarin metabolism 
assays were subsequently employed.  Under our conditions there was no significant effect of b5 on 
CYP2A6 7-hydroxycoumarin formation.  Neither kcat or Km were substantially altered in the 
presence of b5 (Figure 2.2D).  Thus, it was not surprising that neither the D65N or E49Q b5 mutants 
altered coumarin metabolism (Figure 2.2D). 
Although the presence of wild type b5 did not alter formation of the 7-hydroxycoumarin 
product, coupling studies revealed that NADPH consumption was reduced by ~60% (Figure 2.2E, 
red).  Thus, wild type b5 increased productive coupling of the reaction by ~1.9-fold (Figure 2.2F, 
red).  The b5 D65N mutant which appeared to decrease b5 binding to CYP2A6(coumarin) in the 
NMR experiments yielded a much smaller decrease in NADPH consumption (Figure 2.2E, green) 
and had similar coupling to when b5 was not present (Figure 2.2F, green vs. black).  The E49Q b5 
which did not appear to alter b5 binding to CYP2A6(coumarin) in the NMR experiments 
functioned more like wild type b5, with a similar NADPH consumption (Figure 2.2E blue vs. red) 
and productive coupling (Figure 2.2 blue vs. red).  Overall wild type and E49Q b5 acted similarly, 
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with 1.9 and 1.6-fold increases in coupling, respectively, while D65N has little effect on coupling 
(a 1.2-fold increase in coupling over reactions without b5). 
While the effects of b5 on NADPH consumption observed herein are consistent with the 
~50% reduction previously reported for CYP2A6 coumarin 7-hydroxylation (33,35), there have 
also been reports that b5 can increase product formation in the range of 1.5 to 2.5-fold (30,33-35).  
However, no such increase in 7-hydroxycoumarin was observed herein.  This apparent discrepancy 
could be due to other differences in experimental conditions.  Of particular importance are the 
protein ratios used for P450:CPR:b5 in catalytic assays.  Experimental evidence to date strongly 
supports mutually-exclusive, overlapping binding sites for CPR and b5 on the proximal face of 
P450 enzymes.  As a result, the ratio and relative affinities of reductase and b5 for a particular P450 
would dictate the observed effects (1).  At high relative ratios and/or affinities, b5 could inhibit 
required reduction of ferric P450 by reductase, while at lower relative ratios and/or affinities b5 
may exert stimulatory effects on other steps of the P450 catalytic cycle to increase coupling (13).  
That b5 significantly inhibits NADPH consumption without changes in product formation suggests 
that for this enzyme(substrate) combination the 1:2:2 ratio may balance the inhibitory and 
stimulatory effects of b5.  However, other significant differences, for example in the species and 
quantitation of b5 and reductase, the presence of lipid, etc., may also contribute to different 
observations across the literature with respect to b5 effects on product formation. 
Regardless, NMR and functional assays herein consistently suggest that D65N in b5 helix 
4 is important in both binding to CYP2A6(coumarin) and in improving coupling of NADPH 
consumption to product formation.  More broadly the NMR data suggest that b5 surface residues 
in both helix 4 and helix 5 are involved in binding to CYP2A6(coumarin). 
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2.4.3 Interaction and catalytic effects of b5 on CYP2E1 
CYP2E1-mediated oxidation of many different substrates is reportedly stimulated by b5.  
These include chlorzoxazone, acetaminophen, aniline, and N-nitrosodimethylamine (28,29).  
Studies suggest that b5 may play a redox role with CYP2E1, as apo-b5 does not increase product 
formation (30,31). 
NMR experiments performed in this study revealed that titration of b5 with 
CYP2E1(chlorzoxazone), like CYP2A6(coumarin), also caused fairly substantial overall 
broadening at moderate P450:b5 ratios.  At 1:0.25, for example, an average of ~55% signal 
remained (Figure 2.3A) and by 1:0.5 only ~28% of the original signal was present (Figure 2.3C).  
The resonances for b5 residues V34, H68, S69, T70, and S76 had signal losses more than one 
standard deviation below this average (Figure 2.3A).  Each of these residues except for V34 reside 
on a5 or the preceding loop (Figure 2.3B). This result is consistent with a monofacial interaction 




Figure 2.3  Interaction of CYP2E1(chlorzoxazone) with 15N-b5 by NMR and b5 modulation of CYP2E1 catalysis.  A, a single 
NMR spectrum of 0.25:1 CYP2E1(CZN):15N-b5 is shown graphically as described in Figure 2A. B, mapping of differentially 
affected residues (red) on human b5.  Legend as described in Figure 2B.  C, resonance intensity plots comparing line broadening 
for wild type b5 and b5 mutants at a 0.5:1 CYP2E1(CZN):15N-b5 ratio.  D, effect of wild type and mutated b5 on Michaelis-Menten 
kinetic parameters of CYP2E1-mediated chlorzoxazone 6-hydroxylation.  Each sample was generated in triplicate with standard 
deviation illustrated by error bars.  Steady-state kinetic constants below are shown with standard deviation.  E, NADPH consumed 
(nmol NADPH/min/nmol CYP2E1) for CYP2E1-mediated chlorzoxazone metabolism at a fixed chlorzoxazone concentration of 
600 µM.  Samples were generated in duplicate with the standard deviation illustrated by error bars.  F, percent coupling of CYP2E1-
mediated chlorzoxazone 6-hydroxylation.  Samples were generated in duplicate with the standard deviation illustrated by error 
bars.  ns, >0.05; **, P£0.01; ***, P£0.001; ****, P £ 0.0001. 
Consistent with the above idea, when evaluated at a consistent P450:b5 ratio of 0.5:1, the 
b5 D65N mutant had less loss of average signal intensity (to 66%; Figure 2.3C, middle panel) than 
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wild type b5 (Figure 2.3C, left panel).   This suggests the D65N b5 mutant reduces binding to 
CYP2E1(CZN).  Notably, the E49Q mutant on the opposite b5 surface had an intermediate effect 
on average signal intensity to ~41% of the original signal. 
Comparison of the mutational effects are clearer when evaluating chlorzoxazone 6-
hydroxylation.  Consistent with previous literature reports (39,40), the effect of wild type b5 on 
2E1 chlorzoxazone 6-hydroxylation was pronounced, with both an increased kcat and decreased Km 
(Figure 2.3D).  Specifically, experiments herein revealed an ~1.7-fold increase in kcat and a 2-fold 
decrease in Km, yielding an ~3.5-fold increase in kcat/Km.   The E49Q b5 mutant performed very 
similar to wild type b5 (Figure 2.3D), suggesting that this residue is not critical.  However, using 
the b5 mutant D65N in these reactions yielded substrate metabolism and steady-state kinetic 
parameters more similar to when b5 was not present at all (Figure 2.3D).  Thus, the surface near 
D65 is important in both b5 binding to CYP2E1(CZN) and stimulation of product formation. 
Coupling between NADPH consumption and product formation are typically very poor for 
CYP2E1 in general.  Under the current conditions in the absence of b5, CYP2E1 coupling was 
only ~3%.  Addition of wild type b5 significantly decreased the NADPH consumption by 48% 
(Figure 2.3E) while increasing product formation, resulting in increased coupling of the reaction 
by ~2.5-fold (Figure 2.3F).  The b5 mutant E49Q behaved similarly to wild type b5 in that NADPH 
consumption was decreased to a similar extent (Figure 2.3E) and combined with increased product 
formation the coupling increased ~3.1-fold (Figure 2.3F)—slightly more than in the presence of 
wild type b5.  The b5 mutant D65N also reduced NADPH consumption (~38%, Figure 2.3E), but 
had little effect on product formation, thus increasing coupling by ~1.7-fold when compared to 
reactions in the absence of b5 (Figure 2.3F).  
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Interactions between b5 and CYP2E1 have previously been studied using cross-linking of 
the complex coupled with mass spectrometry.  Those studies also identified residues on the same 
surface of b5:  D58 and E61 in one study (6) and D58 and D65 in another study (41).  In the latter 
study these interactions were further tested for their functional role and both residues appeared to 
be important in b5 stimulation of the 6-hydroxylation of CZN (41).  Unfortunately, the resonance 
for D58 in b5 has not been assigned, but it would be predicted to experience differential line 
broadening.  Overall the current experiments and previous studies support the concept that the 
region surrounding D65 is involved in both physical interaction between b5 and CYP2E1 and 
increases observed in product formation. 
2.4.4 Interaction and catalytic effects of b5 on CYP3A4 
Influence of b5 on CYP3A4 has been reported broadly.  A number of CYP3A4-mediated 
reactions are stimulated by both holo and apo-b5 (32), which may support a more allosteric role 
for b5.  The current studies evaluated interactions and the effects of b5 on the hypotensive drug 
nifedipine (NFP). 
Using solution NMR to visualize the interaction between CYP3A4(NFP) and b5 it was 
clear that considerable broadening occurred for the average b5 resonance with low concentrations 
of CYP3A4(NFP), suggesting substantial formation of the P450/b5 complex.  With a 
CYP3A4(NFP):b5 ratio of 1:0.1, 85% of the average b5 signal remained.  Additional 
CYP3A4(NFP) resulted in further decreases in the average resonance signal (1:0.2 = ~59%, 1:0.3 
= ~59%, 1:0.4 = ~41%, 1:0.5 = ~29%). 
Although the trends were similar throughout the titration range, differential line broadening 
was most distinct at the 0.2:1 ratio of CYP3A4(NFP):b5 (Figure 2.4A).  Residues of b5 
differentially broadened more than one standard deviation below the average are L41, E42, H44, 
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G47, E48, E49, L51, R52, H68, S69, A72, and R73 (Figure 2.4A).  These residues cluster on 
helices 2, 3, and 5, as well as the loop between helices 2 and 3, and the loop preceding helix 5 




Figure 2.4  Figure 4. Interaction of CYP3A4(nifedipine) with 15N-b5 as determined by NMR and catalytic modulation of b5 
on CYP3A4 mediated metabolism of nifedipine.  A, b5 resonance intensity plot at a 0.2:1 (CYP3A4(nifedipine):15N-b5) ratio 
normalized to the free b5 resonance intensity.  The average (µ) and 1 SD minus average (1s) lines are indicated on the plot and 
base the selection criteria of b5 binding hot-spots.  B, human soluble domain b5 structure (PDB: 2I96) with residues displaying 
differential broadening effects colored in red, residues which are assigned in the NMR spectrum are colored in grey, and unassigned 
residues are colored white.  C, b5 resonance intensity plots comparing the effects of line broadening between WT b5 and b5 mutants 
D65N and E49Q at a fixed 0.5:1 (CYP3A4(nifedipine):15N-b5) ratio.  D, effect of WT b5 and mutants on Michaelis-Menten kinetic 
parameters of CYP3A4 mediated oxidation of nifedipine.  Each sample was generated in duplicate with standard deviation 
illustrated by error bars.  Steady-state kinetic constants below are shown with standard deviation. 
To evaluate the significance of these two surfaces, the b5 mutants D65N and E49Q were 
used to further evaluate the physical interaction between b5 and CYP3A4(NFP).  As with the other 
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enzymes, this was conducted at the P450:b5 ratio of 0.5:1.  While CYP3A4(NFP) resulted in a 
signal reduction to an average of 29% for wild type b5 (Figure 2.4C, left panel), this effect was 
dampened for both b5 mutants.  At this same ratio, ~45% of the average signal remained for D65N 
(Figure 2.4C, middle panel) and ~60% for E49Q (Figure 2.4C, right panel).  Thus, both mutations 
appeared to reduce CYP3A4(NFP)/b5 complex formation.  Notably, even though the overall 
average intensities were higher for each b5 mutant compared to wild type, distinctive differential 
broadening still occurred (Figure 2.4C, middle and right panels), suggesting that specific 
interactions between b5 and 3A4(nifedipine) were not completely disrupted by either single point 
mutation. 
 CYP3A4 converts nifedipine to dehydronifedipine.  The addition of wild type b5 to such 
reactions resulted in inhibition of this reaction (Figure 2.4D).  The addition of b5 both decreased 
the kcat and increased the Km such that the kcat/Km was almost half that when b5 was not present.  
Literature has reported varied stimulation of nifedipine by b5, typically ~1.3 to 3-fold increased 
product formation (30,42).  The differences in these observations may lie in the protein ratios used 
to perform the experiments.  Peng & Auchus (42) used a 1:2:4 ratio in their assays, while Yamazaki 
et al. (30) used a 1:4:1 ratio.  The overlapping b5 and reductase binding sites and the variability in 
these results under different conditions may suggest that at higher concentrations of b5 relative to 
reductase that b5 may begin to outcompete reductase binding, resulting in an overall reduction in 
product formation while lower relative concentrations of b5 could be stimulatory.  However there 
were also other potentially significant differences between how the assays were accomplished in 
different reports, including the presence of lipid, the constructs or buffer used.  CYP3A4-mediated 
metabolism seems to be more sensitive to these environmental parameters than many other P450 
enzymes.  Notably, the single b5 mutants D65N and E49Q had effects on nifedipine oxidation most 
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similar to wild type b5.  Thus, the two-point interactions between CYP3A4(NFP) and b5 are not 
disrupted enough by the single point mutations to ameliorate the effect of b5 on product formation.  
Unfortunately, NADPH consumption and coupling of the 3A4(nifedipine) reaction were not 
successful due to low turnover rates of the reaction under the conditions employed for all the assays 
herein. 
Overall, the differential line broadening of NMR signal suggests that CYP3A4(NFP) 
interacts with b5 over the widest surface area for any of the b5/P450 complexes in this study.  
Interactions between CYP3A4 and b5 have been reported previously in cross-linking and 
mutational studies.  Zhao et al. used mass spectrometry to identify crosslinks between the two 
proteins, residues on human b5 identified were E42 or E48, and E61, which are located on a2, a3, 
and the start of a4 (7).  Another study reported similar residues, where mutations in human b5 
residues E48, E49, D58, and D65 had significant decreases in the ability of b5 to enhance CYP3A4-
mediated testosterone and nifedipine oxidation (42).  Moreover, the b5 double mutant D58G/D65G 
significantly impaired the ability to form cross-links with CYP3A4, while the double mutant 
E48G/E49G had reduced stimulation but was highly dependent on the type of phospholipid in the 
assay (42).  Overall, the current NMR data of the CYP3A4/b5 complex is consistent with reported 
interactions in these previous studies, but highlights additional residues. 
2.4.5 Interaction and catalytic effects of b5 on CYP2D6 
CYP2D6 metabolizes numerous pharmaceuticals including many antidepressants and 
antipsychotics.  It exhibits substantial polymorphism in humans (36).  To assess whether 2D6 
forms a complex with b5 NMR-monitored titrations of 15N-b5 with CYP2D6 were carried out using 
a saturating amount of its common antitussive substrate dextromethorphan (DXM).  The titrations 
resulted in line broadening, consistent with complex formation between the two proteins, but 
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required much higher concentrations of CYP2D6 than any of the other drug-metabolizing enzymes 
in this study.  For example, it takes a 1:1 CYP2D6(DXM):b5 ratio before the average signal 
intensity drops to about half (48%, Figure 2.5A).  In comparison, CYP2A6(coumarin) had more 




Figure 2.5  Figure 5.  Interaction of CYP2D6(dextromethorphan) with 15N-b5 as determined by NMR and catalytic 
modulation of b5 on CYP2D6 mediated metabolism of dextromethorphan.  A, b5 resonance intensity plot at a 1 : 1 
(CYP2D6(DXM):15N-b5) ratio normalized to the free b5 resonance intensity.  The average (µ) and 1 SD minus average (1s) lines 
are indicated on the plot and base the selection criteria of b5 binding hot-spots.  B, human soluble domain b5 structure (PDB: 2I96) 
with residues displaying differential broadening effects colored in red, residues which are assigned in the NMR spectrum are 
colored in grey, and unassigned residues are colored white.  C, b5 resonance intensity plots comparing the effects of line broadening 
between WT b5 and b5 mutants D65N and E49Q at a fixed 0.5:1 (CYP2D6(DXM):15N-b5) ratio.  D, effect of WT b5 and mutants 
on Michaelis-Menten kinetic parameters of CYP2D6 mediated O-demethylation of dextromethorphan.  Each sample was generated 
in triplicate with standard deviation illustrated by error bars.  Steady-state kinetic constants below are shown with standard 
deviation.  E, measurement of NADPH consumed (nmol NADPH / min / nmol CYP2D6) for CYP2D6 dextromethorphan reaction 
at a fixed dextromethorphan concentration of 1 mM.  Samples were generated in duplicate with the standard deviation illustrated 
by error bars.  F, percent coupling of CYP2D6 mediated O-demethylation of dextromethorphan. Samples were generated in 
duplicate with the standard deviation illustrated by error bars.  *: P £ 0.05, **: P £ 0.01, ***: P £ 0.001. 
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 Within these data, the resonances for four residues are broadened more than one standard 
deviation from the average.  G47, E49, H68, and S69 are all differentially broadened (Figure 2.5A).  
On the b5 surface these residues fall into two disconnected regions of b5: the start of a3 (G47 and 
E49) and the loop between a4 and a5 (H68 and S69) (Figure 2.5B).  This data suggests that when 
a complex is formed at higher concentrations of CYP2D6(DXM), that both faces of b5 are 
involved. 
To probe the importance of these distinct faces, the E49Q and D65N b5 mutants were also 
evaluated for their ability to bind CYP2D6(DXM).  At the uniform ratio of 0.5:1, wild type b5 
retained an average signal intensity of 69% (Figure 2.5C, left panel), but both mutants retained 
even more signal intensity.  E49Q and D65N retained ~80%, and ~84% of the signal intensity, 
respectively (Figure 2.5C, right and middle panels).  This is consistent with both charges 
contributing to the b5/CYP2D6(DXM) complex when it does occur. 
To link these structural observations with the effects of b5 on CYP2D6 dextromethorphan 
metabolism, both wild type and mutant b5 proteins were employed in steady-state turnover assays.  
Similar to other in vitro reports on CYP2D6 reactions (30,43), the presence of wild type b5 had no 
significant effects on kinetics of metabolite formation from dextromethorphan (Figure 2.5D).  
Thus, not surprisingly, neither b5 mutant altered product formation. 
When NADPH consumption was measured, however, the presence of b5 did result in a 
two-thirds reduction (Figure 2.5E) and therefore an increase in coupling (from ~23% to ~72%; 
Figure 2.5F).  Each of the single E49Q and D65N b5 mutants also reduced NADPH consumption 
(to ~59% and ~65%, respectively; Figure 2.5E), but not as effectively as wild type b5. Thus the 
~2.0-fold increases in coupling with E49Q and D65N b5, were less than the ~3-fold increase in 
coupling observed for wild type b5 (Figure 2.5F). 
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CYP2D6(DXM) interaction with b5 appeared to be similar to CYP3A4(NFP) in that 
opposite surfaces of b5 were implicated, but extensive broadening of b5 resonances did not occur 
until an equal molar (1:1) ratio of 2D6(DXM):b5, a feature that would be consistent with a weaker 
interaction with CYP2D6(DXM) compared to the other P450/b5 pairs studied.  Most previous 
studies have reported no b5 stimulation of CYP2D6-mediated in vitro bufuralol 1'-hydroxylation, 
tamoxifen 4-hydroxylation, or acetaminophen conversion to its toxic metabolite NAPQI 
(30,31,37,38).  There is one conflicting report indicating that b5 could modulate CYP2D6 
metabolite formation in vivo, as mice humanized for CYP2D6 have decreased bufuralol and 
debrisoqine turnover upon hepatic deletion of the b5 gene.  This could be ameliorated by the 
addition of membranes containing b5 (44). 
2.4.6 Interactions and catalytic effects of b5 on CYP2A6 saturated with p-nitrophenol 
To begin to probe the effects that the identity of a given P450 substrate might have on 
interactions with b5, the interactions of CYP2A6 saturated with p-nitrophenol (pNP) were also 
investigated using NMR and functional assays and compared with earlier results for 
CYP2A6(coumarin). 
When 15N-b5 was titrated with CYP2A6(pNP) differential line broadening was observed 
for very similar residues observed with 2A6(coumarin).  Specifically, b5 residues significantly 
affected were E64, H68, S69, T70, and R73 (Figure 2.6A), which comprise b5 a4, a5, and the 
intervening loop (Figure 2.6B).  However, the average reduction in signal was not as pronounced 
when CYP2A6 was saturated with pNP as it was when CYP2A6 was saturated with coumarin.  
For example, at a P450:b5 ratio of 1:0.5, ~49% of the average b5 signal remained for the 
CYP2A6(pNP)/b5 mixture (Figure 2.6C, left panel), compared to ~22% remaining signal for the 
CYP2A6(coumarin)/b5 mixture (Figure 2.2C, left panel). 
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Figure 2.6  Interaction of CYP2A6(pNP) with 15N-b5 as determined by NMR and catalytic modulation of b5 on CYP2A6 
mediated metabolism of para-nitrophenol.  A, b5 resonance intensity plot at a 0.5:1 (CYP2A6(pNP):15N-b5) ratio normalized to 
the free b5 resonance intensity.  The average (µ) and 1 SD minus average (1s) lines are indicated on the plot and base the selection 
criteria of b5 binding hot-spots.  B, human soluble domain b5 structure (PDB: 2I96) with residues displaying differential broadening 
effects colored in red, residues which are assigned in the NMR spectrum are colored in grey, and unassigned residues are colored 
white.  C, b5 resonance intensity plots comparing the effects of line broadening between WT b5 and b5 mutants D65N and E49Q at 
a fixed 0.5:1 (CYP2A6(pNP):15N-b5) ratio.  D, effect of WT b5 and mutants on Michaelis-Menten kinetic parameters of CYP2A6 
mediated 2-hydroxylation of pNP.  Each sample was generated in duplicate with standard deviation illustrated by error bars.  
Steady-state kinetic constants below are shown with standard deviation.  E, measurement of NADPH consumed (nmol NADPH / 
min / nmol CYP2A6) for CYP2A6 pNP reaction at a fixed pNP concentration of 1.6 mM.  Samples were generated in duplicate 
with the standard deviation illustrated by error bars.  F, percent coupling of CYP2A6 mediated 2-hydroxylation of pNP.  Samples 
were generated in duplicate with the standard deviation illustrated by error bars.  ns: P > 0.05, *: P £ 0.05, **: P £ 0.01. 
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The importance of D65 in forming the complex between b5 and CYP2A6(pNP) was similar 
to that observed with the substrate coumarin.  At the uniform 0.5:1 P450:b5 ratio, the b5 D65N 
mutation retained more signal average intensity (~86%, Figure 2.6C, middle panel) than wild type 
b5, (49% signal remaining, Figure 2.6C, left panel), consistent with reduced complex formation 
for the mutant.  By comparison, under the same conditions the b5 E49Q mutant had an average 
intensity (54%, Figure 2.6C, right panel) much more similar to wild type b5, suggesting that this 
b5 residue does not play a significant role in binding CYP2A6(pNP). 
The effects of these b5 mutants on formation of a CYP2A6(pNP)/b5 complex correlated 
with observations of the kinetics of CYP2A6 para-nitrophenol metabolism to 4-nitrocatechol.  
While wild type b5 modestly stimulated the reaction with both an increase in kcat and decrease in 
Km, resulting in an overall ~1.5-fold increase in catalytic efficiency (Figure 2.6D), the b5 mutant 
E49Q performed very similarly (Figure 2.6D), suggesting this residue is not critical for b5 
simulation of CYP2A6-mediated pNP metabolism.  In contrast, reactions substituting the b5 
mutant D65N resulted in steady-state kinetic parameters more similar to reactions containing no 
b5 at all (Figure 2.6D), suggesting that D65 is critical for the b5 stimulation of CYP2A6-mediated 
pNP oxidation.  It has previously been reported that CYP2A6-mediated pNP oxidation is not 
significantly altered by the presence of b5 (45).  However these results were obtained at a single 
pNP concentration that was relatively low (5 µM) and at a CYP2A6:CPR ratio of 1:5.8 (45).  The 
CYP2A6 pNP assays performed in the current study used a range of pNP concentrations (25 µM 
to 1600 µM), and a CYP2A6:CPR ratio of 1:2.  Thus, differences in experimental parameters could 
contribute to observed differences in b5 stimulation and again suggest that the ratio of b5 to CPR 
is likely to determine the outcome since these two proteins both bind, and likely compete for, the 
P450 proximal surface. 
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Evaluation of NADPH coupling herein revealed that wild type b5 decreased NADPH 
consumption by ~30% (Figure 2.6E) and increased coupling of NADPH consumption to formation 
of the 4-nitrocatechol product formation 1.8-fold (Figure 2.6F).  By comparison, neither the E49Q 
or D65N mutation significantly altered NADPH consumption (Figure 2.6E).  However, the 
increased product formation observed for the b5 E49Q results in a ~1.4-fold increase in coupling, 
while the absence of effect of D65N b5 on product formation and NADPH consumption meant 
coupling was the same as in the absence of b5 (Figure 2.6F).  Thus, these studies also support a 
significant role for D65, but less so for E49. 
Overall, the NMR and mutation data herein suggests that the b5 surface involved in binding 
to CYP2A6(pNP) (Figure 2.6B) is very similar to the b5 surface binding CYP2A6(coumarin) 
(Figure 2.2B).  Mutation studies confirmed that D65 on one face of b5 plays a significant role in 
both CYP2A6/b5 interactions, while E49 on the opposing b5 face had relatively little contribution.  
The greater degree of line broadening occurring with the substrate coumarin compared to pNP is 
potentially consistent with a stronger b5 interaction with CYP2A6(coumarin) compared to 
CYP2A6(pNP).  However, we cannot exclude effects due to possible differences in CYP2A6 
paramagnetism when bound to different ligands.  CYP2A6(coumarin) results in almost complete 
conversion to high-spin, while the CYP2A6(pNP) spin state cannot be readily assessed because of 
significant pNP absorbance in the region of interest.  Using immobilized CYP2A6 and biotinylated 
b5, Guengerich and coworkers found no difference in binding for unliganded CYP2A6 vs. 
CYP2A6 bound to coumarin (38).  Like the structural data, the effects of b5 mutants in turnover 
assays support an important role for D65N in coupling and metabolite formation.  In contrast, 
E49Q performed more similarly to wild type enzyme, suggesting this residue isn’t critical for 
changes in CYP2A6-mediated pNP metabolism.  In both CYP2A6-mediated coumarin and pNP 
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metabolism, b5 increased coupling ~2-fold.  However, this mostly stemmed from a decrease in 
NADPH utilization for coumarin hydroxylation, while for pNP oxidation both decreased NADPH 
consumption and increased metabolite formation contributed.  Thus, though the b5 residues 
binding CYP2A6 are conserved across these two substrates, the effects on CYP2A6 catalysis vary. 
2.4.7 Comparison of P450/b5 interactions across P450 enzymes and substrates 
Of the four human P450 enzymes surveyed all of them were found to interact with 
cytochrome b5 and to do so predominately on at least one of the surfaces surrounding the heme-
exposed face of b5.  This is in general agreement with studies assessing b5 interactions with 
CYP17A1 (4,8), CYP2B4 (14), CYP3A4 (7,42), and CYP2E1 (6,41).  However, the use of NMR 
allows one to simultaneously probe all possible b5 residues involved in the interaction without 
modifying either interacting partner aside from isotopic labeling.  As a result, this study identified 
two b5 surfaces differentially interacting with different xenobiotic P450 enzymes.  All four P450 
enzymes in this study interacted with H68 and S69 on the loop between a4 and a5.  Three of them 
(CYP2A6, CYP2E1, and CYP3A4) additionally interacted with adjacent residues in b5 a5.  In 
addition to this patch on one side of the heme, CYP2D6 and CYP3A4 can also bind to the opposite 
surface of b5, a3, with CYP3A4 having the broadest interaction surface for both regions. Notably, 
CYP2A6 saturated with either coumarin or pNP interacted with the same face of b5, but it remains 
to be seen if this is true for other P450/substrate pairs.  It is clear that across these P450/substrate 
pairs and across the different binding interfaces observed that b5 consistently increases coupling 
but may or may not alter product formation, as was also seen for rabbit CYP2B4 (10). 
While the current NMR studies provide detailed structural information about the P450/b5 
interaction, they are not well suited to the determination of dissociation constants.  However, it is 
notable that CYP2D6(DXM) was a very distinct outlier in terms of the amount of line broadening 
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observed for b5 resonances compared to CYP3A4(NFP), CYP2A6(coumarin or pNP), 
CYP2E1(CZN), and even CYP17A1 in a previous parallel study (8).  Although other explanations 
are possible, the simplest explanation is that this observation is consistent with less complex 
formation.  A study evaluating the physical interaction between P450 enzymes immobilized on a 
plastic plate and biotinylated b5 ranked the affinities as unliganded 
CYP3A4>CYP2A6~CYP2D6>CYP2E1, but noted that much less CYP2D6/b5 complex was 
formed in these experimental conditions as well (38).  
2.5 Conclusions 
 In conclusion, it appears that cytochrome b5 interacts with different drug-metabolizing 
P450 enzymes with both shared and distinct surfaces.  Disruption of these surfaces correlates with 
functional effects on metabolite production and/or NADPH consumption.  Thus in the absence of 
X-ray structures, solution NMR is a high-resolution technique to examine these transient P450 
interactions with other proteins.  Further work remains to map the P450 residues involved in 
binding b5, compare b5 and reductase competition for binding different P450 enzymes, and the 
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Structures of Human Cytochrome P450 1A1 with Bergamottin and Erlotinib Reveal 
Active-Site Modifications for Binding of Diverse Ligands* 
 
3.1 Summary 
Human cytochrome P450 1A1 (CYP1A1) is an extrahepatic enzyme involved in the 
monooxygenation of structurally-diverse compounds ranging from natural products to drugs and 
protoxins.  Because CYP1A1 has a role in human carcinogenesis, inhibiting its activity may 
potentially aid in cancer chemoprevention, whereas utilizing CYP1A1’s oxidative activity could 
help selectively activate anticancer prodrugs. Such potential therapeutic purposes require detailed 
knowledge of CYP1A1’s interactions with potential ligands. Known CYP1A1 ligands also vary 
substantially in size and it has not been apparent from a single existing CYP1A1 structure how 
larger, structurally diverse ligands are accommodated within the enclosed active site.  Here, two 
new X-ray structures with the natural product furanocoumarin bergamottin (2.85 Å) and the lung 
cancer drug erlotinib (3.0 Å resolution) revealed binding orientations consistent with the formation 
of innocuous metabolites and of toxic metabolites, respectively.  They also disclosed local changes 
in the roof of the active site that enlarge the active site and ultimately form a channel to the protein 
exterior.  Although further structural modifications would be required to accommodate the largest 
CYP1A1 ligands, knowing which components of the active site are malleable provides powerful 
                                               
* The contents of this chapter have been published: Bart, A.G. & Scott, E.E. (2018) Structures of Human Cytochrome 
P450 1A1 with Bergamottin and Erlotinib Reveal Active-Site Modifications for Binding of Diverse Ligands. Journal 
of Biological Chemistry, 293:19201-19210. 
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information for those attempting to use computational approaches to predict compound binding 
and substrate metabolism by this clinically relevant monooxygenase. 
3.2 Introduction 
The superfamily of enzymes known as cytochrome P450 monooxygenases has vital 
functions in the metabolism and detoxification of a large variety of drugs and environmental 
toxins.  However, in other instances P450 enzymes have been known to initiate deleterious effects, 
such as the production of reactive intermediates leading to toxic and carcinogenic effects (1).  One 
human CYP enzyme with a particular propensity toward activation of protoxins and 
procarcinogens is CYP1A1, a highly inducible, extrahepatic P450.  CYP1A1 has a preference for 
substrates that are polycyclic aromatic hydrocarbons, such as the environmental pollutant 
benzo[a]pyrene (2).  Due to the roles of CYP1A1 in human carcinogenesis, inhibition of CYP1A1 
activity has been considered as a potential target for cancer chemoprevention (3,4).  In contrast, 
other efforts have been explored for utilizing CYP1A1 oxidative metabolism to activate anticancer 
prodrugs in a tissue selective manner (5,6). 
 To employ either CYP1A1 inhibition or leverage its oxidative power for therapeutic 
purposes requires detailed knowledge of the active site interactions with potential ligands.  A single 
crystal structure of CYP1A1 was previously determined, in complex with the small molecule 
inhibitor a-naphthoflavone (ANF) (7).  This structure revealed a narrow and closed active site not 
much larger than the ANF ligand itself.  Structures of the other family 1 human P450 enzymes, 
CYP1A2 (8) and CYP1B1 (9), also have a single structure each, also containing ANF as the bound 
ligand, and similarly reveal relatively small, planar active sites.  However, xenobiotic-
metabolizing P450 enzymes often have rather flexible structures to accommodate the variety of 
substrates an individual enzyme interacts with, so it can be difficult to extrapolate a range of 
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potential P450/ligand interactions from a single structure.  In particular, a number of known 1A1 
substrates and inhibitors reported in the literature reveal substrate and inhibitor sizes and 
geometries that are not compatible with the dimensions of the currently defined CYP1A1/ANF 
active site. 
 The purpose of the current study was to probe CYP1A1 active site flexibility and 
potentially capture CYP1A1 in conformationally distinct states that would be useful in trying to 
employ CYP1A1 as a potential therapeutic target.  To accomplish this, ligands with high CYP1A1 
affinity and larger sizes were co-crystallized with the CYP1A1 enzyme.  This study describes two 
novel CYP1A1 structures, one with the epidermal growth factor receptor (EGFR) inhibitor 
erlotinib used in anticancer therapy, and another with the furanocoumarin P450 inhibitor 
bergamottin.  These new structures of CYP1A1 provide insight into some of the structural 
rearrangements that allow for the accommodation of diverse CYP1A1 ligand structures.  
3.3 Experimental Procedures 
3.3.1 Protein Expression and Purification 
Expression of human CYP1A1 was performed using a construct encoding a N-terminal 
truncation spanning residues 2-34 that was replaced with the sequence AKKTSS and a C-terminal 
6 histidine tag (7).  Expression was based on the previously described method (7) with a number 
of modifications, for clarity a detailed protocol is listed.  The pKK1A1(MAK)H6 plasmid was 
transformed into E. coli DH5a cells that also included the pGro7 plasmid encoding the chaperone 
GroEl/ES (Takara Bio Inc.).  Transformed cells were grown for 18 hours at 37 °C on minimal 
media plates (MDAG-11) using the formulation described in (10) plus 2 µM thiamine, 100 µg/ml 
carbenicillin, and 20 µg/ml chloramphenicol.  A single colony was picked and inoculated into a 
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50 ml starter culture composed of a defined minimal media (MDAG-135) described in (10) with 
the supplemental thiamine and antibiotics described above.  This starter culture was grown for 16 
hours at 37 °C, 300 rpm shaking.  Expression cultures were grown using 250 ml Terrific Broth 
supplemented with 100 µg/ml carbenicillin, and 20 µg/ml chloramphenicol in 1 liter Erlenmeyer 
flasks.  Typical expression volumes were 3.5 liters.  Expression cultures were inoculated with 3 
ml of the grown starter culture and incubated at 37 °C with shaking (250 rpm) until an optical 
density at 600 nm (O.D.600) of 0.4 was reached.  Arabinose was then added at 2 mg/ml and d-
aminolevulinic acid at 1 mM to the cultures, the temperature and shaking were reduced to 25 °C 
and 225 rpm.  Once O.D.600 reached 0.6, CYP1A1 expression was induced by 1 mM IPTG, cultures 
were grown for an additional 48 hours. 
 A number of modifications were also made to the purification method for CYP1A1 
described in Walsh et al. (7) so a detailed protocol is included herein.  CYP1A1 purification was 
initiated by resuspending cells in resuspension buffer consisting of 20 mM potassium phosphate, 
20% (v/v) glycerol, pH 7.4, 1 mM phenylmethanesulfonyl fluoride, and 0.3 mg/ml lysozyme.  
After stirring for 20 minutes at room temperature, an equal volume of 4 °C water was added and 
stirring continued for an additional 10 minutes at 4 °C.  All subsequent purification steps were 
carried out at 4 °C.  The mixture was centrifuged at 7,500 x g for 15 minutes to isolate spheroplasts, 
which were gently washed with resuspension buffer twice, then resuspended with the aid of a 
Dounce homogenizer in lysis buffer consisting of 500 mM potassium phosphate, 300 mM NaCl, 
20% (v/v) glycerol, pH 7.4, and 1 mM PMSF.  The resulting resuspension was lysed by French 
press using one pass at 16,000 psi internal cell pressure.  Detergent extraction of CYP1A1 was 
performed on this lysate by adding 1% (w/v) CHAPS and stirring for 1 hour.  Cell lysate was 
clarified by ultracentrifugation at 142,000 x g and the supernatant loaded onto a 25 ml pre-
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equilibrated Ni-NTA column (Qiagen) with loading buffer consisting of 100 mM potassium 
phosphate, 200 mM NaCl, 20% (v/v) glycerol, 0.5% (w/v) CHAPS, pH 7.4.  Nonspecifically 
bound proteins were washed off the column using 6 column volumes (CV) of loading buffer and 
10 CV of loading buffer containing 3 mM histidine.  CYP1A1 was then eluted with a linear 
gradient from 3 mM histidine-containing loading buffer to elution buffer (10 mM potassium 
phosphate, 100 mM NaCl, 20% (v/v) glycerol, 0.5% (w/v) CHAPS, 80 mM histidine, 2 mM 
EDTA) over 6 CV.  Eluted fractions possessing a UV absorbance of A419/A280 > 0.8 were pooled, 
diluted 2-fold with CM wash buffer (10 mM potassium phosphate, 100 mM NaCl, 20% (v/v) 
glycerol, 0.5% (w/v) CHAPS, 1 mM EDTA, pH 7.4) and loaded onto three 5-ml pre-equilibrated 
Hi-Trap carboxymethyl-Sepharose fast-flow columns (GE Healthcare) connected in series (total 
15 ml column volume).  The column was washed with 10 CV of CM wash buffer, then CYP1A1 
eluted using a 6 CV linear gradient from CM wash buffer to SEC buffer (50 mM potassium 
phosphate, 500 mM NaCl, 20% (v/v) glycerol, 0.5% (w/v) CHAPS, 1 mM EDTA, pH 7.4) 
followed by 100% SEC buffer for an additional 4 CV.  Fractions with A419/A280 > 1 were pooled 
and concentrated to 4 ml, centrifuged at 10,000 x g to remove any precipitated protein, then loaded 
onto a pre-equilibrated Superdex 200 gel filtration column (GE Healthcare) run with the same SEC 
buffer.  Major peaks exhibiting a A419/A280 > 1.1 were pooled and evaluated by SDS-PAGE, UV-
Vis spectroscopy, and the reduced-carbon monoxide difference assay (11).  Protein was 
quantitated using the Soret in the absolute spectrum in the presence of saturating imidazole and an 
extinction coefficient of 100 mM-1cm-1.  Purified CYP1A1 was flash frozen in aliquots in a dry-
ice/ethanol slurry, and stored at -80 °C until use for experiments. 
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 Full-length human NADPH-cytochrome P450 reductase was expressed and purified as 
described (12).  Purity was assessed by SDS-PAGE.  UV-visible spectroscopy was used to quantify 
reductase using the extinction coefficient of 21.4 mM-1cm-1 at 454 nm for oxidized protein (13). 
3.3.2 CYP1A1 Inhibition Assays 
Ligands were evaluated according to their ability to inhibition of CYP1A1-mediated 
metabolism of the P450 GloTM substrate luciferin-ME EGE (Promega).  Inhibition assays for 
CYP1A1 were performed starting with pre-incubation of CYP1A1 and full-length human 
reductase at a 1:2 ratio (to give a final concentration of 10 nM CYP1A1 and 20 nM reductase in 
reaction) in 400 mM potassium phosphate pH 7.4 buffer at room temperature for 20 minutes.  The 
substrate luciferin-ME EGE was added to the pre-incubated protein to give a final concentration 
during the assay of 4 µM, which is equal to the previously-determined Km.  Protein with substrate 
was then dispensed into a white 96-well microplate (Corning), respective inhibitor added (serially 
diluted stocks in DMSO to maintain constant 0.5% solvent concentration) and incubated at room 
temperature for 3 minutes prior to starting reactions with NADPH at a final concentration of 100 
µM in 50 µl total reaction volume.  Reactions were allowed to proceed at room temperature for 45 
minutes.  Reactions were stopped and development of luminescence was initiated by the addition 
of 50 µl of the Luciferin Detection Reagent with esterase (Promega).  To convert luminescence 
into activity, a standard curve using D-luciferin was performed alongside the reaction samples.  
Control samples without inhibitor and controls to determine background luminescence were also 
used.  Prior to reading the luminescence the microplate was incubated at 25 °C for 20 minutes.  
The luminescence signal was measured by a GloMaxâ Discover plate reader (Promega) at 25 °C 
using a 1 second integration time per well.  The data were fit to the dose response-inhibitor (four 
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parameter) equation to determination of the IC50 (Graph-Pad Prism).  Each inhibitor concentration 
was evaluated in duplicate. 
3.3.3 Ligand Binding Assays 
Binding of ligands to CYP1A1 was monitored using a double-beam UV-visible 
spectrophotometer (Shimadzu Scientific Instruments) at 20 °C.  CYP1A1 was diluted into SEC 
buffer to a concentration of 1 µM, and equally divided into the two chambers of two 1-cm path 
length tandem cuvettes (sample and reference).  The other chamber contained only SEC buffer.  
Stock solutions of ligands were created in DMSO (0.2-10 mM).  Ligands were titrated into the 
CYP1A1-containing chamber of the sample cuvette and the buffer only chamber of the reference 
cuvette.  An equal volume of DMSO was titrated into the buffer chamber of the sample cuvette 
and the CYP1A1-containing chamber of the reference cuvette to correct for solvent and dilution 
effects to the spectra.  Absorbance was monitored from 300 to 500 nm.  Dissociation constants 
were determined by non-linear regression fitting (GraphPad Prism) of the change in absorbance 
versus ligand concentration using a tight binding equation described previously (14). 
3.3.4 Co-Crystallization, Data Collection, Structure Determination 
Purified CYP1A1 was concentrated to 17 mg/ml (bergamottin) or 20 mg/ml (erlotinib) by 
three iterative centrifugal ultrafiltration steps that involved dilution with SEC buffer containing 
0.4 M ammonium nitrate and either 20 µM bergamottin or 20 µM erlotinib.  Crystals of CYP1A1 
with the respective ligands were grown using the sitting drop vapor diffusion method in either 24-
well plates (bergamottin) or 96-well plates (erlotinib).  Plates were set up at 20 °C by mixing 1 µl 
CYP1A1/bergamottin with 1 µl of a crystallization solution (0.2 M potassium phosphate dibasic, 
20% (w/v) PEG 3350, 15% (v/v) glycerol) or 0.75 µl CYP1A1/erlotinib with 0.75 µl crystallization 
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solution (0.2 M potassium phosphate dibasic, 20% (w/v) PEG 3350, 10% (v/v) glycerol, 0.5% 
(w/v) n-dodecyl-N,N-dimethylamine-N-oxide).  Plates were sealed and equilibrated against 300 
µl (bergamottin) or 50 µl (erlotinib) of the respective crystallization solution at 4 °C.  Triangular 
prism crystals grew over 2-3 days and were harvested at 5-6 days.  CYP1A1/bergamottin crystals 
were cryoprotected using the bergamottin crystallization solution containing 30% (w/v) PEG 3350, 
while CYP1A1/erlotinib crystals were cryoprotected with erlotinib crystallization solution 
containing 20% (v/v) glycerol.  Crystals were flash cooled in liquid nitrogen and diffraction data 
were collected on beamline 9-2 at the Stanford Synchrotron Radiation Lightsource.  Integration of 
the data and scaling were performed using XDS (15) and AIMLESS (16).  Structures were solved 
using molecular replacement via Phaser (17) with the CYP1A1/ANF structure (7) as a search 
model, (PDB 4I8V, molecule A) resulting in log likelihoods of 20,276 (1A1/Bergamottin) and 
12,779 (1A1/Erlotinib).  Building and refinement of the models were iteratively performed using 
the programs Coot (18) and PHENIX (19) respectively.  Torsion-angle NCS restraints were used 
during refinement with Chain A as the reference selection for the other NCS-related chains.  
Ligand restraints were generated using PHENIX eLBOW (20) with AM1 geometry optimization.  
Active site void volumes were calculated using VOIDOO (21), with probe radius = 1.4 Å and grid 
spacing = 1.0.  All figures were prepared using PyMOL (22). 
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Data Collection   
   Space Group P212121 P212121 
   Cell Dimensions (Å) 65.33, 194.76, 236.14 64.86, 195.08, 238.01 
   Molecules/a.u. 4 4 
   Resolution (Å)a 39.36-2.85 (2.91-2.85) 39.02-2.99 (3.07-2.99) 
   Total reflectionsa 472,057 (27,104) 404,855 (24,710) 
   Unique reflectionsa 71,615 (4,361) 61,715 (4,346) 
   Redundancya 6.6 (6.2) 6.6 (5.7) 
   Rpima 0.060 (0.671) 0.053 (0.755) 
   <I/σ(I)> a 8.6 (1.7) 9.6 (1.3) 
   CC1/2a 0.994 (0.499) 0.997 (0.698) 
   Completeness (%)a 99.7 (97.1) 99.6 (96.1) 
Refinement   
   Resolution (Å) 39.36-2.85 38.98-3.00 
   No. reflections 71,343 61,261 
   R/Rfree (%) 0.204 / 0.240 0.241 / 0.261 
   Ramachandran (%) 
   Favored/Allowed/Outliers 97.42 / 2.53/ 0.05 97.61 / 2.39 / 0 
   No. non-H atoms/B factors (Å2)   
       Protein 15,006 / 75.31 14,852 / 89.10 
       Ligand 100 / 65.57 103 / 80.85 
       Heme 172 / 54.68 172 / 77.59 
       CHAPS 61 / 98.12 56 / 95.69 
       Glycerol 12 / 83.38 - / - 
       Water 46 / 46.14 4 / 66.56 
   RMSD bond (Å) 0.004 0.004 
   RMSD angle (°) 0.655 0.589 
   Coordinate error  
   (max. likelihood based) (Å) 0.37 0.40 
a Statistics for highest resolution shell shown in parentheses. 
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3.4 Results and Discussion 
3.4.1 Inhibition of CYP1A1 by Structurally Diverse Ligands 
 The previous crystal structure of CYP1A1 was with the planar, fused multicyclic ligand a-
naphthoflavone enclosed within a narrow, planar active site (7).  Many CYP1A1 substrates and 
inhibitors do include features of various fused aromatic ring systems, often elongated in one 
dimension.  The active site cavity for the CYP1A1/ANF structure conforms to these aspects, but 
it is not particularly helpful in discerning how other CYP1A1 ligands with larger sizes and/or 
varying dimensions are accommodated by the active site.  While some human cytochrome P450 
enzymes have multiple structures demonstrating significant flexibility in active site conformation 
to accommodate different ligand classes, the CYP1 family enzymes have often been assumed to 
be comparatively static, in part because of the absence of structural evidence otherwise.  To probe 
the malleability of the CYP1A1 active site, reported CYP1A1 ligands (substrates and/or inhibitors) 
that possessed a range of different chemical features and shapes were identified as potential 
candidates for crystallography.  The ligands were broadly segmented into the following classes: 
azole inhibitors, tyrosine kinase inhibitors, anticancer prodrugs, and natural products from the 
furanocoumarin and stilbenoid classes. 
 To provide a ranking according to the potency of their interactions with CYP1A1, IC50 
values were determined (e.g. Table 3.2) for each ligand.  About half of the compounds tested had 
reasonably potent inhibition of CYP1A1-mediated activity (Table 3.2), defined herein as IC50<1 
µM.  This series included a number of azoles, which are often potent, broad spectrum P450 
inhibitors.  Not surprisingly then, the azoles clotrimazole, miconazole, and tioconazole were three 
of the four most potent inhibitors.  These are all smaller azoles (MW 344-417 g/mol) with a 
compact overall structure.  Larger azoles with extended structures like ketoconazole and 
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posaconazole (MW 531 and 700 g/mol) were 4- to 7-fold less potent but still had IC50 values in 
the nanomolar range.   However, fluconazole which is smaller and has an overall structure more 
similar to miconazole and tioconazole did not significantly inhibit CYP1A1, so size is certainly 
not the only consideration. 
 
Figure 3.1  Representative IC50 Curves.  Determination of IC50 values was performed using duplicate samples at each inhibitor 
concentration.  Non-linear curve fitting to the data was accomplished using a four-parameter logistic curve in GraphPad Prism. 
One of the interests of CYP1A1 in human health is its role in cancer, both as a potential 
generator of carcinogenic species and in the metabolism of certain anti-cancer drugs, such as 
tyrosine kinase inhibitors.  Some of the tyrosine kinase inhibitor drugs CYP1A1 has been 
demonstrated to interact with include erlotinib (23), imatinib (24), and ponatinib (25), which were 
also tested for their inhibitory potency.  These drugs displayed nanomolar to low micromolar IC50 
values, with erlotinib being the most potent (IC50 = 180 ± 10 nM).  Again, it was the more extended 
imatinib and ponatinib that were less potent inhibitors (IC50 >1 µM), perhaps indicating that they 
might not fit the CYP1A1 active site as well.  Metabolism of erlotinib and ponatinib by CYP1A1 
have been reported to generate reactive electrophilic metabolites that may contribute to some of 
the observed life-threatening toxicities associated with these drugs (25,26). 
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CYP1A1 has yet another connection to cancer therapeutics in that the tissue location and 
metabolic capability of CYP1A1 have suggested its utility in the activation of several different 
prodrugs to reactive electrophilic species leading to DNA damage and cell death (6,27,28).  This 
included the benzothiazole GW610 (29), which current results suggested had a fairly potent IC50 
of 300 ± 80 nM.  In contrast, the compound AQ4N is activated by CYP1A1 to the active 
topoisomerase inhibitor AQ4 under hypoxic conditions (30), but under normoxic conditions 
evaluated herein showed essentially no inhibition of CYP1A1. 
Two natural products were suggested as CYP1A1 ligands in the literature and were tested.  
The first was the furanocoumarin bergamottin found in grapefruit and other citrus and well known 
to inhibit CYP3A4 and cause variations on CYP3A4-mediated metabolism of common drugs (31).  
Bergamottin also displayed potent inhibition of CYP1A1, with an IC50 of 140 ± 20 nM.  
Bergamottin also inhibits CYP1A2, but with attenuated potency (32,33).  This could potentially 
be due to size and shape complementarity of the respective active sites.  At least in the ANF-bound 
structures, CYP1A1 possesses a slightly larger active site volume compared to CYP1A2 (7), which 
may allow for greater accommodation of the larger furanocoumarin compounds.  Additionally, 
comparison of selective ligand features between CYP1A1 and CYP1A2, suggested a preference 
of CYP1A1 for ligands with longer strip-like geometry, while CYP1A2 selective compounds were 
more triangular in shape (34).  The other natural product suggested in the literature to interact with 
CYP1A1 was the trans-stilbene resveratrol found in red wine.  Herein resveratrol was an order of 
magnitude less potent than bergamottin at inhibiting CYP1A1 activity.  The resveratrol IC50 value 
of ~1.4 µM was more similar to the tyrosine kinase drugs imatinib and ponatinib. 
 A number of other diverse compounds ranging from moieties such as imidazole and indole 
to the analgesic acetaminophen were also tested for inhibitory potency towards CYP1A1.  
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Additionally endogenous fatty acids, such as arachidonic acid (35) have been reported to be 
efficiently metabolized by CYP1A1.  The small chemical moieties indole, imidazole, and drug 
acetaminophen resulted in exceedingly weak inhibition of CYP1A1 activity, with IC50 values 
greater than 100 µM.  The binding affinity of these small compounds are likely weak, and may not 
make extensive interactions with the active site.  The endogenous arachidonic acid substrate was 
only weakly inhibitory with an IC50 value of 3.8 µM. 
 Overall, this screen of many CYP1A1 ligands suggested that several of the imidazole 
azoles, bergamottin, and erlotinib had significantly different structures from a-naphthoflavone but 
IC50 values less than 200 nM and might be good candidates for structural studies probing the 
flexibility of the CYP1A1 active site. 
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Table 3.2  Inhibition of CYP1A1 given as IC50 ± standard error. 
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3.4.2 Characterization of Bergamottin and Erlotinib Binding to CYP1A1 
As examples of structurally diverse CYP1A1 ligands with relatively low IC50 values, the 
binding of bergamottin and erlotinib were further characterized by determining their affinities and 
binding modes via UV spectroscopy.  Tandem cuvettes were employed to blank out the intrinsic 
absorbance of both bergamottin and erlotinib, which overlap the wavelength range of the P450 
heme Soret peak monitored to detect ligand binding.  Titration of CYP1A1 with either bergamottin 
or erlotinib resulted in a blue shift of the Soret peak, with a peak forming at ~391 nm and a trough 
at 427-429 nm when observed in difference mode (Figure 3.2A & B).  Such a Type I binding 
profile is indictive of displacement of the water from the heme iron.  The Kd for bergamottin was 
370 ± 40 nM (Figure 3.2A), which is in a similar range to its IC50 value determined herein and the 
dissociation constant for ANF (~300 nM) reported previously (7).  The Kd measured for erlotinib 
was 1.07 ± 0.04 µM (Figure 3.2B), indicating that erlotinib binds to the CYP1A1 resting state with 
lower affinity compared to bergamottin and ANF.  However both ligands have affinities and 
solubilities that can support saturation of CYP1A1 for structure determination. 
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Figure 3.2  Bergamottin and erlotinib binding to CYP1A1.  Absorbance difference spectra of CYP1A1 (1 µM) titrated with 
increasing concentration of A) bergamottin and B) erlotinib reveal type I shifts, with peaks forming at ~391 nm and troughs at 427-
429 nm.  Insets are the change of absorbance (peak-trough) vs. compound concentration fit by nonlinear regression to the tight-
binding equation.  Kd and absorbance maximum (Amax) are given ± standard error. 
3.4.3 Overall CYP1A1 X-Ray Structures 
Structures were subsequently determined with both bergamottin and erlotinib at resolutions 
of 2.85 Å and 3.0 Å, respectively. Both structures solved in the P212121 space group with very 
similar unit cell dimensions, and contained four copies of the protein within the asymmetric unit.  
For both structures, all four copies within the asymmetric unit were very similar, though two of 
them tended to be more disordered with regions of weaker electron density for some protein side-
chains and the active site ligand.  The 1A1/erlotinib structure disorder prevented reliable modeling 
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of the loop between E and F helices in one molecule (D). Like the previous CYP1A1/ANF crystal 
structure, the loop connecting the H and I helices had significant disorder in both the 
CYP1A1/bergamottin and CYP1A1/erlotinib structures of most molecules and could only be 
reliably modeled in one chain for each respective co-crystal structure.  This most complete and 
best defined molecule (molecule A) will be specifically referenced in the following discussion. 
The overall tertiary structure of the two new CYP1A1 ligand complexes with bergamottin 
and with erlotinib are highly similar to the previously determined structure of CYP1A1 with the 
ligand ANF (Figure 3.3).  Compared to the previous CYP1A1/ANF structure, the new structures 
with bergamottin and erlotinib both had root mean square deviations of 0.37 Å for Ca atoms.  A 
distinctive feature of the previous CYP1A1/ANF structure—one conserved in the homologous 
CYP1A2 and CYP1B1 structures but not other human P450 enzymes—is a disruption in the helical 
character of the F helix as it passes over the active site.  This five-residue break in the F helix is 
also present in the two new CYP1A1 structures.  It has been postulated that this disruption of the 
F-helix could be significant in terms of allowing flexibility in substrate binding and dynamics (7). 
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Figure 3.3 CYP1A1 structures bound to bergamottin (orange), erlotinib (green), and previously determined 𝛼-
napthoflavone (purple), all superimposed by Ca atoms. 
The density does support the localization of some additional small molecules from the 
crystallization solutions.  In both structures a molecule of the detergent CHAPS is found on the 
protein surface oriented lengthwise along the G helix of some molecules, distant from the active 
site. 
3.4.4 Bergamottin Binding to CYP1A1 
 In all four of the molecules in the asymmetric unit bergamottin is positioned similarly in 
the CYP1A1 active site.  Its fused psoralen ring system is oriented distal from the heme, with  p-
p interactions to the parallel side chain of the F-helix residue Phe-224.  The geranyloxy chain of 
bergamottin extends towards the heme, bending at the 3’ position so that the rest of the chain lies 
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over the heme, slightly off center of the iron.  The terminal dimethyl portion of this ligand chain 
is directed toward a cluster of hydrophobic residues that are part of the b4 and K/b1-4 loops, 
including Val382 (Figure 3.4A).  These residues close off the bottom portion of the CYP1A1 active 
site cavity opposite from the I-helix.  There is a hydrogen bond formed between the ketone oxygen 
of the bergamottin psoralen moiety and the side chain nitrogen of Asn222.  This combination of 
interactions between bergamottin and the CYP1A1 active site result in the 6' and 7' carbons of the 
geranyloxy chain closest to the heme iron, at distances of 4.8 Å and 5.1 Å, respectively, suggesting 
that oxidation might occur at one or more of these positions. 
 
Figure 3.4  CYP1A1 active site interactions with A) bergamottin and B) erlotinib.  Shown are polar CYP1A1 active site 
residues (sticks) that make hydrogen-bonds (black dashed lines) with the ligands.  Electron density is shown as 2Fo – Fc simulated 
annealing composite omit maps (blue mesh) contoured at 1.0 s. Heme is shown as black sticks.  Key sites of metabolism are 
indicated by red dashed lines to the heme iron.  Distances for hydrogen-bonds and ligand-heme iron distances (red dashed lines) 
are shown in Å. 
Reports of bergamottin metabolism by P450 enzymes in the literature are few but important 
in terms of the “grapefruit juice effect” wherein metabolism of the furan ring of the psoralen moiety 
results in reactive intermediates causing mechanism-based inhibition of the P450 enzyme, while 
metabolism on the geranyloxy chain produces stable metabolites (36).  Metabolism by CYP1A1 
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has not been previously reported, but the Hollenberg group investigated bergamottin metabolism 
by CYP3A4 (31), CYP3A5, and CYP2B6 (36).  Bergamottin is a potent mechanism-based 
inhibitor of CYP3A4, consistent with metabolism on the psoralen ring.  For CYP3A5 the primary 
metabolite involved oxidization at the 1'-carbon of the geranyl-oxy chain leading to cleavage of 
the geranyl chain to form bergaptol.  In contrast, CYP2B6 produced major metabolites from 
oxidations on the terminal end of the geranyl-oxy chain.  Both CYP3A5 and CYP2B6 were also 
capable of generating bergamottin metabolites that formed glutathione conjugates following furan 
ring oxidation, but the dominant metabolite was different for each enzyme, suggesting different 
preferences for bergamottin orientation in the respective active sites. 
The current crystal structure of CYP1A1 with bergamottin suggests that this enzyme 
prefers to bind bergamottin more like CYP2B6 than CYP3A5 and would be more likely to oxidize 
the terminal portion of the geranyl chain.  The current CYP1A1 structure does not indicate the 
potential for complete reorientation of bergamottin within the active site cavity, which would be 
necessary for reactive metabolites.  Though this cannot be ruled out, the observed orientation 
would suggest CYP1A1 would have less tendency towards bergamottin bioactivation compared to 
other P450 enzymes, due to the specific interactions with the CYP1A1 active site cavity that dictate 
ligand orientation. 
3.4.5 CYP1A1 Bergamottin Metabolism 
 In order to determine whether the binding pose for bergamottin in the CYP1A1 active site 
is consistent with metabolite generation, turnover assays were performed with human CYP1A1 
and human NADPH-cytochrome P450 reductase.  CYP1A1 produced at least four major 
metabolites at different substrate concentrations.  At low concentrations of bergamottin only one 
major metabolite was observed.  At higher concentrations a second metabolite was observed, then 
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a third metabolite (Figure 3.5).  The third metabolite coelutes with authentic 6',7'-
dihydroxybergamottin, while the other two metabolites are slightly less polar, suggesting they are 
likely to be the individual 6'-hydroxy and 7'-hydroxy products.  The identity of the much more 
polar fourth metabolite is unknown.  Overall, however, the metabolite profile is generally 
consistent with the binding orientation observed in the X-ray structure. 
 
Figure 3.5  Bergamottin metabolism by CYP1A1 yields one major metabolite that coelutes with authentic 6',7'-
dihydroxybergamottin (26.6 min) and two slightly less polar metabolites (27.6 and 27.7 min) that occur at lower substrate 
concentrations and are likely the individual 6'-monohydroxy and 7'-monohydroxy metabolites.  Thus at least three major 
metabolites are consistent with the bergamottin orientation observed in the X-ray structure.   
3.4.6 Erlotinib Binding to CYP1A1 
Erlotinib, marketed as Tarceva, is a tyrosine kinase inhibitor that inhibits the epidermal 
growth factor receptor (EGFR) and was approved for treatment of non-small cell lung cancer 
(NSCLC).  The use of erlotinib has been related to a number of adverse drug effects including rash 
(37), skin toxicities (38), and diarrhea (39) that vary in severity, with more life-threating effects 
such as pulmonary toxicity (40) and toxic epidermal necrolysis (Tarceva package insert).  
Metabolism of erlotinib and other kinase inhibitors by P450 enzymes can generate reactive 
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metabolites and could explain some of the associated toxicities of these drugs (25,26).  In humans, 
erlotinib is metabolized primarily by P450 enzymes CYP3A4, CYP3A5, and CYP1A1, with the 
latter extrahepatic enzyme playing an important role in the lung, and in pharmacokinetic variability 
(23).  Of particular clinical significance is the inducibility of CYP1A1.  Tobacco smoke can 
increase CYP1A1 expression levels in the lung (41,42), which in turn can have large effects on 
erlotinib clearance (43,44).  As a result, higher concentrations of erlotinib may be required to treat 
NSCLC in smokers (45). 
Cocrystallization of CYP1A1 with the EGFR inhibitor erlotinib revealed this ligand 
binding in a slot-like, planar active site, with its planar quinazoline core distal to the heme making 
p-p interactions with the aromatic side chain of Phe224 (Figure 3.4B).  The terminal alkyne moiety 
is clearly positioned above the heme and extends into a pocket formed by hydrophobic residues of 
the b4 and K/b1-4 loops, similar to positioning of the geranyloxy chain of bergamottin.  The two 
2-methoxyethoxy sidechains of erlotinib extend away from the heme towards the roof of the 
CYP1A1 active site, one positioned between the F and G helices and the other sidechain protruding 
between the F and I helices underneath the F helix break.  Erlotinib appears to potentially form a 
number of hydrogen bonding contacts with the CYP1A1 active site (Figure 3.4B).  Two of these 
involve Asp320.  If protonated, Asp320 is positioned to be a hydrogen bond donor to one of the 
side chain oxygens.  Asp320 also appears to make a water-mediated interaction with the nitrogen 
connecting the quinazoline and phenyl-acetylene moieties but this active site water could only be 
reliably modeled into molecule A and B, which had the best electron density.  Additionally, 
Asp222 makes a potential hydrogen bonding interaction with an oxygen on the methoxyethoxy 
sidechain (Figure 3.4B).  The subterminal oxygen of the other side chain hydrogen bonds with the 
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side chain Asn255.  Finally, a nitrogen of the quinazoline core forms a water-mediated hydrogen 
bond the backbone of Ser116. 
The primary metabolic reactions in humans are O-demethylation of the methoxyethoxy 
side chain, oxidation of the terminal alkyne, and hydroxylation of the para position on the phenyl-
acetylene moiety (46). The position of erlotinib observed in the CYP1A1 crystal structure is 
consistent with metabolism of either the terminal alkyne carbon or the para carbon of the aromatic 
aniline ring.  The distances to the iron are 4.6 Å and 4.9 Å for the terminal alkyne and para carbons, 
respectively.  Oxidation at these two positions of erlotinib are significant in terms of their potential 
to produce reactive species that might underlie erlotinib-associated toxicities.  The 4-hydroxylation 
of the phenyl-acetylene carbon results in formation of a para-hydroxyanaline, which can be 
oxidized by P450 to form the reactive quinoneimine.  Conversely, oxidation of the terminal alkyne 
can result in reactive oxirene or ketene intermediates (26). 
Li et al. detected glutathione conjugates of erlotinib metabolism by CYP1A1.  These 
conjugates were formed on the aniline ring, consistent with CYP1A1 hydroxylation at the para 
position and consistent with the orientation observed herein.  Mechanism-based inactivation of 
CYP1A1 was not observed, suggesting the initial hydroxylated product may be released prior to 
formation of the reactive quinoneimine (26).  Indeed, p-hydroxyerlotinib is the major metabolite 
circulating in human plasma (26).  In contrast, CYP3A4 and CYP3A5 oxidize the terminal alkyne 
(47), resulting in reactive intermediates that do result in adduction of these P450 enzymes and 
mechanism-based inactivation.  The fact that CYP1A1 is not inactivated suggests that CYP1A1 
does not modify the terminal alkyne.  Reports indicate that both CYP3A4/5 and CYP1A1 (23) can 
also generate active, non-toxic des-methyl metabolites of the side chains, suggesting that both 
enzymes can bind erlotinib in multiple orientations. 
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3.4.7 Comparison of all Three CYP1A1 Structures Yields Insights into Residues Involved 
in Accommodating Diverse Ligand Structures 
 The new co-crystal structures of CYP1A1 in this study have many overall structural 
elements consistent with the previous CYP1A1/ANF structure.  Thus, the CYP1A1 structure 
accommodates bergamottin and erlotinib with minimal perturbations of the tertiary and secondary 
structure.  Both bergamottin and erlotinib are positioned in the active site with their respective 
planar components in the same plane that ANF adopted and other known CYP1A1 ligands that 
were previously docked into the experimental CYP1A1/ANF structure (7).  This common binding 
plane is likely driven by the conserved orientation of Phe224 which has favorable p-p interactions 
and sandwiches the planar ligand core against the I helix. 
 
Figure 3.6  Active site cavities for CYP1A1 structures with A) α-naphthoflavone, B) bergamottin, and C) erlotinib.  The side 
chains of Asn222 and Leu254 (sticks) display altered positioning between the structures, contributing to expansion of the CYP1A1 
active site cavity. 
 Within this overall context, however, important differences arise in a key localized portion 
of the structure.  The unusual break in the F helix for the CYP1A1 structure appears to assist in 
accommodation of different CYP1A1 ligands.  While the active sites with ANF and bergamottin 
are enclosed (Figure 3.6A&B), in the erlotinib structure Asn222 in the F helix break adjusts its 
positioning, resulting in an opening that extends the active site cavity to the surface (Figure 3.6C).  
One of the methoxyethoxy chains of erlotinib extends into this channel between the F-helix break 
 92 
and portions of the b4-loop.  Since the open channel in the CYP1A1/erlotinib structure extends to 
bulk solvent, the end of the channel was artificially closed to permit comparison of active site 
volumes.  It appears that concerted torsioning of the Asn222 and Leu254 side chains approximately 
doubles the volume of the CYP1A1/erlotinib active site (806 Å3) compared to those for the 
CYP1A1/ANF (408 Å3) and CYP1A1/bergamottin (456 Å3) structures (Figure 3.6).  In the 
CYP1A1/ANF structure, this channel is closed by hydrogen bonding between Asn222 and I helix 
residue Asp320 (Figure 3.6A).  In the CYP1A1/bergamottin structure, Asn222 is torsioned in yet 
a different way, breaking the interaction with Asp320 but not opening the channel (Figure 3.6B).  
In each case the various rotamers of Asn222 (Figure 3.7) are accommodated by differential 
positioning of the spatially adjacent G helix residue Leu254.  Larger CYP1A1 substrates and 
inhibitors might utilize an expanded version of this channel to access the active site.  Certainly the 
channel as currently observed would have to widen further to accommodate entry/exit of just the 




Figure 3.7  CYP1A1 structures with erlotinib (green), bergamottin (orange), and ANF (purple) are overlaid with the active 
site cavity for erlotinib (grey mesh).  F helix residue Asn222 and adjacent G helix Leu254 (sticks) display altered positioning 
between the structures, and are in part responsible for expansion of the 1A1 active site cavity.  The orientation is from the protein 
distal surface looking down through the active site roof to the heme (black sticks). 
3.5 Conclusions 
In summary, two new experimental structures with erlotinib and bergamottin are consistent 
with known metabolism.  The erlotinib structure suggests that CYP1A1 participates in the first 
step in formation of chemically reactive metabolites that may contribute to lung and other 
toxicities.  On the other hand, bergamottin interacts with CYP1A1 in an orientation suggestive of 
innocuous metabolite generation.  In combination, the known structures suggest that while many 
of the structural elements of the CYP1A1 active site are rigid, that structurally diverse, somewhat 
larger ligands can be accommodated by local modifications.  The structures of CYP1A1 with 
bergamottin and erlotinib in this study establish one approach by which CYP1A1 accommodates 
somewhat larger ligands.  This consists of side-chain repositioning in the roof of the CYP1A1 
active site, even generating a channel to the surface in the erlotinib structure.  It is possible that 
even larger CYP1A1 ligands like ketoconazole and posaconazole might be accommodated by 
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further expanding the channel observed in the erlotinib structure.  Knowing which components of 
the active site are malleable and which are not provides powerful information for those attempting 
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Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate* 
 
4.1 Summary 
The human cytochrome P450 1A1 (CYP1A1) is well-known for chemical activation of 
procarcinogens and often has a substrate scope towards small and highly planar compounds.  
Substrates deviating from these characteristics are certainly known, but how these larger and 
nonplanar substrates are accommodated and oriented within the CYP1A1 active site is not 
understood.  Herein a new X-ray structure of CYP1A1 bound to the pan-Pim kinase inhibitor GDC-
0339 reveals how the CYP1A1 active site cavity is reconfigured to bind larger and nonplanar 
compounds.  The shape and size of the cavity are controlled by structural elements in the active 
site roof, with major changes in the conformation of the F helix break and relocation of Phe224 
from the active site to the protein surface.  This altered CYP1A1 active site architecture is 
consistent with the proposed mechanism for CYP1A1 generation of an unusual aminoazepane-
rearranged metabolite for this substrate. 
4.2 Introduction 
 Many human cytochrome P450 enzymes are promiscuous monooxygenases capable of 
metabolizing chemically and morphologically diverse sets of drugs, environmental contaminants, 
                                               
* The contents of this chapter have been accepted for publication: Bart, A.G., Takahashi, R.H., Wang, X., & Scott, 
E.E. Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate. Drug Metabolism and 
Disposition. 
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and endogenous compounds.  While some generalizations can be made about the substrate scope 
of an individual P450 enzyme based on known active site characteristics such as size and features 
of the residues lining the cavity (1,2), there are also many examples of validated substrates and 
inhibitors that do not conform to known active site bounds.  This indicates that we do not yet 
understand the full range of active site malleability for different human P450 enzymes.  These 
limitations in our knowledge of the conformational flexibility of a P450 enzyme significantly 
retards the utility of structure to predict drug metabolism, carcinogen/toxin activation, and to 
design selective P450 inhibitors. 
Cytochrome P450 1A1 is a human enzyme most well-known for its role in chemical 
carcinogenesis (3).  Until recently there was only a single structure of human cytochrome P450 
1A1 (CYP1A1) available (4).  This structure, solved with the compact, highly planar ligand ɑ-
naphthoflavone (ANF; molecular weight 272 g/mol) revealed a spatially complementary enclosed, 
highly planar active site.  This void is compatible with a subset of known CYP1A1 ligands (4) 
with low molecular weights (200-500 g/mol) and compact structures like benzo[a]pyrene (252 
g/mol), but not its larger and nonplanar CYP1A1 substrates.  While CYP1A1 has not historically 
not been recognized for playing an extensive role in drug metabolism, Jungmann and Lang recently 
reported that screening a library of 650 drugs revealed ~35% had appreciable metabolism by 
CYP1A1 (5).  This diverse library probably represents the most unbiased evaluation of CYP1A1 
substrates.  Those with appreciable metabolism typically have molecular weights from 200-500 
g/mol, but surprising exceptions of larger compounds include the macrolide antibiotic 
troleandomycin (813 g/mol), the muscle relaxant atracurium (929 g/mol), the macrolide antibiotic 
tylosin (916 g/mol) and even the immunosuppressant cyclosporin A (1202 g/mol) and the 
decapeptide gonadotropin releasing hormone agonist gosrelin (1269 g/mol).  Clearly 
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conformational changes must occur to accommodate such ligands.  Recently two additional 
structures of CYP1A1 were solved with two ligands larger than alpha-naphthoflavone that had 
both planar and nonplanar constituents, the natural product bergamottin (338 g/mol) and the 
tyrosine kinase inhibitor erlotinib (393 g/mol) (6).  These structures revealed conformational 
alterations allowing for a more extended substrate profile for CYP1A1.  The structure with 
erlotinib was particularly important because CYP1A1 is known to bioactivate tyrosine kinase 
inhibitor drugs into reactive metabolites that have been implicated in patient toxicities (7-9).  
However, all three structures of CYP1A1 demonstrated a planar active site and thus did not answer 
the question of how nonplanar ligands are accommodated. 
Genentech researchers recently demonstrated that CYP1A1 could efficiently metabolize 
the pan-Pim kinase inhibitor GDC-0339 (5-amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-
1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide) (10).  CYP1A1 
converted the flexible, nonplanar GDC-0339 into an unusual aminoazepane-rearranged metabolite 
(G-1025, Figure 4.1A), with the proposed mechanism requiring a highly nonplanar intermediate 
(10).  This intramolecular rearrangement was difficult to rationalize based on any of the currently 
known CYP1A1 structures with highly planar active sites.  To help understand how CYP1A1 is 
able to accommodate this larger and potentially non-planar substrate, CYP1A1 was cocrystallized 
with GDC-0339.  The observed orientation of GDC-0339 in CYP1A1 is consistent with initiation 
of the proposed rearrangement reaction mechanism (10) and also reveals the ability of CYP1A1 
to deviate from the previously observed planar active site through conformational flexibility 
involving the F helix portion of the active site roof.  This new structure furthers our understanding 
of the plasticity of this human enzyme, revealing how CYP1A1 accommodates and metabolizes a 




Figure 4.1  Pim kinase inhibitor GDC-0339, its metabolite G-1025, and analogs.  A) GDC-0339 is reported to undergo a 
CYP1A1-mediated rearrangement to G-1025 via a key nonplanar intermediate.  B)  Structures of close-in analogs G-0546 and G-
0194 used for spectral binding experiments. 
4.3 Experimental Procedures 
4.3.1 Materials 
GDC-0339 and two structurally related compounds, G-0546 and G-0194, (Figure 4.1B) 
were synthesized at Genentech Inc (South San Francisco, CA) and provided for research purposes. 
4.3.2 Protein Expression and Purification 
Human CYP1A1 was generated using a construct containing a synthetic, codon-optimized 
gene with an N-terminal truncation and C-terminal 6x histidine tag, as described previously (4).  
Expression and purification of the CYP1A1 construct was performed without modification as 
described (6).  Protein purity was assessed by SDS-PAGE.  The reduced carbon monoxide-
difference spectrum was used to evaluate protein quality (11).  Protein concentration was 
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quantified by UV-Vis spectroscopy, from the absorbance of the Soret peak with an extinction 
coefficient of 100 mM-1cm-1 in a buffer containing 50 mM potassium phosphate, 500 mM NaCl, 
20% (v/v) glycerol, 250 mM imidazole, 0.5% (w/v) CHAPS, 1 mM EDTA, pH 7.4. 
4.3.3 Ligand Binding Assays 
Assays to measure ligand binding to CYP1A1 were performed in tandem cuvettes as 
described previously (6).  Ligand binding data was determined in duplicate.  Each of the ligands 
examined herein bound tightly enough (Kd values <400 nM) that significant ligand is depleted 
from solution and the assumption that ligand concentration doesn’t substantially change is not 
valid.  Thus the quadratic equation for tight binding ligands was used to fit the data (12). 
4.3.4 Crystallization, Data Collection, and Structure Determination 
Cocrystallization of purified CYP1A1 with the pan-Pim kinase inhibitor GDC-0339 was 
performed as previously described (6), with a few modifications as listed below.  Purified CYP1A1 
was saturated with ligand by addition of 100 µM GDC-0339 (stock in 100% DMSO) to dilute 
protein and subsequently concentrated by centrifugal ultrafiltration to 20 mg/mL, measured by the 
Soret peak in the buffer described above.  Crystals of CYP1A1 with GDC-0339 were grown using 
the sitting-drop vapor diffusion method in 96-well plates by mixing 0.75 µL CYP1A1 saturated 
with GDC-0339 with 0.75 µL crystallization solution (0.2 M potassium phosphate dibasic, 20% 
PEG 3350, 10% glycerol, 1 mM hexadecyltrimethylammonium bromide).  Triangular-prism 
shaped crystals grew over three to five days, and were cryoprotected using the crystallization 
solution plus 20% glycerol before being flash cooled in liquid nitrogen.  A dataset was collected 
on a single crystal at Advanced Photon Source LS-CAT beamline 21-ID-G.  Data processing was 
performed using HKL2000 (13), and an initial structure solution was obtained by molecular 
replacement via Phaser (14) with the CYP1A1/bergamottin structure (6) (PDB 6DWM, molecule 
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A), with a log likelihood score  of 1,244.  This solution placed two copies of CYP1A1 in the 
asymmetric unit, chains A and B.  This partial structure, along with the PDB 6DWM, molecule A, 
were used in Phaser to find a third copy, chain C, with a log likelihood score of 6,549.  Additional 
electron density and packing indicated the presence of a fourth copy of CYP1A1 in the asymmetic 
unit, chain D, which was modeled by partially building helices and then using the secondary 
structure matching alogrithm in COOT to superpose the competely built chain A onto the partial 
model for chain D.  This was followed by a round of simulated annealing using torsion angles in 
PHENIX.  Manual model building and refinement were performed using COOT (15) and PHENIX 
(16), respectively.  Coordinates and restraints for GDC-0339 were generated using PHENIX 
eLBOW (17) with AM1 geometry optimization.  Calculation of the active site void volume was 
performed using VOIDOO (18), with probe radius set to 1.4 Å and grid spacing of 1.0.  Crystal 
structure figures were prepared using PyMOL (19). 
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Table 4.1  Data collection and refinement statistics. 
 CYP1A1/GDC-0339 
(6O5Y) Data Collection  
   Space Group P212121 
   Cell Dimensions (Å) 65.15, 195.90, 236.98 
   Molecules/a.u. 4 
   Resolution (Å)a 50.00-3.16 (3.21-3.16) 
   Total reflectionsa 343,766 (13,457) 
   Unique reflectionsa 52,336 (2,539) 
   Redundancya 6.6 (5.3) 
   Rpima 0.102 (0.786) 
   <I/σ(I)> a 16.5 (1.8) 
   CC1/2a 0.991 (0.490) 
   Completeness (%)a 99.6 (97.6) 
Refinement  
   Resolution (Å) 49.32-3.17 
   No. reflections 52,207 
   R/Rfree (%) 24.0 / 26.7 
   Ramachandran (%) 
   Favored/Allowed/Outliers 
92.39 / 6.90 / 0.71 
No. non-H atoms B factors (Å2)  
       Protein 14,918 / 81.27 
       Ligand 32 / 87.42 
       Heme 172 / 68.31 
       NO3 4 / 64.02 
       Water 10 / 61.61 
   RMSD bond (Å) 0.005 
   RMSD angle (°) 0.706 
   Coordinate error  
   (max. likelihood based) (Å) 
0.43 




4.4.1 Binding of GDC-0339 and analogs to CYP1A1 
 Spectral binding experiments were employed in order to further examine the binding mode 
and affinity of GDC-0339 towards human CYP1A1.  Titrations of GDC-0339 to CYP1A1 resulted 
in unusual spectral shifts, with the difference spectra revealing an absorbance peak emerging at 
approximately 414-415 nm and a shallow trough at 437 nm (Figure 4.2A).  These changes do not 
correspond to classical P450 ligand binding modes of Type I, Type II, or reverse Type I.  However, 
fitting these spectral changes required the tight-binding equation and revealed that CYP1A1 has 
very high affinity for GDC-0339 at 51 ± 5 nM (Figure 4.2A inset).  By comparison, bergamottin 




Figure 4.2  CYP1A1 (1 µM) spectral binding assays with GDC-0339 (A), G-0546 (B), and G-0194 (C) result in atypical 
binding response.  Inserts, the peak-trough absorbance change versus compound concentration fit by nonlinear regression to a 
tight-binding equation.  Kd is given ± S.E. (error bars). 
 Binding assays were also performed with two analogs of GDC-0339 (Figure 4.1B), to 
determine if various extensions on this ligand framework could also be accommodated by 
CYP1A1.  G-0546 was selected to probe the impact of an increased bulk such as a difluoromethyl 
group on the pyrazole moiety relatively close to the center of rearrangement. The CYP1A1 
catalyzed rearrangement was observed for the methyl (in place of difluoromethyl) analog of G-
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0546 (10).  Titrations of G-0546 resulted in a broad peak, which has approximate lmax values of 
409 nm and 395-396 nm, and a pronounced trough at 432-433 nm (Figure 4.2B).  This spectral 
response is consistent with G-0546 binding in the active site and furthermore suggests multiple 
binding modes, with the lmax of 409 nm most similar to the observations with GDC-0339 and the 
lmax at 395-396 more representative of a typical Type I binding profile where the ligand displaces 
a water from the heme iron.  If the amino-azepane moiety of G-0546 is directed towards the heme, 
as the metabolite G-1025 suggests, addition of the bulky difluoromethane group on the pyrazole 
could logically alter the ligand’s spatial relationship to the heme iron, giving rise to the classical 
Type I character.  The binding affinity of G-0546 was 250 ± 20 nM (using the absorbance at 409 
nm) or 390 ± 50 nM (using the absorbance at 396 nm) (Figure 4.2B insert).  Both Kd values indicate 
that the substitutions in G-0546 (Figure 4.1B) weaken the binding in comparison to the 1A1/GDC-
0339 complex (Kd 50 nM). 
 The second analog tested was G-0194 (Figure 4.1B), which differs from GDC-0339 in 
three areas.  1) G-0194 replaces the central aminothiazole with a slightly larger fluoropyridine and 
removes the aniline NH2 group. 2) G-0194 adds a second fluorine and both fluorine groups are at 
the g-position of the amine group on the amino-azepane ring in contrast to the b-position in GDC-
0339. 3) G-0194 adds a hydroxyethyl group extending from the difluorophenyl moiety.  Knowing 
that the g-difluoro-amino-azepane moiety could still rearrange, we were interested to know how 
the increased diversity away from the center of rearrangement could impact CYP1A1’s binding 
and catalysis.  Spectral changes from G-0194 titrations to CYP1A1 resulted in responses similar 
to GDC-0339, where difference spectra evolved an absorbance peak at 413-414 nm and a smaller 
trough at ~434 nm (Figure 4.2C).  The broader, bifurcated peak observed for G-0546 was not 
present. This is consistent with the major changes in structure of G-0194 are further distant from 
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the amino-azepane epicenter.  The Kd for G-0194 binding to CYP1A1 was 170 ± 30 nM (Figure 
4.2C insert), which is intermediate between the other two compounds examined herein.  Due to 
multiple changes to the analogs it is unknown which specific alterations are attributed to effects 
on binding mode and/or affinity. 
4.4.2 CYP1A1 Structure with GDC-0339 
 Since CYP1A1 produced a unique rearranged GDC-0339 metabolite and unusual spectral 
behavior upon binding, an X-ray structure was determined using co-crystallization (3.17 Å).  The 
space group and unit cell dimensions were similar to previously determined CYP1A1 structures 
(4,6).  There were four copies of the protein within the asymmetric unit, with weaker electron 
density for chains C and D. 
Among these four copies of the CYP1A1 protein, there are three types of structures.  
Molecule B has some density for only the ligand azepane ring, located low in the active site just 
above the heme, consistent with partial occupancy of GDC-0339, and the conformation of the F 
helix forming part of the active site roof is similar to that observed in previous structures, most 
similar to the CYP1A1 structure with a-naphthoflavone bound.  Molecules C and D have 
essentially no active side density consistent with the ligand in the active site and the poor density 
for side chains in the F helix preclude definition of their orientation either into or out of the active 
site.  However, the active site of molecule A contains electron density clearly defining an elongated 
conformation of the GDC-0339 ligand in concert with significant corresponding differences in the 
F helix and upper active site (Figure 4.3). 
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Figure 4.3  CYP1A1 (light blue ribbons and sticks) active site with GDC-0339 (cyan sticks) bound.  Heteroatoms are as 
indicated:  nitrogen, royal blue; oxygen, red; sulfur yellow; fluorine, light blue; iron, rust.  Electron density is shown as 2Fo – Fc 
composite omit map contoured at 1.0 s (grey mesh) for ligand and heme.  Distances from the heme iron to the closest GDC-0339 
atoms are shown by red dashed lines and labeled with the respective distances. 
 Correct orientation of GDC-0339 within the active site density was aided by the large, 
seven-membered fluoro-amino-azepane ring.  This ring system is located closest to the heme with 
the fluorine and primary amine approximately 4.8 and 5.3 Å from the iron, respectively (Figure 
4.3).  This binding orientation is consistent with the mechanism proposed by Takahashi et al. where 
production of the rearranged metabolite was initiated by hydrogen abstraction at the primary amine 
on the fluoro-amino-azepane (10).  Moving away from the heme-oriented fluoro-amino-azepane 
ring, the ligand methyl-pyrazole is directed toward the central I helix (Figure 4.3).  The subsequent 
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amide linkage directs both the aminothiazole and difluorophenyl moieties of ligand towards the 
roof of the active site and the F helix.  The aminothiazole has less electron density, suggesting that 
it may adopt multiple conformations.  Regardless, the ligand aminothiazole and difluorophenyl 
rings occupy the space where Phe224 and the protein backbone between the two halves of the F 
helix normally reside in structures with other ligands. 
 Despite the high affinity, as measured in spectral assays here and reflected in efficient 
GDC-0339 turnover by and potent competitive inhibition for CYP1A1 (10), there are relatively 
few specific interactions between GDC-0339 and CYP1A1.  The fluorine group on the fluoro-
amino-azepane is confined by hydrophobic residues such as V382 and L496 from the K/b1-4 and 
b4 loops near the bottom of the active site (Figure 4.3).  The aromatic thiazole ring has favorable 
pi-pi edge-to-face interaction with Phe251 on the G helix (Figure 4.3).  Overall, slightly weaker 
density is observed for the aminothiazole and fluoropyridine moieties of GDC-0339 as it begins 
to extend towards the roof and edge of the active site bounds.  This suggests less complete 
immobilization of the ligand in this area, while the methyl-pyrazole and fluoro-amino-azepane 
moieties lie in a more confined environment near the heme. 
4.5 Discussion 
 Many CYP1A1 substrates share physicochemical features of high planarity, aromaticity, 
small size, and compact shape.  The structural basis for this profile was evident when the first 
CYP1A1 structure, bound to ANF, was solved (4).  This structural architecture was also observed 
in the other family 1 human P450 enzymes, 1A2 (20) and 1B1 (21).  Synthetic derivatives based 
on the flavonoid core like 4’-propargyloxy-b-naphthoflavone (22), and tyrosine kinase inhibitors 
(6-8) suggested the capacity of CYP1A1 to accommodate more elongated ligands which still 
maintain a predominately planar shape.  A recent report revealed CYP1A1-mediated metabolism 
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of the flexible, nonplanar Pim-kinase inhibitor GDC-0339.  This compound inhibited CYP1A1 
competitively and with greater potency than a-naphthoflavone when phenacetin was used as a 
substrate (10), indicating GDC-0339 binds in close proximity to the heme and with high affinity.  
Based on the rearranged metabolite and structural analogs of GDC-0339, Takahashi et al. proposed 
that CYP1A1 initiated the reaction through hydrogen abstraction from the primary amine on the 
fluoro-amino-azepane moiety (10), indicating this group on GDC-0339 would be close to the heme 
iron.  This rearrangement mechanism involves the compound folding on itself in the active site 
with interactions between this primary amine radical and the adjacent methylpyrazole (10), also 
strongly suggesting the CYP1A1 active site would have to be substantially reconfigured to allow 
such a reaction. 
 
4.5.1 Binding of GDC-0339 and analogs to CYP1A1 
 In general, the bulkier analogs had decreased affinity to CYP1A1 compared to GDC-0339, 
although binding was still in the nanomolar range.  The main spectral binding changes induced by 
all three of these compounds do not correspond to common P450 binding modes.  They are most 
similar to observations reported for CYP46A1 binding bicalutamide (23).  In this case there is 
crystallographic evidence of the bicalutamide cyano group hydrogen bonding to a water molecule, 
which is in turn coordinated to the heme iron.  While it was possible that the primary amine of the 
fluoro-amino-azepane also hydrogen bonds to a water coordinated to the heme iron, this is not 
consistent with the X-ray structure herein.  Addition of difluoromethane on the pyrazole adjacent 
to the fluoro-amino-azepane ring in G-0546 might reposition the ligand, consistent with the 
addition of a classical Type I response for displacement of the heme-coordinated water.  For all 
three ligands, the net absorbance change in the spectral binding experiments is low.  This suggests 
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a low proportion of CYP1A1 is binding GDC-0339 despite high affinity and is consistent with 
ligand occupancy in only one of the four CYP1A1 molecules in the asymmetric unit. 
4.5.2 CYP1A1 Structure with GDC-0339 
Since the top of the GDC-0339 ligand occupies the space where the F helix normally 
resides in structures with other ligands, this region is substantially reconfigured (Figure 4.4).  As 
in most human P450 enzymes, this F helix forms the roof of the active site.  In CYP1 enzymes 
there is typically a break in this helix as it passes over the active site.  The positioning of this break 
is key in determining whether the CYP1A1 active site is enclosed or open to the surface and its 
preference for planar ligands.  In the a-naphthoflavone complex, F helix residue Asn222 hydrogen 
bonds to I helix Asp320 to close off access to the protein exterior between these two structural 
elements (Figure 4.4A).  In the bergamottin complex, these two side chains torsion so that there is 
no longer a hydrogen bond between them and a little additional space is made available to 
accommodate the furanocoumarin ring (6).  In the erlotinib complex, both Asn222 and Asp320 
torsion farther apart, opening up a channel between them all the way to the protein surface (Figure 
4.4B).  In each of these latter two structures, Asn222 instead interacts with various oxygens in the 
ligands and the torsions of the side chains occur without changing the backbone conformation of 
the F helix break (Figure 4.4B).  However, in this new GDC-0339 structure, the protein backbone 
between the two halves of the F helix adopts an entirely new conformation, with the Asn222 side 
chain disordered on the protein surface and not interacting with the ligand at all (Figure 4.4C).  
The second important impact of F helix break reconfiguration is positioning of Phe224.  In all 
other known CYP1A1 structures, the F helix backbone conformation positions Phe224 to project 
into the active site, pi-pi stacking with the planar portions of ligands (Figure 4.4A and 4.4B).  This 
is a key feature reinforcing planarity in the middle and top portions of the CYP1A1 active site.  
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With nonplanar GDC-0339, however, the new conformation of the F helix break instead projects 
Phe224 in the opposite direction, projecting from the protein surface toward solvent (Figure 4.4C).  
Distances between the nearest side chain atoms of Asp320 and Asn222 vary from 3.5 Å in the 
hydrogen bond in the a-naphthoflavone structure to 6.2 Å in the erlotinib structure, to 10 Å in the 
GDC-0339 structure. 
 
Figure 4.4  Comparison of active-site cavities for CYP1A1 structures with a-naphthoflavone (A), erlotinib (B), and GDC-
0339 (C).  Heteroatoms are as indicated:  nitrogen, blue; oxygen, red; sulfur yellow; fluorine, light blue; iron, rust.  The F helix 
break conformation in the CYP1A1/GDC-0339 structure results in both Phe-224 and Asn-222 positioned outside of the active-site, 
with increased width of the cavity volume compared to the much more planar nature of the CYP1A1 structures and active sites 
shown in (A) and (B).  Black dashed lines indicate hydrogen-bonds. 
 
Restructuring of the F helix break as observed in the CYP1A1/GDC-0339 structure and 
repositioning Phe224 outside the active site significantly expand the active site cavity.  
Comparisons to other CYP1A1 co-crystal structures (Figure 4.4, grey mesh) reveal that the volume 
of the CYP1A1/GDC-0339 active site at 820 Å3 is much larger than structures with a-
naphthoflavone (408 Å3, Figure 4.4A) or bergamottin (456 Å3) and similar to erlotinib (806 Å3).  
Although the CYP1A1 structures with GDC-0339 and erlotinib structures have similar cavity 
volumes, the identity of the repositioned residues and structural elements differed and the shape 
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of the upper active site/channel is different.  Expansions in the CYP1A1/erlotinib active site cavity 
were largely a result of torsioning of Asn222 (F helix break), Asp320 (I helix), and Leu254 (G 
helix), with an additional offset of the G helix away for the active site (Figure 4.4B).  In contrast, 
the CYP1A1/GDC-0339 active site increased substantially more in width at about the level of the 
aminothiazole ring (Figure 4.4C). 
 This increased width of the middle of the active-site cavity is interesting in the context of 
the proposed GDC-0339 rearrangement mechanism (10).  The mechanism that was proposed to 
form the rearranged metabolite would proceed through an intramolecular tetrahedral intermediate 
occurring between the pyrazole and primary amine radical (Figure 4.1A), which likely would have 
to be accommodated within the active site.  The reconfiguration of the F helix break, to swing 
Phe224 outside the active site cavity may not only accommodate the nonplanar substrate, but also 
permit the formation of this 3-dimensional intermediate.  Therefore, the F helix break 
conformation observed in this crystal structure might help prime CYP1A1 for accommodating 
large deviations to the normally highly planar active site, such as the GDC-0339 rearrangement 
intermediate.  Notably none of the five residues in the middle of this F helix break are conserved 
in human CYP1A2, which could correlate with the selectivity for GDC-0339 metabolism by 
CYP1A1 over CYP1A2 (10).  The F helix break in CYP1A2 may not be able to adopt a 
conformation consistent with the binding of GDC-0339 in this orientation. 
  The therapeutic target for GDC-0339 are the Pim kinases, where the ligand is a potent pan-
inhibitor designed to interact with the ATP binding pocket.  Recently a structure of GDC-0339 
bound to Pim-1 was reported (24).  When bound to Pim-1, GDC-0339 adopts a compact U-shaped 
conformation (Figure 4.5, grey sticks).  In contrast when GDC-0339 is bound to CYP1A1, the 
conformation is much more extended (Figure 4.5, green sticks).  GDC-0339 is metabolized 
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efficiently by CYP1A1 to form the rearranged metabolite G-1025, which displays 10- to 20-fold 
reduction in potency towards Pim isoforms (10).  This likely results from loss of key salt-bridges 
formed between the primary amine on the fluoro-amino-azepane with an acidic region in the Pim 
kinase (24).  Engineering conformational constraints into GDC-0339 to favor the U-shaped Pim-
compatible conformation may be desirable to reduce its binding to and metabolic deactivation by 
CYP1A1, as a strategy to sustain its efficacy and avoid multiple myeloma drug resistance.  
CYP1A1 expression levels and activity have previously been shown to have a resistance role in 
for the multiple myeloma drug bortezomib (25). 
 
 
Figure 4.5  Comparison of the GDC-0339 conformation when bound to CYP1A1 (green sticks) versus the conformation bound to 
Pim-1 (grey sticks, PDB Code: 6NO9) reveals significant conformational differences that could be used to decrease CYP1A1 
metabolism. 
4.6 Conclusions 
 In conclusion, our structural investigations into CYP1A1 revealed that this enzyme has 
greater degrees of conformational malleability than previously observed, permitting the binding 
and metabolism of nonplanar compounds and their likely intermediates.  Specifically, this structure 
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demonstrates the CYP1A1 active site can increase approximately twice in volume and rearrange 
both polar and aromatic residues.  Even larger nonplanar CYP1A1 substrates such as the macrolide 
antibiotics troleandomycin and tylosin, the immunosuppressant cyclosporin A, and the 
decapeptide gosrelin may take advantage of this nonplanarity and/or protrude outside of the active 
site through the channel observed.  The roles observed for CYP1A1 in chemical carcinogenesis 
and the generation of reactive metabolites underscore the importance in predicting chemical 
liabilities of various dietary compounds, pollutants, and drugs.  This more complete understanding 
of the structural elements contributing to flexibility within the CYP1A1 active site should help in 
predicting a broader range of substrates potentially susceptible to CYP1A1 bioactivation, and in 
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Metabolism and Structural Interactions of Pro-Duocarmycins with Cytochrome P450 
Enzymes 1A1 and 2W1* 
 
5.1 Introduction 
Human cytochrome P450 enzymes are perhaps most broadly recognized for their capacity 
to convert xenobiotics, including drugs, into metabolites that are more readily cleared from the 
body.  However, in the process some foreign chemicals are activated to reactive intermediates or 
toxins that have significant adverse effects and/or initiate disease.  One such example is the 
metabolism of a ring-opened form of nicotine by lung cytochrome P450 2A13 to a metabolite that 
forms DNA adducts and can thus initiate lung cancer in smokers (1).  However, this attribute of 
cytochrome P450 enzymes to bioactivate foreign molecules can also be used advantageously to 
activate prodrugs in vivo.  Cytochrome P450 enzymes activate a range of anticancer prodrugs 
including FDA-approved DNA-alkylating cyclophosphamide/ifosfamide and 
dacarbazine/procarbazine compounds, the thymidylate synthase inhibitor tegafur, the nonsteroidal 
antiandrogen flutamide, the selective estrogen receptor modulator tamoxifen, and the bioreductive 
topoisomerase II inhibitor AQ4N (reviewed in (2)). 
 The ultrapotent cytotoxic duocarmycin natural products also have significant anticancer 
potential, but the absence of selectivity for cancer cells absolutely prevents systemic use.  A 
number of novel duocarmycin prodrugs, seco-duocarmycins, have been developed (3-5) that are 
                                               
* The contents of this chapter are currently in preparation with collaborator Dr. Klaus Pors for journal submission. 
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bioactivated by two cytochrome P450 enzymes expressed in selected tissues:  CYP1A1 and 
CYP2W1.  CYP1A1 is an inducible, primarily extrahepatic enzyme present in lung, placenta, and 
endothelial cells of the skin, intestine, and bladder.  Literature reports of CYP1A1 expression 
levels vary significantly between tissues and individuals (6,7).  If endogenous CYP1A1 is present 
and tissue-specific, then it’s ability to activate seco-duocarmycins might be useful.  But if CYP1A1 
normal vs. cancerous tissue levels are similar or endogenous levels are high in an individual or 
tissue, then selective duocarmycin bioactivation would be much reduced.  On the other hand, 
CYP2W1 is selectively expressed in colon cancer tissues (8-13) where its ability to activate seco-
duocarmycins could be a promising therapy for colorectal tumors. Additionally, mice harboring 
human colon cancer xenografts expressing CYP2W1 have shown significant tumor growth 
inhibition upon administration of a seco-duocarmycin, with no signs of host toxicity (4).  This 
suggests that this approach holds promise for selective colon tumor targeting, without systemic 
toxicity if selectivity can be engineered for CYP2W1 over CYP1A1. 
 Both CYP1A1 and CYP2W1 bioactivate the seco-duocarmycin prodrug, ICT2700 by 
hydroxylation at a specific position on a chloromethyl indoline substructure at one end of the 
molecule (Figure 5.1, red circle) (3).  The hydroxylated chloromethyl indoline then undergoes a 
spontaneous spirocyclization reaction such that the chlorine atom is released and a cyclopropyl 
ring forms on the indoline ring system (5).  The indole at the opposite end of the molecule serves 
as a DNA-recognition motif and binds DNA in a sequence-selective manner, so that the unstable 
cyclopropane ring is appropriately located to form DNA adducts that are lethal to the cell.  Thus, 




Figure 5.1  Duocarmycin analogs ICT2700 and ICT2726 (shown in boxes, differences colored in red).  The ICT2700 analog 
has been reported to undergo bioactivation by CYP1A1 and CYP2W1 via a specific hydroxylation (red dotted oval) on the 
chloromethyl indoline substructure (4).  Spontaneous spirocyclization occurs producing a reactive cyclopropane moiety.  DNA 
adenine bases can be alkylated with this reactive group leading to cytotoxic DNA adducts.  The ICT2726 analog does not undergo 
bioactivation.  Instead this analog can serve as a biomarker for CYP2W1 activity because it forms a unique non-toxic metabolite 
specific to CYP2W1 (3). 
 The specificity of cytochrome P450 hydroxylation is highly dependent on ligand 
orientation in the active site with the desired site of metabolism adjacent to the heme iron.  While 
no experimental structures are available for CYP2W1, there are several structures available for 
CYP1A1 with other ligands bound in the active site.  The initial CYP1A1 structure was with a-
naphthoflavone housed within a highly planar, slot-like enclosed active site (14).  Recently several 
other structures of CYP1A1 have been solved with the furanocoumarin bergamottin from 
grapefruit juice and the tyrosine kinase inhibitor erlotinib (15) and significant portions of these 
molecules and their active sites are also planar.  One half of ICT2700 and ICT2726 (Figure 5.1) 
consists of an indole core while the other half consists of another indole with a fused furan or 
pyrrole ring.  These fused ring systems confer a high degree of planarity which would correspond 
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well to a highly planar and narrow CYP1A1 active site, but they are connected by a linker that 
does not constrain the two ring systems to the same plane.  The chloromethyl arm of these 
duocarmycins deviates significantly from planarity.  Depending on the overall orientation of these 
ligands in the CYP1A1 active site, this functional group could sterically clash with narrow portions 
of the active site.  While flexibility has been observed in certain structural elements in CYP1A1, 
it is not clear how these ICT ligands would be accommodated or known if the seco-duocarmycin 
molecules would cause structural perturbations. 
 To optimize clinical utility, the seco-duocarmycin scaffold should be further modified for 
selective activation, preferably by CYP2W1, due to its exclusive expression in tumor tissue.  
Binding and activation by CYP1A1 should be reduced.  Previous studies (3) suggested that 
functionalization of the seco-duocarmycin DNA-binding motif improved the selectivity for 
activation by CYP1A1 over CYP2W1, but structural changes favoring selective CYP2W1 
activation are unknown.  Additional engineering is needed to engender absolute selectivity for 
CYP2W1, but this has been impaired by the absence of information about how these CYP1A1 and 
CYP2W1 interact with current seco-duocarmycins.  Thus, the goal of the current study was to 
characterize the interactions of synthetic seco-duocarmycins with CYP1A1 and CYP2W1.  Of 
specific interest is determining how CYP1A1 and CYP2W1 bind the prodrug duocarmycin 
(ICT2700) and a biomarker version (ICT2726).  This latter analog is selectively metabolized by 
CYP2W1 to produce a unique nontoxic metabolite that can be used to identify CYP2W1-
expressing cells prior to treatment.  The current work examined the binding of enantiomers of both 
ICT2700 and ICT2726 to CYP1A1 and CYP2W1, as well as determining structures of CYP1A1 
with the S-enantiomers of each compound.  This revealed key interactions that could be used to 
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design second generation seco-duocarmycins with improved selectivity for CYP2W1 activation in 
vivo. 
5.2 Experimental Procedures 
5.2.1 Isolation of Pro-duocarmycin Stereoisomers  
 The stereoisomers of the seco-duocarmycin analogs ICT-2700 and ICT-2726 were a gift 
from Klaus Pors. 
5.2.2 Protein Expression and Purification 
Human CYP1A1 and CYP2W1 enzymes were generated that had truncation of the N-
terminal membrane-anchoring helix to increase solubility and addition of a C-terminal histidine 
tag to facilitate purification.  The construct for CYP1A1 has been described (14).  For CYP2W1, 
a synthetic codon-optimized gene was generated in which the resulting amino acid sequence was 
almost the same as the 2W1 #3 construct described by Wu et al. (16), in that residues 3-31 were 
replaced with KKTSSKGKL but the C-terminal histidine tag consisted of only four histidines 
instead of five. 
Expression and purification of CYP1A1 was performed without modification as described 
(15).  Expression of CYP2W1 was based on the method described for CYP1A1, with some 
modifications.  Modifications included inoculation with 5 mL of starter culture per 1 L expression 
culture and growing in 2.8 L Fernbach flasks, a lower shaking speed of 225 rpm during cell growth 
and 200 rpm after induction, and addition of 5 mM imidazole to expression cultures to help 
stabilize CYP2W1.  Purification of CYP2W1 was initially based on the CYP1A1 purification 
method, however substantial modifications were made, therefore for clarity a detailed protocol is 
provided below. 
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Purification of CYP2W1 began with thawing frozen expression cell pellets in a buffer 
consisting of 20 mM potassium phosphate, 20% (v/v) glycerol, 5 mM imidazole, 1 mM 
phenylmethanesulfonyl fluoride (PMSF), pH 7.4.  Thawed and resuspended cells were lysed by 
French Press using a single pass with a pressure of 15,000 psi.  The lysed cell suspension was then 
subjected to ultra-centrifugation for 30 minutes at 142,000 x g in order to isolate membranes.  
Pelleted membranes were gently washed twice with the buffer used in lysis, then resuspended by 
homogenization in an extraction buffer composed of 100 mM potassium phosphate, 500 mM NaCl, 
20% (v/v) glycerol, 15 mM imidazole, 1% (w/v) CHAPS, and 1 mM PMSF, pH 7.4.  Resuspended 
membranes were stirred for 1 hour to promote efficient protein extraction.  The sample was then 
clarified by a second ultra-centrifugation using the above parameters.  Clarified supernatant was 
loaded onto a 25 mL Ni-NTA column (Qiagen) equilibrated with the extraction buffer.  To remove 
unbound and non-specifically bound proteins, the column was washed with four column volumes 
(CV) of extraction buffer, followed by 10 CV of a Ni-NTA wash buffer (100 mM potassium 
phosphate, 100 mM NaCl, 20% (v/v) glycerol, 15 mM imidazole, 9 mM CHAPS, pH 7.4).  Elution 
of CYP2W1 was performed using a linear gradient from Ni-NTA wash buffer to Ni-NTA elution 
buffer (10 mM potassium phosphate, 100 mM NaCl, 20% (v/v) glycerol, 250 mM imidazole, 9 
mM CHAPS, pH 7.4) over 6 CV, with addition of 2 CV of 100% Ni-NTA elution buffer to ensure 
complete elution.  Ni-NTA fractions with A426/A280 > 0.8 were pooled and diluted 5-fold with an 
ion-exchange wash buffer (10 mM potassium phosphate, 50 mM NaCl, 20% (v/v) glycerol, 1 mM 
EDTA, pH 7.4).  Diluted sample was then applied to two 5-ml Hi-Trap carboxymethyl-Sepharose 
fast-flow columns (GE Healthcare) connected in series (total 10 ml column volume).  This was 
first washed with 10 CV of ion-exchange wash buffer, then a 6 CV linear gradient was applied 
from ion-exchange wash buffer to an ion-exchange elution buffer (50 mM potassium phosphate, 
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500 mM NaCl, 20% (v/v) glycerol, 1 mM EDTA, pH 7.4) to elute the bound protein.  An additional 
2 CV of ion-exchange elution buffer was run through the column to ensure complete elution.  
Eluted fractions from the CM column with A419/A280 > 1.0 were pooled together and concentrated 
to ~2 ml for application onto a Superdex 200 gel filtration column (GE Healthcare) that was run 
isocratically using the ion-exchange elution buffer.  The major elution peak fractions with 
A419/A280 > 1.0 were pooled, flash-frozen in aliquots, and stored at -80 °C. 
The purified proteins were evaluated by SDS-PAGE to assess purity.  The reduced carbon 
monoxide-difference assay served as a method to evaluate P450 stability (17).  Quantification of 
both CYP1A1 and CYP2W1 for use in ligand binding assays and crystallography was performed 
by UV-vis spectroscopy, using the Soret peak extinction coefficient of 100 mM-1cm-1.  This was 
accomplished in the final buffer for the respective proteins plus 250 mM imidazole. 
5.2.3 Ligand Binding Assays 
The affinities and binding modes of seco-duocarmycin compounds to CYP1A1 and 
CYP2W1 (1 µM) were measured in 2 cm tandem quartz cuvettes using the method previously 
described (15).  Spectral binding data was determined in duplicate and fit to a quadratic equation 
used for tight binding (18). 
5.2.4 Crystallization, Data Collection, and Structure Determination 
CYP1A1 was co-crystallized with the seco-duocarmycin compounds (S)-ICT2700 and (S)-
ICT2726 as described previously (15), with modifications listed below.  Purified CYP1A1 was 
saturated with the respective seco-duocarmycin by three iterative dilution (in ion-exchange elution 
buffer with 0.4 M NH4NO3) and centrifugal ultrafiltration concentration steps.  Ligand was added 
at 20 µM for (S)-ICT2726 or 100 µM for (S)-ICT2700 during each dilution.  The CYP1A1/ICT 
samples were then concentrated to a final protein concentration of 20 mg/ml.  Crystals of both 
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complexes were grown at 4 °C using the sitting-drop vapor diffusion method.  For CYP1A1/(S)-
ICT2700, crystals were grown in a 96-well plate mixing 0.75 µL CYP1A1 with 0.75 µL of 
crystallization solution (0.18 M sodium phosphate dibasic, 18% (w/v) PEG 3350, 9% (v/v) 
glycerol, 5 mM (S)-O-methyl-serine dodecylamide hydroxhloride) against a 50 µL reservoir of the 
same crystallization solution.  Crystals of the CYP1A1/(S)-ICT2726 complex were grown in a 24-
well plate by mixing 1 µL CYP1A1, 0.2 µL 18 mM n-decyl-b-D-maltoside, and 0.8 µL 
crystallization solution (0.2 M sodium phosphate dibasic, 20% (w/v) PEG 3350), equilibrated with 
a 100 µL reservoir of the same crystallization solution.  Crystals were harvested by transferring 
into the respective crystallization solution containing 20% glycerol and flash cooled in liquid 
nitrogen.  Diffraction data for the CYP1A1/(S)-ICT2700 crystal was collected on beamline 21-ID-
G at the Advanced Photon Source LS-CAT, while data for CYP1A1/(S)-ICT2726 was collected 
on beamline 9-2 at the Stanford Synchrotron Radiation Lightsource. 
Data processing for the CYP1A1/(S)-ICT2700 dataset was performed using HKL2000 
(19), and a structure solution was obtained by molecular replacement via Phaser (20) with the 
CYP1A1/a-naphthoflavone structure as the search model (PDB 4I8V, molecule A), resulting in a 
log likelihood of 667 and translation function Z score of 27.3.  For the CYP1A1/(S)-ICT2726 
complex, data was processed in XDS (21) and scaled in AIMLESS (22).  A molecular replacement 
solution for this structure was obtained from MolRep (23), again using chain A of the CYP1A1/a-
naphthoflavone structure as the search model (contrast score of 30.59).  Iterative model building 
and refinement of both structures were performed using COOT (24) and PHENIX (25), 
respectively.  Ligand coordinates and restraints for the seco-duocarmycins were generated using 
PHENIX eLBOW (26) with AM1 geometry optimization.  Data collection and refinement statistics 
are provided in Table 5.1.  Crystal structure figures were prepared using PyMOL (27). 
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Data Collection   
   Space Group P212121 P3121 
   Cell Dimensions (Å) 65.37, 196.15, 237.22 241.28, 241.28, 125.30 
   Molecules/a.u. 4 4 
   Resolution (Å)a 50.00-2.85 (2.90-2.85) 39.64-3.07 (3.14-3.07) 
   Total reflectionsa 510,182 (17,794) 783,762 (35,174) 
   Unique reflectionsa 72,081 (3,422) 77,258 (3,944) 
   Redundancya 7.1 (5.2) 10.1 (8.9) 
   Rpima 0.080 (0.942) 0.054 (0.631) 
   <I/σ(I)> a 28.0 (2.1) 9.7 (1.6) 
   CC1/2a 0.990 (0.322) 0.997 (0.518) 
   Completeness (%)a 99.8 (97.3) 99.0 (85.6) 
Refinement   
   Resolution (Å) 48.80-2.85 39.64-3.10 
   No. reflections 71,709 76,831 
   R/Rfree (%) 23.8 / 28.7 20.1 / 22.1 
   Ramachandran (%) 
   Favored/Allowed/Outliers 96.19 / 3.81/ 0.00 97.15 / 2.85 / 0.00 
   No. non-H atoms/B factors (Å2)   
       Protein 15,015 / 68.60 15,026 / 80.62 
       Ligand 54 / 57.62 104 / 80.66 
       Heme 172 / 57.09 172 / 68.49 
       CHAPS - / - 42 / 100.77 
       Water 1 / 49.31 - / - 
   RMSD bond (Å) 0.008 0.007 
   RMSD angle (°) 0.765 0.636 
   Coordinate error  
   (max. likelihood based) (Å) 0.37 0.37 
a Statistics for highest resolution shell shown in parentheses. 
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5.3 Results and Discussion 
5.3.1 Seco-Duocarmycin Binding Modes and Affinities for Human CYP1A1 and CYP2W1 
ICT2726 (Figure 5.1) was first evaluated for its ability to bind both CYP1A1 and 
CYP2W1.  CYP2W1, but not CYP1A1, hydroxylates this compound on the chlorine atom and the 
resulting unique metabolite (4) can be used as a biomarker for the presence of CYP2W1 in tissues 
to identify those that might benefit from pro-duocarmycin activated in situ by CYP2W1.  ICT2726 
is a chiral compound and is produced as a mixture of the two stereoisomers at this position (3).  
While previous studies have used the racemic compound, in this study we were able to evaluate 
the individual stereoisomers for binding to both enzymes. 
Binding of ligands in a cytochrome P450 active site can typically be monitored by 
observing shifts in the absorbance maximum of the heme Soret peak.  Substrates typically shift the 
Soret peak to shorter wavelengths as they bind in the active site close enough to the heme iron that 
they displace water from its central iron and thereby shift the iron spin equilibrium from the six-
coordinate, low-spin form toward the five-coordinate, high-spin form.  This is typically observed 
in the form of UV-visible difference spectra, where such “Type I” binding is associated with 
decreases in absorbance at ~430 nm and increases at ~393 nm.  These were exactly the changes 
observed when CYP1A1 was progressively titrated with both ICT2726 enantiomers (Figure 5.2A 
and 5.2B).  Both (S)- and (R)-ICT2726 bound CYP1A1 with relatively high affinity, with Kd values 
of 0.23 ± 0.02 µM and 0.71 ± 0.05 µM (insets to Figure 5.2A and 5.2B), respectively.  This 
suggests that both ICT2726 enantiomers bind in the active site such that they may be substrates 
for CYP1A1, producing other metabolites, but and not just the dechlorinated one. 
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Figure 5.2  Spectral binding experiments of CYP1A1 and CYP2W1 with the seco-duocarmycin enantiomers of ICT2726.  
Representative difference binding spectra are shown of CYP1A1 (A & B) and CYP2W1 (C & D), with respective ICT2726 
enantiomer.  Inserts display the difference in peak-trough absorbance versus compound concentration and are fit by nonlinear 
regression to a tight-binding equation.  The fitted compound affinities (Kd values) are reported with ± S.E. (error bars). 
 CYP2W1 also bound (S)-ICT2726 with classic Type I spectral changes (Figure 5.2C).  The 
affinity of (S)-ICT2726 was also relatively high for CYP2W1, with a Kd of 0.41 ± 0.03 µM (Figure 
5.2C, inset).  However, (R)-ICT2726 addition to CYP2W1 did not result in significant spectral 
shifts in the difference spectra at concentrations as high as ~10 µM (Figure 5.2D).  This result 
suggests that either the R-enantiomer does not bind CYP2W1 with significant affinity, or it binds 
but a different mode that does not perturb the water coordinated to the heme iron in the active site. 
Similar titrations were used to evaluate CYP1A1 and CYP2W1 binding of the ICT2700 
seco-duocarmycin which is bioactivated by both enzymes (Figure 5.1).  ICT-2700 is also chiral at 
the carbon adjacent to the chloromethyl group, the region involved in formation of the 
cyclopropane ring essential for cytotoxic activity (Figure 5.1).  ICT2700 is produced as a mixture 
of the two stereoisomers at this position (3,4) and previous studies have used this racemic form.  
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While the racemic form demonstrated potency in growth inhibition and cell death in CYP1A1 and 
CYP2W1 transfected cancer cells (3), it is unknown if differences in chirality of ICT2700 would 
confer bioactivation preference between the two enzymes. 
Since ICT2700 is a validated substrate for both CYP1A1 and CYP2W1 enzymes, it was 
expected that the titrations might show similar Type I spectral shifts as observed for ICT2726 
above.  However, the binding modes observed with ICT2700 were markedly distinct.  The 
dominant feature of CYP1A1 binding of both ICT2700 enantiomers were increases in absorbance 
eventually emerging at 412-415 nm with a smaller trough forming at 432-434 nm Figure 5.3A&B).  
Early in both titrations the peak is broader and for the R-enantiomer this is maintained through the 
titration yielding absorbance increases at 398 nm secondary to the primary maximum (Figure 
5.3B).  First, a broad peak shape is consistent with the presence of multiple binding modes for 
ICT2700 in the CYP1A1 active site, and there seems to be more binding heterogeneity for the R-
enantiomer than for the S-enantiomer.  Second, the primary maximum at ~412-415 nm suggests 
that ligand binding promotes oxygen interaction with the heme iron, rather than displacing the 
iron-coordinated water.  It is possible that either ligand binding reinforces water coordination to 
the heme iron or that an oxygen of the ligand (e.g. the methoxy group) interacts with the heme 
iron.  Third, the affinities for (S)- and (R)-ICT2700 for CYP1A1 were 1.9 ± 0.1 µM (Figure 5.3A, 
inset) and 1-2 µM (depending on the wavelength used, Figure 5.3B, inset), respectively.  Thus (S)-
ICT2726 has about an 8-fold higher affinity for CYP1A1 than (S)-ICT-2700, while the affinities 
for the R-enantiomers are similar. 
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Figure 5.3  Spectral binding experiments of CYP1A1 and CYP2W1 with the seco-duocarmycin enantiomers of ICT2700.  
Difference binding spectra are shown of CYP1A1 (A & B) and CYP2W1 (C & D) binding the ICT2700 enantiomers.  Inserts 
display the difference in peak-trough absorbance versus compound concentration, and are fit by nonlinear regression to a tight-
binding equation.  The fitted compound affinities (Kd values) are reported with ± S.E. (error bars). 
Titrations of the ICT2700 enantiomers into CYP2W1 again revealed a distinct preference 
for one enantiomer.  Addition of up to ~15 µM (S)-ICT2700 into 1 µM CYP2W1 had minimal 
effects on the spectra (Figure 5.3C).  Again, this could indicate that either the S-enantiomer has 
weak or no affinity towards CYP2W1 or does not bind in the active site close enough to perturb 
the water on the heme iron.  In contrast, the R-enantiomer produced a unique binding mode 
characterized primarily by a peak around 423 nm (Figure 5.3D).  While there does not appear to 
be a clear corresponding decrease in absorbance, this could be partially obscured by changes in 
background absorbance caused by this compound itself in the UV range (350-380 nm).  This red-
shifting of the Soret peak position is consistent with spectral changes known to occur when a ligand 
nitrogen replaces the heme-coordinated water to coordinate itself to the heme iron.  ICT2700 has 
two nitrogen-containing indole ring systems that are possibilities for direct iron coordination 
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(Figure 5.1), but the most likely position would be the indole on the alkylation arm as it is sterically 
less hindered.  The affinity for this interaction is relatively weak, with a Kd = 8 ± 1 µM (Figure 
5.3D, inset).  Since the N-Fe coordination appears to be weak, it is quite possible that this N-Fe 
feature helps to orient the molecule in the active site for bioactivation but also allows for the 
dissociation such that hydroxylation occurs at the adjacent C5 as required for bioactivation.  
Notably, replacement of this indole with a naphthyl moiety drastically reduced activation by 
CYP2W1 (and CYP1A1), which would be consistent with the nearby nitrogen directing the critical 
C5 towards the heme iron (3). 
It is interesting that CYP2W1 appears to be distinctively affected by changes in the 
chirality of the chloromethyl moiety for both the ICT2700 and ICT2726 analogs.  This 
demonstrates that distinctive structural features are present in the CYP2W1 active site that control 
the enantiomers in binding and/or positioning.  In comparison to CYP1A1, spectral binding 
experiments indicate that chirality has some effects on binding affinity and possible binding modes 
in the CYP1A1 active site, but the effects are not as pronounced as observed with CYP2W1.  Thus 
structures of both complexes are desirable to elucidate the key distinctive interactions. 
5.3.2 Co-Crystal Structures of CYP1A1 with (S)-ICT2700 and (S)-ICT2726 
Co-crystallization for both enantiomers of ICT2700 and ICT2726 were attempted for both 
CYP1A1 and CYP2W1 enzymes.  No structures have been reported for CYP2W1 with any ligand 
and our efforts with ICT series compounds did not yield crystals.  However, diffraction quality 
crystals were obtained for CYP1A1 with the (S)-ICT2700 and with (S)-ICT2726, yielding 
structures at 2.9 Å and 3.1 Å, respectively.  The (S)-ICT2700 complex was solved in the 
orthorhombic P212121 crystal form that other CYP1A1 structures have displayed, however the co-
crystal structure with (S)-ICT2726 solved in a new crystal system, with a trigonal P3121 space 
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group.  Even with different symmetry, crystal contacts between molecules were shared and each 
structure contained four copies of the complex in the asymmetric unit.  In both complexes the 
overall fold of CYP1A1 was as seen in previous solved structures of the enzyme (14,15).  The one 
region of CYP1A1 that has varied conformations when different ligands are bound consists of 
helices F through G that form the roof of the active site (15).  Both seco-duocarmycin complexes 
displayed a conformation of this region most similar to that reported when a-naphthoflavone is 
bound in an enclosed CYP1A1 active site (14).  This includes a five-residue break in the F helix 
as it passes over the active site, a distinct feature which has now been observed in all CYP1A1 
structures to date, as well as CYP1A2 and CYP1B1 crystal structures with a-naphthoflavone 
(28,29). 
The (S)-ICT2726 ligand is present in all four CYP1A1 copies of the crystal structure and 
the binding mode appears to be consistent among them.  The best fit to the observed electron 
density positions the 5-fluoroindole ring of (S)-ICT2726 above the heme (Figure 5.4A) with the 
closest carbon atoms of the six-membered ring each 4.3 Å from the iron (Figure 5.4A, red dashed 
lines).  The fluorine projects towards a cluster of hydrophobic residues forming the bottom portion 
of the CYP1A1 active site.  On the opposite half of the molecule the pyrrole ring pi-pi stacks with 
Phe224 in the F helix break.  The linker between the two rings is co-planar with the two ring 
systems and packs against the Gly316 and Ala317 peptide bond of the I helix.  These and other 
interactions constrain the molecule in an overall planar conformation.  The only exception is the 
chloromethyl arm of the ligand, which is directed into the F helix break, and is in close contact 
(2.7 Å) to the side-chain oxygen of Asn222, which could potentially form a halogen-oxygen 
interaction (Figure 5.4A, yellow dashed line).  Additionally, in some copies of the complex there 
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is evidence of placement of an active site water forming a hydrogen bond between the side chain 
of Ser-122 (B'/C loop) and the ligand’s linker carbonyl oxygen. 
 
Figure 5.4  Co-crystallization structures of CYP1A1 (ribbons) bound to (A) (S)-ICT2726 and (B) (S)-ICT2700 (grey sticks).  
Electron density is shown as 2Fo – Fc composite omit map contoured at 1.0 s (blue mesh) around the ligand and heme (black sticks 
with orange Fe sphere).  Potential hydrogen bonds (black dashes), halogen bonds (yellow dashes), and ligand atoms in closest 
proximity to the heme iron (red dashes) are shown with their corresponding distances. 
This binding mode is consistent with the observed binding spectra for (S)-ICT2726 with 
CYP1A1.  The crystal structure reveals the fluoroindole ring in close proximity to the heme iron, 
which would likely displace the resting heme water, giving rise to the observed Type I shift.  
Although the overall binding pose might not be the same for the R enantiomer of ICT2726, if the 
primary scaffold occupies the same plane, then the approximately 3-fold lower affinity for this 
enantiomer and the structure suggests that the R-chloromethyl arm may sterically clash with Phe-
224. 
Overall, these interactions do not position (S)-ICT2726 in the CYP1A1 active site in an 
orientation primed for bioactivation and this is consistent with the observations that CYP1A1 does 
not yield the cytotoxic metabolite of the racemic version of this compound. 
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 The second CYP1A1 structure was determined with (S)-ICT2700, which is bioactivated by 
both CYP1A1 and CYP2W1.  This molecule could only be placed into the observed electron 
density in two of four CYP1A1 molecules in the asymmetric unit due to ligand disorder and/or 
low occupancy.  In these two CYP1A1 molecules, the overall conformation of (S)-ICT2700 is 
planar and the orientation similar to (S)-ICT2726 (Figure 5.4B).  The DNA recognition motif is 
above the heme and the DNA-alkylating motif oriented away from the heme, though its fused ring 
system and the chloromethyl substituent are reversed by 180° compared to (S)-ICT2700.  This 
reorientation of the DNA-alkylating ring system directs the chloromethyl arm toward the B' helix 
and the fused pyrrole into the F helix break.  This still permits stacking between Phe224 and the 
aromatic pyrroloindole system of ICT2700.  The indole nitrogen of this portion of the ligand makes 
a hydrogen bond interaction with the oxygen of Asn222 (2.8 Å).  As in ICT2726, the chlorine of 
the chloromethyl substituent also makes a potential halogen-oxygen interaction, but in this case it 
is a longer interaction with the oxygen of Ser116 in the B' helix (3.5 Å, Figure 5.4B, yellow dashed 
line).  In one molecule electron density suggested water-mediated hydrogen bonding interactions 
between Ser122, and the ligand linker carbonyl oxygen and nitrogen of the methoxy-indole ring 
similar to the CYP1A1/(S)-ICT2726 complex. 
One of the differences between ICT2700 and ICT2726 is the substitution of a methoxy 
group on the DNA-recognition motif of ICT2700 vs. a fluorine substituent at this position for 
ICT2726.  The positioning of these two groups is quite similar in a hydrophobic pocket over the 
heme, but the oxygen in ICT2700 is only 4.8 Å from the iron and may directly interact with the 
iron in solution or upon a small shift of the ligand.  This would be consistent with the spectral 
binding information, which indicates that (S)-ICT2700 binds in such a way as to reinforce an 
oxygen-Fe interaction, but (S)-ICT2726 does not. 
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Although (S)-ICT2700 is bioactivated by CYP1A1 into a reactive metabolite through 
hydroxylation on a specific aryl-carbon on the chloromethylpyrroloindoline (Figure 5.1), the 
orientation of this ligand in the CYP1A1 active site places the oxidized carbon >9 Å away from 
the heme iron.  There are two possible explanations for this.  First, the orientation observed in the 
crystal structure may be the dominant binding pose, with a minor pose being responsible for 
bioactivation.  This would be consistent with the reported observation that the activated species 
undergoing spirocyclization is a minor product rather than the major product (5).  The overall 
ICT2700 scaffold is relatively symmetrical and flipping the compound by 180° would locate the 
requisite carbon near the iron.  A second possibility is that in CYP1A1 it is the R-enantiomer of 
ICT2700 that is bioactivated.  The spectral binding studies support at least two binding modes for 
this enantiomer. 
5.3.3 Comparisons and Applications of CYP1A1/CYP2W1 Interactions with Seco-
duocarmycins 
 Design of seco-duocarmycin prodrugs for selective in situ bioactivation by CYP1A1 could 
be of potential clinical utility in tissues such as the lung and bladder where the enzyme can be 
expressed at higher levels, however this enzyme is also expressed at low levels in other tissues.  
Thus, maintaining a low level of seco-duocarmycin activation may be advantageous and promoting 
a dominant binding mode where the alkylating domain is distant from the heme may be desirable.  
Such an application would not be complicated by CYP2W1 activation because this P450 is not 
normally expressed in adult tissues.  Using CYP2W1 exclusive expression in colon cancer cells to 
activate seco-duocarmycins would require more selective compounds with minimal or no 
activation by CYP1A1.  While there are no structures of CYP2W1 with duocarmycins or any other 
ligands, the binding information herein suggests differences between the two active sites that could 
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potentially be exploited.  First, only CYP2W1 forms the unique ICT2726 metabolite with 
hydroxylation of the chloromethyl substituent, suggesting that steric restraints may differ between 
the two active sites such that this substituent is not located near the heme for CYP1A1.  Second, 
while the enantiomers of both ICT compounds bound to CYP1A1, CYP2W1 appeared to display 
a strict preference for only one stereoisomer:  S for ICT2726 and R for ICT2700.  This could 
suggest that the CYP2W1 active site might be less flexible than that of CYP1A1.  This 
enantiomeric preference could therefore be potentially useful in the design of advanced seco-
duocarmycin prodrugs. 
Although little is known about the substrate scope of CYP2W1, there are a number of 
reports suggesting a partially overlapping substrate profile with CYP1A1.  In addition to the 
engineered seco-duocarmycins, CYP1A1 and CYP2W1 both metabolize substrates such as the 
benzothiazole anticancer compounds 5F 203 and GW 610 (30), AQ4N (31,32), all-trans-retinoic 
acid (33,34), and the polycyclic aromatic hydrocarbon benzo[a]pyrene (16).  This indicates that 
shared elements in active-site topology are present between the two enzymes.  CYP2W1 is still 
classified as an orphan enzyme with no clear defined metabolic role.  Based on sequence identity, 
CYP2W1 groups largely with the xenobiotic-metabolizing P450 enzymes, with CYP2D6 sharing 
the highest identity (12).  Of the six substrate recognition sites (SRS), there does seem to be 
relatively high identity between CYP2W1 and CYP1A1 in SRS-1 (corresponding to the B’ helix 
region).  In other SRS regions the identity is not as high, which may contribute to differences 
observed in the binding of the seco-duocarmycins.  Despite the unclear role of CYP2W1 in normal 
human physiology or predominate substrate class, its tumor localization and ability to bioactivate 
seco-duocarmycin prodrugs, makes CYP2W1 an attractive enzyme for selective cancer 
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therapeutics.  The apparent selectivity of CYP2W1 (R)-ICT2700 serves as a potentially useful 




1. Zhang, X., D'Agostino, J., Wu, H., Zhang, Q. Y., von Weymarn, L., Murphy, S. E., and 
Ding, X. (2007) CYP2A13: variable expression and role in human lung microsomal 
metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone. The Journal of pharmacology and experimental therapeutics 323, 
570-578 
2. Ortiz de Montellano, P. R. (2013) Cytochrome P450-activated prodrugs. Future Med Chem 
5, 213-228 
3. Sheldrake, H. M., Travica, S., Johansson, I., Loadman, P. M., Sutherland, M., Elsalem, L., 
Illingworth, N., Cresswell, A. J., Reuillon, T., Shnyder, S. D., Mkrtchian, S., Searcey, M., 
Ingelman-Sundberg, M., Patterson, L. H., and Pors, K. (2013) Re-engineering of the 
duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 
and CYP2W1 for biological activity. Journal of medicinal chemistry 56, 6273-6277 
4. Travica, S., Pors, K., Loadman, P. M., Shnyder, S. D., Johansson, I., Alandas, M. N., 
Sheldrake, H. M., Mkrtchian, S., Patterson, L. H., and Ingelman-Sundberg, M. (2013) 
Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent 
tumor cytotoxins. Clinical cancer research : an official journal of the American 
Association for Cancer Research 19, 2952-2961 
5. Pors, K., Loadman, P. M., Shnyder, S. D., Sutherland, M., Sheldrake, H. M., Guino, M., 
Kiakos, K., Hartley, J. A., Searcey, M., and Patterson, L. H. (2011) Modification of the 
duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. Chemical 
communications 47, 12062-12064 
6. Shimada, T., Yun, C. H., Yamazaki, H., Gautier, J. C., Beaune, P. H., and Guengerich, F. 
P. (1992) Characterization of human lung microsomal cytochrome P-450 1A1 and its role 
in the oxidation of chemical carcinogens. Molecular pharmacology 41, 856-864 
7. Lang, D., Radtke, M., and Bairlein, M. (2019) Highly Variable Expression of CYP1A1 in 
Human Liver and Impact on Pharmacokinetics of Riociguat and Granisetron in Humans. 
Chemical research in toxicology 32, 1115-1122 
8. Edler, D., Stenstedt, K., Ohrling, K., Hallstrom, M., Karlgren, M., Ingelman-Sundberg, M., 
and Ragnhammar, P. (2009) The expression of the novel CYP2W1 enzyme is an 
independent prognostic factor in colorectal cancer - a pilot study. European journal of 
cancer 45, 705-712 
9. Gomez, A., Karlgren, M., Edler, D., Bernal, M. L., Mkrtchian, S., and Ingelman-Sundberg, 
M. (2007) Expression of CYP2W1 in colon tumors: regulation by gene methylation. 
Pharmacogenomics 8, 1315-1325 
10. Gomez, A., Nekvindova, J., Travica, S., Lee, M. Y., Johansson, I., Edler, D., Mkrtchian, 
S., and Ingelman-Sundberg, M. (2010) Colorectal cancer-specific cytochrome P450 2W1: 
intracellular localization, glycosylation, and catalytic activity. Molecular pharmacology 
78, 1004-1011 
11. Karlgren, M., Gomez, A., Stark, K., Svard, J., Rodriguez-Antona, C., Oliw, E., Bernal, M. 
L., Ramon y Cajal, S., Johansson, I., and Ingelman-Sundberg, M. (2006) Tumor-specific 
expression of the novel cytochrome P450 enzyme, CYP2W1. Biochemical and biophysical 
research communications 341, 451-458 
12. Karlgren, M., and Ingelman-Sundberg, M. (2007) Tumour-specific expression of 
CYP2W1: Its potential as a drug target in cancer therapy. Expert Opin Ther Tar 11, 61-67 
 141 
13. Stenstedt, K., Hallstrom, M., Ledel, F., Ragnhammar, P., Ingelman-Sundberg, M., 
Johansson, I., and Edler, D. (2014) The expression of CYP2W1 in colorectal primary 
tumors, corresponding lymph node metastases and liver metastases. Acta oncologica  
14. Walsh, A. A., Szklarz, G. D., and Scott, E. E. (2013) Human cytochrome P450 1A1 
structure and utility in understanding drug and xenobiotic metabolism. The Journal of 
biological chemistry 288, 12932-12943 
15. Bart, A. G., and Scott, E. E. (2018) Structures of human cytochrome P450 1A1 with 
bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands. 
The Journal of biological chemistry 293, 19201-19210 
16. Wu, Z. L., Sohl, C. D., Shimada, T., and Guengerich, F. P. (2006) Recombinant enzymes 
overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 
and limited activity of human cytochrome P450 2S1. Molecular pharmacology 69, 2007-
2014 
17. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver 
microsomes. I. Evidence for its hemoprotein nature. The Journal of biological chemistry 
239, 2370-2378 
18. DeVore, N. M., Smith, B. D., Wang, J. L., Lushington, G. H., and Scott, E. E. (2009) Key 
residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. 
Drug Metab Dispos 37, 1319-1327 
19. Otwinowski, Z., and Minor, W. (1997) Processing of X-ray diffraction data collected in 
oscillation mode. Methods Enzymol 276, 307-326 
20. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and 
Read, R. J. (2007) Phaser crystallographic software. Journal of applied crystallography 
40, 658-674 
21. Kabsch, W. (2010) XDS. Acta Crystallogr. D 66, 125-132 
22. Evans, P. R., and Murshudov, G. N. (2013) How good are my data and what is the 
resolution? Acta Crystallogr. D 69, 1204-1214 
23. Vagin, A., and Teplyakov, A. (1997) MOLREP: an automated program for molecular 
replacement. J. Appl. Cryst. 30, 1022-1025 
24. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development 
of Coot. Acta Crystallogr. D 66, 486-501 
25. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, 
J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., 
Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, 
P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular 
structure solution. Acta Crystallogr. D 66, 213-221 
26. Moriarty, N. W., Grosse-Kunstleve, R. W., and Adams, P. D. (2009) electronic Ligand 
Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint 
generation. Acta Crystallogr. D 65, 1074-1080 
27. Schrodinger, L. The PyMOL Molecular Graphics System, Version 1.8.6.2.   
28. Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D., and 
Johnson, E. F. (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons 
exhibited by the structure of human P450 1A2. The Journal of biological chemistry 282, 
14348-14355 
 142 
29. Wang, A., Savas, U., Stout, C. D., and Johnson, E. F. (2011) Structural characterization of 
the complex between alpha-naphthoflavone and human cytochrome P450 1B1. The 
Journal of biological chemistry 286, 5736-5743 
30. Wang, K., and Guengerich, F. P. (2012) Bioactivation of Fluorinated 2-Aryl-benzothiazole 
Antitumor Molecules by Human Cytochrome P450s 1A1 and 2W1 and Deactivation by 
Cytochrome P450 2S1. Chemical research in toxicology 25, 1740-1751 
31. Yakkundi, A., McErlane, V., Murray, M., McCarthy, H. O., Ward, C., Hughes, C. M., 
Patterson, L. H., Hirst, D. G., McKeown, S. R., and Robson, T. (2006) Tumor-selective 
drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N. Cancer 
Gene Ther 13, 598-605 
32. Nishida, C. R., Lee, M., and de Montellano, P. R. O. (2010) Efficient Hypoxic Activation 
of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1. Molecular pharmacology 78, 
497-502 
33. Zhao, Y., Wan, D., Yang, J., Hammock, B. D., and Ortiz De Montellano, P. R. (2016) 
Catalytic Activities of Tumor-Specific Human Cytochrome P450 CYP2W1 Towards 
Endogenous Substrates. Drug Metab Dispos  
34. Marill, J., Cresteil, T., Lanotte, M., and Chabot, G. G. (2000) Identification of human 
cytochrome P450s involved in the formation of all-trans-retinoic acid principal 









Mammalian cytochrome P450 enzymes often metabolize many pharmaceuticals and other 
xenobiotics, a feature which is valuable in a biotechnology setting, but they are typically relatively 
unstable with T50 values ~ 30 - 40 ºC.  Reconstructed ancestral cytochrome P450 enzymes tend to 
have variable substrate selectivity compared to related extant forms but also higher thermostability 
and may be an excellent approach for commercial biosynthesis of important intermediates, final 
drug molecules, or drug metabolites.  The mammalian ancestor of the cytochrome P450 1B 
subfamily was herein characterized structurally and functionally, revealing differences from the 
extant human CYP1B1 in ligand binding, metabolism, and potential contributors to its 
thermostability.  While human CYP1B1 has one copy of α-naphthoflavone in a closed active site, 
subtle amino acid substitutions outside the active site yielded an open active site with four ligand 
copies in the ancestor CYP1B1.  A structure of the ancestor with 17β-estradiol revealed only one 
copy in the active site, which still had the same open conformation.  Detailed comparisons between 
the extant and ancestor forms reveal increases in electrostatic and aromatic interactions between 
distinct secondary structure elements that may contribute to thermostability. 
                                               
* The contents of this chapter are currently in revision: Bart, A.G., Harris, K.L., Gillam, E.M.J., & Scott, E. E. Structure 





 Cytochrome P450 enzymes are a diverse superfamily of hemoproteins, which carry out a 
wide variety of important physiological functions in organisms ranging from bacteria to higher 
animals and plants.  In humans, the cytochrome P450 1 (CYP1) family consists of three genes 
(CYP1A1, CYP1A2 and CYP1B1).  The corresponding proteins each metabolize a broad but 
overlapping set of endogenous and environmental chemicals including steroids, pharmaceutical 
compounds, and dietary pro-carcinogens. CYP1 gene expression is regulated by the aryl 
hydrocarbon receptor, a transcriptional regulator with roles in both development and the response 
to exposure to environmental toxins such as dioxins and polycyclic aromatic hydrocarbons.  Many 
CYP1 substrates are aryl hydrocarbon receptor agonists, inducing the upregulation of CYP1 gene 
expression and thereby their own clearance (reviewed in (1-3)). 
 CYP1B1, the most recently identified of the human forms, metabolizes a wide range of 
compounds including xenobiotics, such as 7-ethoxyresorufin, caffeine, and theophylline (4), as 
well as endobiotics including testosterone, estradiol, retinol, arachidonic acid, and melatonin (4-
9).  CYP1B1 is expressed in numerous extrahepatic tissues including eye, brain, kidney, and breast 
(reviewed in (10)) and is overexpressed in various cancer cell types (11,12).  This distribution is 
of interest given the ability of CYP1B1 to bioactivate environmental carcinogens, including 
polycyclic aromatic hydrocarbons and estradiol, to DNA-reactive products (13-15).  CYP1B1 is 
essential for the immune response in mice (16,17) and CYP1B1 polymorphisms have been 
associated with congenital glaucoma (18,19), hinting at an important but as yet unidentified 
physiological role. 
 The physiological relevance of CYP1B1 is also reflected in its relatively high degree of 
conservation in vertebrates, compared to the CYP1A subfamily forms.  The CYP1A and CYP1B 
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lineages were created by a gene duplication event which took place in early deuterosomes, 
resulting in the CYP1A/CYP1D and CYP1B/CYP1C clades. The CYP1C and CYP1D subfamilies 
diverged from the CYP1B and CYP1A lineages respectively after a second duplication event in 
fish (20-22).  CYP1C forms are present in amphibia, fish, reptiles, and some avian species (20) 
whereas CYP1D forms are present in fish, amphibia, reptiles, and some mammals but are 
pseudogenes in humans (23). 
 Little is known about the historical function of the CYP1B/CYP1C clade aside from what 
has been gleaned from observing the activities of modern-day forms. In an effort to explore the 
evolution of the CYP1 forms, we recently reconstructed a series of CYP1 ancestors from key nodes 
of the evolutionary tree (24).  In line with studies on other ancestral P450s, many of the CYP1 
ancestors showed increased thermal tolerance compared to extant CYP1 human enzymes. 
N98_CYP1B1_Mammal, the predicted ancestor of mammalian CYP1B1 forms, was closest to the 
extant human mammalian CYP1B1 forms, sharing 81.8% sequence identity to human CYP1B1, 
yet had a 60T50 (the temperature at which 50% of the protein remains folded after heating for 60 
minutes) of 43 ºC, which is six degrees higher than that of extant human CYP1B1 (24).  While 
P450 enzymes are of interest for use in biotechnology, the extant forms are not stable enough for 
such applications, but engineered forms with increased thermostability are more likely candidates. 
 The N98_CYP1B1_Mammal ancestor also showed intriguing differences in the 
metabolism of representative substrates compared to the extant human CYP1B1 enzyme.  For 
example, human CYP1B1 predominantly metabolizes estradiol to 4-hydroxyestradiol (25).  
However, while both N98_CYP1B1_Mammal and an older common ancestor of all CYP1B forms 
(N20_CYP1B) were less active than human CYP1B1, they produced both 4- and 2-
hydroxyestradiol in similar amounts.  However, these ancestors both showed slightly greater 
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activity than human CYP1B1 towards testosterone.  Both human CYP1B1 and the two ancestors 
produced similar, small amounts of 6b-hydroxytestosterone and 16a-hydroxytestosterone, plus 
trace quantities of two unidentified metabolites (8) 24).  Thus, the reconstructed ancestors vary in 
both thermostability and metabolic capabilities, both important characteristics to understand for 
biotechnology applications (24). 
 To initiate an analysis of how CYP1 ancestral sequences have resulted in increased 
thermostability and varied substrate metabolism, structures of several ancestral forms are being 
pursued.  Crystals of the N98_CYP1B1_Mammal ancestor were successfully produced with either 
estradiol or the polycyclic aromatic compound a-naphthoflavone, diffracting to limiting 
resolutions of 3.1 and 2.95 Å, respectively (Table 6.1).  The structure of this ancestral CYP1B1 
with the small, planar a-naphthoflavone permits comparison with structures of all three extant 
human CYP1B1, CYP1A1, and CYP1A2 enzymes generated with this same ligand (PDB 3PM0 
(26), 4I8V (27), and 2HI4 (28), respectively).  This is particularly useful because many cytochrome 
P450 enzymes from families 1-3 demonstrate substantial reconfiguration of the active site 
dimensions with different active site ligands.  To evaluate the ligand-specific effects on 
N98_CYP1B1_Mammal conformation, a structure with the endogenous steroid estradiol was 
subsequently solved.  Both represent the first reported ancestral cytochrome P450 structures and 
suggest structural features that may modulate catalytic activity and thermostability.  
6.3 Experimental Procedures 
6.3.1 Materials 
 pCW plasmids containing CYP1B1, N98_CYP1B1_Mammal and human NADPH-
cytochrome P450 reductase (hCPR) were constructed in previous studies (7,24,26).  Catalytic 
assays with human CYP1B1 used construct #3 from (7).  All binding, catalytic assays and 
 147 
crystallography for the ancestral CYP1B1 were done with the N-terminally truncated, C-terminally 
His-tagged version of N98_CYP1B1_Mammal (24), with the sequence shown in Figure 6.1.  The 
chaperone co-expression plasmid, pGro7, was obtained from Prof. K. Nishihara (HSP Research 
Institute, Kyoto, Japan) (29) and from Takara Bio Inc. DH5aF’IQ E. coli cells were purchased 
from ThermoFisher Scientific (Scoresby, Australia). 
 Bactotryptone, bactopeptone and yeast extract were supplied by Becton Dickinson Pty Ltd 
(North Ryde, Australia). 17b-Estradiol metabolites were purchased from Steraloids Inc. (Newport, 
MI, USA) and kindly made available for this work by Prof. F. P. Guengerich, Vanderbilt 
University, USA.  Emulgen 913 and 911 were obtained from Kao Chemicals (Tokyo, Japan).  All 
other materials including a-naphthoflavone and 17b-estradiol were purchased at the highest 
available grade from Sigma-Aldrich-Merck (Castle Hill, Australia) where possible, or from a local 
supplier.  
6.3.2 Preparation of Bacterial Membranes for Activity Assays 
 P450s and hCPR were expressed in Escherichia coli and isolated in bacterial membranes 
as previously described (30,31).  P450 content was quantified by Fe(II).CO vs. Fe(II) difference 
spectroscopy (32,33).  CPR was quantified by the reduction of the surrogate electron acceptor, 
cytochrome c, as previously described (34).  
6.3.3 Metabolic Assays 
 Metabolic incubations were carried out as previously described with modifications (35).  
Bacterial membranes containing 0.5 µM P450 were incubated for 60 minutes at 37 ºC in 100 mM 
potassium phosphate pH 7.4 with 25 µM a-naphthoflavone in the presence and absence of an 
NADPH generating system (100 mM glucose-6-phosphate, 250 µM NADP+ and 0.5 U/ml 
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glucose-6-phosphate dehydrogenase).  Progesterone (5 µM) was added as internal standard for a-
naphthoflavone assays, prior to quenching and extraction with 1 ml ethyl acetate. 
 a-Naphthoflavone and its metabolites were identified using a Shimadzu Nexera 
Ultraperformance LC system coupled to an Orbitrap Elite mass spectrometer.  Chromatography 
was performed on an Accucore™ C30 column (150 x 2.1 mm, 2.6 um) at 0.4 ml per minute at 
50°C.  Buffer A comprised 1% acetonitrile, 0.1% formic acid and buffer B comprised 90% 
acetonitrile, 0.1% formic acid.  The gradient was developed as follows: 0-0.5 mins 50% B, 0.5-3 
mins linear gradient to 98% B, 3-4.5 mins 98% B, 4.5-4.6 mins linear gradient to 50% B, 4.6-5 
mins 50% B.  The mass spectrometer was operated in positive mode.  Source parameters included 
S lens 60; ion spray voltage 4.5 kV; capillary temperature 380° C; heater 400° C; sheath gas and 
auxiliary gases 50 and 16 respectively.  Data dependent acquisition was performed across 50 – 
1500 m/z and the top 5 precursors selected.  HCD fragmentation was optimized to use a normalized 
collision energy (NCE) of 60.  Data was processed using Xcalibur™ software.  Spectra were 
searched against publicly available databases.  a-Naphthoflavone metabolites were quantified 
using UPLC-APCI-MRM with the same chromatography conditions, but with a SCIEX 5500 
QTRAP mass spectrometer operating in positive multiple reaction monitoring (MRM) mode.  
Source parameters included: a nebulizer current of 3 µA; temperature at 500 °C; nebulizing gas 
(GS1) at 45; declustering potential (DP) at 120; and collision cell exit potential (CXP) of 12.  For 
each compound the collision energy (CE), entrance potential (EP) and CXP were optimized for 
maximum sensitivity by manual infusion.  Data was processed using both Analyst™ 1.7 and 
Multiquant™ 3.0 (SCIEX) software.  MRM transitions used for detection are listed in Table 6.4 
and the recovery of a-naphthoflavone and its metabolites were estimated based on the relative 
intensity of MS/MS fragment 103. 
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6.3.4 Protein Expression and Purification for Ligand Binding Assays and Crystallization 
 Expression and purification of the N98_CYP1B1_Mammal for crystallization were based 
on methods used for expression of human CYP1A1 for crystallography  (36), but modified 
extensively so a detailed expression protocol is described below for clarity.  The expression 
plasmid pCW_N98_1B1_Mammal was transformed into E. coli DH5a chemically competent cells 
already containing the plasmid pGro7 for coexpression of the molecular chaperones GroEl/GroES.  
Transformed cells were plated on lysogeny broth (LB)-agar supplemented with 100 µg/ml 
carbenicillin for selection of the P450 plasmid, and 20 µg/ml chloramphenicol for selection of the 
pGro7 plasmid and grown for ~18 hours at 37 °C.  A single colony from this plate was inoculated 
into a 5 ml LB starter culture, supplemented with antibiotics described above and grown for ~7 
hours at 37 °C and shaking at 250 rpm.  This starter culture (50 µl) was then used to inoculate a 
200 ml LB culture, supplemented with the above antibiotics, grown for ~16 hours at 37 °C with 
shaking at 250 rpm.  Finally, this overnight culture (10 ml) was used to inoculate 250 ml cultures 
of Terrific Broth in 1 liter Erlenmeyer flasks containing the above antibiotics.  The culture volume 
grown for a single purification typically totaled 2 liters or 8 flasks.  These expression cultures were 
grown at 37 °C with 250 rpm shaking until they reached an optical density at 600 nm (O.D.600) of 
0.3.  At this point chaperone expression was induced by addition of 2 mg/ml arabinose and d-
aminolevulinic acid was added to 1 mM as a heme precursor.  The temperature and shaking of the 
cultures were then reduced to 25 °C and 225 rpm respectively.  At O.D.600 of 0.6, 
N98_CYP1B1_Mammal expression was induced by adding 1 mM IPTG.  Cultures were grown 
for 48 hours after induction. 
 Isolation of ancestral N98_CYP1B1_Mammal was performed using a purification method 
that was developed for human CYP1A1 engineered for crystallization as described (36) with only 
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slight changes.  Modifications included depletion of the detergent CHAPS during ion-exchange 
chromatography by using a carboxymethyl (CM) Sepharose wash buffer (10 mM potassium 
phosphate, 100 mM NaCl, 20% (v/v) glycerol, 1 mM EDTA, pH 7.4) for the wash step and CM 
elution buffer (50 mM potassium phosphate, 500 mM NaCl, 20% (v/v) glycerol, 1 mM EDTA, pH 
7.4) to elute the bound protein.  Additionally, the final protein buffer used during gel filtration was 
a lower ionic size exclusion chromatography (SEC) buffer (20 mM potassium phosphate, 20% 
glycerol, 0.1 M NaCl, pH 7.4).  Under these conditions, the main N98_CYP1B1_Mammal peak 
eluted from the size exclusion column as a trimer, with a shoulder corresponding to a dimeric 
species.  The major trimeric peak was pooled and used in ligand binding and crystallization 
experiments.  The final purity of the protein was assessed by SDS-PAGE and the ratio of the Soret 
peak to the 280 nm peak.  The protein appeared to be a single band on the SDS-PAGE gel and 
typically had A416 nm/A280 nm = 1.2.  The protein concentration was determined using the absorbance 
of the Soret band and an extinction coefficient of 100 mM-1cm-1 in the SEC buffer listed above.  
Finally, a reduced carbon monoxide-difference spectrum (33) revealed a peak exclusively at 450 
nm, consistent with active enzyme, and no peak or shoulder at 420 nm. 
6.3.5 Ligand Binding Assays 
 a-Naphthoflavone and 17b-estradiol binding to N98_CYP1B1_Mammal were monitored 
spectrophotometrically.  Initial titrations in the absolute spectrum mode employed 1 µM P450 in 
SEC buffer in 1 cm quartz cuvettes, with additions of ligand dissolved in DMSO being added to 
the sample cuvette and equal volumes of ligand added to the reference cuvette only containing 
SEC buffer.  Subsequent titrations accomplished in difference mode to focus on ligand-induced 
changes used 1 µM protein in 2 cm tandem quartz cuvettes and were performed as described 
previously (36). 
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6.3.6 Crystallization, Data Collection, Structure Determination, and Analysis 
 Purified N98_CYP1B1_Mammal was first saturated with either a-naphthoflavone or 17b-
estradiol by addition of 100 µM ligand during final concentration using centrifugal ultrafiltration 
(Amicon Ultra-15 filters with a molecular weight cut-off of 50 kDa), once for a-naphthoflavone 
and three times for estradiol.  Crystals of the ancestral CYP1B1 protein with a-naphthoflavone 
were then grown at 20 °C using the sitting-drop vapor diffusion method in 96-well plates by mixing 
0.5 µL N98_CYP1B1_Mammal/a-naphthoflavone (protein at 290 µM as determined by absolute 
spectrum) with 0.5 µL crystallization solution (900 mM sodium citrate tribasic, 90 mM Tris 
base/HCl pH 7.0, 180 mM NaCl, 10% glycerol) and equilibrating against a 50 µL reservoir of the 
same crystallization solution.  Cocrystallization with estradiol was performed at 20 °C in sitting-
drop 24-well plates by mixing 0.9 µL N98_CYP1B1_Mammal/estradiol (290 µM) with 1.1 µL 
crystallization solution (1 M sodium citrate tribasic, 0.1 M Tris/HCl pH 7.0, 0.2 M NaCl) and 
equilibrating against 250 µL of the same crystallization solution.  Cubic crystals grew in two to 
three days.  Harvested crystals were cryoprotected using the respective crystallization solution 
supplemented with either additional 20% glycerol (a-naphthoflavone) or 22% glycerol (estradiol) 
before being flash cooled in liquid nitrogen.  The N98_CYP1B1_Mammal/a-naphthoflavone 
diffraction data was collected on a single crystal at the Advanced Photon Source LS-CAT beamline 
21-ID-G.  The N98_CYP1B1_Mammal/estradiol diffraction data was collected on a single crystal 
on beamline 12-2 at the Stanford Synchrotron Radiation Lightsource. 
 Data processing for the N98_CYP1B1_Mammal/a-naphthoflavone dataset was performed 
with HKL2000 (37).  The N98_CYP1B1_Mammal/estradiol dataset was processed in XDS (38) 
with scaling in AIMLESS (39).  A molecular replacement solution for N98_CYP1B1_Mammal/a-
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naphthoflavone was initially obtained using MolRep (40) using the CYP1B1/a-naphthoflavone 
crystal structure (PDB: 3PM0) as a search model (contrast score of 9.9).  Inspection of packing 
and electron density as well as initial statistics after one round of refinement (R=0.34 and 
Rfree=0.43) indicated a correct solution with two molecules in the asymmetric unit.  A molecular 
replacement solution for the N98_CYP1B1_Mammal/estradiol structure was obtained using 
Phaser (41) and the N98_CYP1B1_Mammal/a-naphthoflavone (PDB: 6OYU) structure as a 
search model.  The molecular replacement solution was successful with a log likelihood of 3,702 
and translation function Z score of 58.  For both structures multiple rounds of model building and 
refinement were performed using COOT (42) and PHENIX (43).  Torsion angle non-
crystallographic symmetry (NCS) with automatic group NCS group determination was employed 
in Phenix for the slightly lower resolution 17b-estradiol structure. Coordinates and restraints for 
a-naphthoflavone and estradiol were obtained from the CCD (Chemical ID: BHF, and EST 
respectively) and minimzed through PHENIX eLBOW (44) using AM1 geometry optimization. 
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Data Collection   
   Space Group I4 I4 
   Cell Dimensions (Å) 164.64, 164.64, 96.30 162.36, 162.36, 95.69 
   Molecules/a.u. 2 2 
   Resolution (Å)a 50.00-2.95 (3.00-2.95) 38.27-3.10 (3.31-3.10) 
   Total reflectionsa 207,156 (27,530) 154,025 (27,165) 
   Unique reflectionsa 27,530 (1,364) 22,678 (4,085) 
   Redundancya 7.5 (6.6) 6.8 (6.6) 
   Rpima 0.064 (0.788) 0.047 (0.883) 
   <I/σ(I)> a 53.0 (5.0) 10.4 (1.2) 
   CC1/2a 0.998 (0.399) 0.998 (0.688) 
   Completeness (%)a 100 (100) 99.9 (97.6) 
Refinement   
   Resolution (Å) 48.15-2.95 38.27-3.10 
   No. reflections 26,007 22,189 
   R/Rfree (%) 19.9 / 25.8 24.3 / 27.7 
   Ramachandran (%) 
   Favored/Allowed/Outliers 94.41 / 5.25/ 0.34 93.66 / 5.89 / 0.45 
   No. non-H atoms/B factors (Å2)   
       Protein 7,244 / 54.11 7,159 / 111.56 
       Ligand 168 / 48.84 40 / 107.37 
       Heme 86 / 32.45 86 / 113.04 
       Glycerol 36 / 54.47 - / - 
       Water 44 / 38.13 - / - 
   RMSD bond (Å) 0.006 0.003 
   RMSD angle (°) 0.679 0.609 
   Coordinate error  
   (max. likelihood based) (Å) 0.33 0.42 
a Statistics for highest resolution shell shown in parentheses. 
  
 154 
 Structural comparisons with extant human P450 enzymes were executed using molecule B 
of N98_CYP1B1_Mammal complexed with a-naphthoflavone.  While the two molecules in the 
asymmetric unit of each structure with both ligands are all similar, the rationale was that the a-
naphthoflavone structure had higher resolution than the estradiol structure, that all of the human 
CYP1 structures were obtained with a-naphthoflavone as the ligand, and chain B of the a-
naphthoflavone structure is most complete.  By comparison chain A of the a-ancestral CYP1B1 
naphthoflavone structure has an additional disordered gap for amino acids 448-452 comprising the 
K'-K'' loop.  Calculation of the active site void volumes for both N98_CYP1B1_Mammal/a-
naphthoflavone and human CYP1B1 (PDB 3PM0) (26) was performed using VOIDOO (45) with 
probe radius of 1.4 Å and grid spacing of 1.0.  For the N98_CYP1B1_Mammal/a-naphthoflavone 
structure it was necessary to add a network of water molecules to close the large cleft on the surface 
of the protein for the purposes of active site volume calculation. Structural alignments were 
performed using the super command in PyMOL (46).  Sequence alignment was performed using 
CLC Genomics Workbench (47).  Analysis of salt-bridges was performed in COOT (42) using a 
definition of £4 Å between the oxygen of Glu or Asp side chains and the nitrogen group(s) of Arg, 
His, or Lys (48,49).  Aromatic and pi-cation stacking interactions were defined by selection of 
aromatic residues with ring-to-ring or ring-to-arginine guanidinium group distances of £4 Å using 
Schrödinger Maestro (Schrödinger, LLC, New York, NY, 2017).  All salt-bridge and stacking 
interactions were visually inspected to ensure residue positions were well defined in the electron 
density.  Structure figures were prepared using PyMOL (50) with electrostatic potential surfaces 
generated using APBS (51). 
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6.4 Results and Discussion 
6.4.1 Comparison of Overall Structures:  Ancestral CYP1B1 vs. Extant Human CYP1B1 
 Structures of the ancestral reconstructed mammalian CYP1B1 enzyme, 
N98_CYP1B1_Mammal, with α-naphthoflavone as the bound ligand revealed that this enzyme 
maintains a canonical cytochrome P450 fold (Figure 6.1A).  Structural comparison with the extant 
human CYP1B1 (PDB: 3PM0) reveals the mammalian ancestor has similar Ca backbone 
positioning.  The Cα root-mean-square deviation between the two structures with α-
naphthoflavone is 1.43 Å (Figure 6.1A).  While most of the boundaries for helices and beta-strand 
regions are also conserved, significant differences are observed in the conformation of the F helix 
(Figure 6.1A).  First, the ancestral CYP1B1 has its F helix extended by eight residues compared 
to the extant human CYP1B1 (Figure 6.1B).  Second, while the extant human CYP1B1 and all the 
other human CYP1 family enzymes have an unusual break near the middle of the F helix (26-28), 
the ancestral CYP1B1 F helix is intact throughout these residues (Figure 6.1B).  The net result is 
that the C-terminus of the F helix is much farther away from the heme in the ancestral CYP1B1 
structure than in the extant human structure and this substantially changes the active site 
accessibility and ligand binding (vide infra). 
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Figure 6.1  Comparisons of the mammalian ancestral and human CYP1B1 cytochrome P450 enzymes.  A.  The global 
structure of the extant human CYP1B1 (green) compared to that of the ancestral CYP1B1 (blue).  Brighter blue in the ancestral 
CYP1B1 structure indicates the positions of differences in the amino acid sequences.  Both were crystallized with a-naphthoflavone 
(not shown for clarity).  The heme is shown as black sticks with the iron as an orange sphere.  B.  Aligned amino acid sequences 
for both enzymes are annotated with the non-conserved amino acids (in red text) and secondary structure features (helices 
highlighted in blue; beta strands highlighted in green; named above the sequence).  Amino acid numbering corresponds to the full 
length human CYP1B1 sequence.  N98 1B1_M is the N98_CYP1B1_Mammal sequence.  Note:  The extant human CYP1B1 
structure (PDB 3PM0) was determined from a version of the protein that has a naturally-occurring single nucleotide polymorphism 
resulting in an Ala119Ser substitution. 
 The residues that form the immediate central active site cavity are largely conserved, as 
well as regions important for heme binding and proximal cysteine ligation such as the L-helix.  
Differences in the primary sequences of the CYP1B1 forms are distributed throughout the tertiary 
structure and generally occur farther from the heme and active site (Figure 6.1A, bright blue).  
Examination of the amino acid differences in the linear alignment (Figure 6.1B, red text) reveals 
some notable groupings of divergent amino acids compared to the human enzyme.  Portions of the 
H helix and H/I loop have multiple substitutions, but there is considerable disorder in this region 
(Figure 6.1A) for both the human structure (amino acids 308-311 of the H/I loop disordered) and 
the ancestral CYP1B1 structure (amino acids 300-311 of the H/I loop disordered) which precludes 
structural comparisons. 
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6.4.2 Ancestral CYP1B1 Structure with a-Naphthoflavone 
 Co-crystallization of the mammalian ancestral CYP1B1 with the flavonoid a-
naphthoflavone was initially pursued to facilitate comparison with the human CYP1B1 structure 
containing the same ligand.  Surprising substantial differences were first observed in ligand 
binding.  While the human CYP1B1 enzyme has a single copy of a-naphthoflavone (Figure 6.2A) 
within a relatively small, planar, enclosed active site cavity, the ancestral CYP1B1 structure 
displays clear evidence for binding four copies of a-naphthoflavone within a substantially 





Figure 6.2  Comparison of CYP1B1/ligand interactions.  Comparison of CYP1B1/ligand interactions.  A.  The extant human 
CYP1B1 crystal structure (PDB 3PM0, ribbons) with α-naphthoflavone (green sticks) shown from the same perspective as the 
ancestral CYP1B1 structures in B and C.  B.  The mammalian ancestral CYP1B1 structure (ribbons) with α-naphthoflavone (blue 
sticks) clearly indicates four copies of this ligand in the active site.  All four are located higher up in the active site, while a putative 
water network (red spheres) is closer to the heme (black sticks).  C.  The mammalian ancestral CYP1B1 structure (ribbons) with 
estradiol (purple sticks) has the same overall structure as when α-naphthoflavone is bound, but only one copy of estradiol is present, 
located near the heme and oriented with C6, C7, and C15 closest to the heme (black sticks) iron (orange sphere).  In both B and C, 
blue mesh represents electron density for the respective ligands and heme using a sigmaA-weighted composite omit map at 1 sigma.  
D.  Titration of the mammalian ancestral CYP1B1 with α-naphthoflavone.  The initial, ligand-free spectrum (main plot, black line) 
is consistent with water coordination of the heme iron (λmax=416 nm).  As α-naphthoflavone is titrated in, the 416 nm peak 
decreases in intensity and a shoulder at 393 nm, consistent with water displacement by the ligand, increases to approximately equal 
intensity (main plot, red line=titration midpoint).  However, upon further addition of α-naphthoflavone the 393 peak progressively 
regresses, leaving only the peak at 416 nm (main plot, blue line).  The upper inset emphasizes the decrease in the 416 nm peak 
(black points) and the increase and subsequent decrease in the 393 nm peak (red points).  Thus a simple Kd cannot be fit to these 
absorbance changes (lower inset).  These ligand concentration-dependent spectral changes suggest that α-naphthoflavone is 
positioned near the heme at low ligand concentrations but relocates to allow water interaction with the heme at high ligand 
concentrations.  The structure in B is most consistent with the high concentrations of ligand employed in crystallization.  E.  In 
contrast, titration of estradiol into the mammalian ancestral CYP1B1 reveals a progressive decrease in the 416 nm peak (main plot) 
associated with water coordination to the heme iron with concomitant but smaller decreases at 393 nm (upper inset).  
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 In the ancestral CYP1B1 structure the benzochromenone core of the α-naphthoflavone 
closest to the heme essentially occupies the same space as it does in the human structure, tilted 
toward the central I helix.  However the ligand is flipped by 180° such that the phenyl ring is 
directed toward the heme in the human structure and away from the heme in the ancestral CYP1B1 
complex.  As a result, in the ancestral CYP1B1 complex α-naphthoflavone atoms C8 and C9 on 
the fused ring are closest to the heme iron, but with distances of 7.4 and 7.2 Å respectively.  This 
orientation is consistent with these atoms as likely sites of metabolism, as opposed to the 
orientation found in the human CYP1B1 structure.  However, this α-naphthoflavone molecule 
would need to move closer to the heme (to 4-5 Å) for metabolism.  In both α-naphthoflavone 
complexes, this ligand forms a pi-pi stacking interaction with the conserved F helix Phe-231 
(Figure 6.2A and 6.2B).  This interaction was also key in α naphthoflavone binding within human 
CYP1A1 (27) and CYP1A2 (28).  In all three human structures the positioning of this Phe helped 
to define the narrow and planar active site architecture.  While this interaction is maintained in the 
ancestral enzyme, repositioning of the end of the F helix 5-8 Å toward the distal side means that 
Phe-231 in the F helix is located higher up in the active site, consistent with the ligand location 
further from the heme.  An additional interaction is formed with this same copy of α-
naphthoflavone in the N98_CYP1B1_Mammal structure.  The F helix His-227 is a hydrogen bond 
donor to the α-naphthoflavone carbonyl oxygen.  This interaction is not observed in the human 
CYP1B1 structure because the F helix break and repositioning of the C-terminal end of the F helix 
result in direction of this residue away from the active site cavity. 
In the ancestral CYP1B1 complex the next two copies of a-naphthoflavone pack parallel 
with each other via pi stacking.  They are mostly confined by van der Waals and/or hydrophobic 
interactions between the F helix and sequences immediately following the K helix.  While the K 
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helix side is largely unperturbed compared to the human structure, the ancestral CYP1B1 F helix 
repositioning 5-8 Å toward the distal side opens up the active site to bulk solvent.  The fourth a-
naphthoflavone ligand is at the mouth of this cleft or channel.  It is possible that the captured 
positioning of the a-naphthoflavone molecules in the ancestral structure represents a substrate 
entry and/or egress pathway. 
 The active site of the ancestral CYP1B1 enzyme also had residual electron density between 
the heme and one of the paired, mid-channel a-naphthoflavone molecules.  This density was not 
consistent with a-naphthoflavone or any of the crystallization components, but rather with a water 
network (Figure 6.2B).  Hydrogen bonding appears to occur among these waters, as well as with 
atoms on the backbone of I helix residues Ala-330 and Asp-333, Leu-509 of the b4-loop, and with 
a carbonyl of one of the a-naphthoflavone molecules.  The presence of water within the active site 
is not unexpected considering that the N98_CYP1B1_Mammal active site is ultimately open to 
bulk solvent (Figure 6.3A). 
 The striking differences in the conformations of the extant and ancestral CYP1B1 enzymes 
with a-naphthoflavone are the result of significant alterations in positioning of structural elements 
forming parts of the active site roof.  The most significant structural change between is the 
conformation of the F helix (Figure 6.3A).  The root-mean-square deviation for Ca in this region 
is 3.2 Å, compared to 1.43 Å overall.  As described previously, the extant human CYP1B1 
structure (and those of CYP1A1 and CYP1A2 with a-naphthoflavone) have a notable break in the 
F helix (Figure 6.3B, green) which is not typically observed in other family 2 P450 enzymes and 
which contains a conserved Phe that projects into the active site to pi stack with the planar elements 
of ligands (26-28).  In the ancestral CYP1B1 structure this break is not observed and the F helix 
maintains its a-helical character as it passes above the active site (Figure 6.3B).  This longer, intact 
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helix and a slight change in the tilt angle of the F helix overall mean that the C-terminal portion of 
the F helix is substantially farther away from the active site (Figure 6.3A).  Repositioning of the F 
helix is accommodated by corresponding shifts in the G'- and G-helices but it is the F helix shift 
that is the major change opening up the channel from the active site proper to the protein surface 
(Figure 6.3A).  In the extant human CYP1B1 structure the N-terminal half of the F helix interacts 
with the loop at the tip of the b4 system to close off this channel, but in the ancestral CYP1B1 
structure this region is retracted in the opposite direction from the F helix shift and also contributes 
to the open channel, resulting in an ~16-fold increase in volume (Figure 6.3A). 
 
Figure 6.3  Comparison of ancestral CYP1B1 (blue) and extant human CYP1B1 (green) enzymes highlighting structural 
differences in helices F through G, the β4 loop, and helix I.  Shown are the protein backbone (ribbons) and heme (black sticks).  
A) The active site for the extant human CYP1B1 (solid green) is much smaller than the active site and channel observed for the 
ancestral CYP1B1 (blue mesh).  B) a-naphthoflavone ligands (colored sticks). 
 Another region of significant structural difference between the extant and ancestral enzyme 
structures occurs in the middle of the I helix as it crosses the heme and forms one wall of the active 
site.  While the overall backbone and side-chain positions of the I helix are highly conserved, in 
the ancestral enzyme a single helical turn (residues 329-333) has a significant bulge such that Ala-
330 protrudes into the lower part of the active site cavity (Figure 6.3B).  This potentially restricts 
the ligand a-naphthoflavone from obtaining closer proximity to the heme in the ancestral structure. 
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6.4.3 Ancestral CYP1B1 Titrations with a-Naphthoflavone 
 To further probe a-naphthoflavone binding and interactions near the heme, the effects of 
ligand binding on the heme coordination were monitored by changes in the Soret heme absorbance.  
The as-isolated ancestral CYP1B1 protein has its Soret peak absorbance maximum at 416 nm 
(Figure 6.2D, black spectrum), consistent with water coordination to the heme iron as is typical 
for isolated P450 enzymes in the oxidized state.  Titration of this enzyme with a-naphthoflavone 
to concentrations at or below the protein concentration produced partial high-spin character with 
absorbance increases at 393 nm and decreases at 416 nm (Figure 6.2D, red spectrum).  This 
response is consistent with a-naphthoflavone binding in the active site and partially displacing 
coordinated water from the heme.  Indeed, difference spectra showing these initial titrations are 
characteristic of these “type I” spectral changes (not shown).  However, when adding a-
naphthoflavone in excess of the ancestral N98-CYP1B1-Mammal enzyme concentration, the high-
spin component at 393 nm began to decrease, eventually returning to a Soret maximum at 
absorbance at 416 nm indicating water binding to the heme (Figure 6.2D, blue spectrum).  This 
increase and subsequent decrease in the absorbance at 393 nm is more easily seen in Figure 6.2D 
(upper inset, red points).  With the reversal in absorbance maximum half way through the titration, 
the typical plot for the absorbance change vs. ligand concentration is not hyperbolic and cannot be 
fit to a simple two-state model for Kd determination (Figure 6.2D, lower inset).  Human CYP1B1 
only shows this latter “reverse type I” spectral change upon binding a-naphthoflavone (52), which 
is likely the result of ligand binding in such a way as to promote water ligation.  Overall, the 
spectral changes observed for the ancestral CYP1B1 enzyme are consistent with a-naphthoflavone 
binding near the heme iron at lower concentration where the ligand:P450 stoichiometry is 1:1 or 
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lower and reverting to water-coordinated heme when additional molecules pack into the protein, 
as observed in the crystal structure. 
6.4.4 Ancestral CYP1B1 Metabolism of a-Naphthoflavone 
 Both the human CYP1B1 and N98_CYP1B1_Mammal enzymes convert a-
naphthoflavone to three monooxygenated products (Figure 6.4, M1, M2, M3).  M1 was the major 
product in both cases (12 ± 4% and 20 ± 6% relative yield for human CYP1B1 and 
N98_CYP1B1_Mammal respectively), followed by M2 (~1%), and M3 (<0.05%).  Application of 
a 2-tailed, unpaired Student’s t-test suggested there was no significant difference between the ratio 
of M1:M2 produced by the two P450 enzymes (however N98_CYP1B1_Mammal had a slightly 
higher ratio of M2:M3 compared to human CYP1B1 (15:1 vs. 13:1, p<0.01). 
 
Figure 6.4  Metabolism of a-naphthoflavone by ancestral and extant CYP1B1 forms.  The percentages of a-naphthoflavone 
converted to each of three metabolites (M1, M2 and M3) by the extant human CYP1B1 and the ancestral N98_CYP1B1_Mammal 
are compared to a negative control (bacterial membranes containing human NADPH-cytochrome P450 reductase but no P450).  
Reactions were carried out at 37 °C for 1 hour, with 0.5 µM P450 and 25 µM a-naphthoflavone.  a-Naphthoflavone and its 
metabolites were analyzed by LC-MS/MS and quantified by the relative size of MS/MS fragment 103, which is present in the mass 
spectra of both.  Data is the mean ± SD of n=3 reactions.  Asterisks indicate statistically significant differences to the negative 
control (unpaired 2-tailed Student’s t-test, * p<0.05, ** p<0.01, *** p<0.001). 
 Human CYP1B1 has previously been shown to metabolize a-naphthoflavone to more 
polar, unidentified metabolites (53), but a-naphthoflavone is also a potent inhibitor of human 









































human enzymes had a mass of 289, consistent with the addition of a single oxygen.  While these 
metabolites could not be identified unambiguously by LC-MS alone, and the quantities produced 
precluded identification by NMR, the fragmentation patterns of M1 and M2 are consistent with an 
oxide or hydroxyl group added to one of the terminal rings, in positions 5-10 (Figure 6.7). The 
substrate specificity of the human CYP1 enzymes frequently overlaps so  M1, the major metabolite 
for both human CYP1B1 and N98_CYP1B1_Mammal, may be the 5,6-oxide reported for human 
CYP1A1 and CYP1A2 (Figure 6.7) (54).  Similar reasoning suggests that M2 may result from 7-
hydroxylation and M3 from 6- or 9-hydroxylation as observed for rat CYP1A1 (Figure 6.8). 
6.4.5 Ancestral CYP1B1 Structure with 17b-Estradiol 
 One of the key questions that arises from the ancestral CYP1B1 crystal structure with a-
naphthoflavone is whether the open conformation of the protein was induced by the stacking of 
multiple ligand molecules within the active site channel or whether this is an intrinsic feature of 
the ancestral CYP1B1 protein.  In order to potentially answer this question attempts were made to 
co-crystallize with several other ligands.  17b-Estradiol could be co-crystallized with the ancestral 
CYP1B1 by employing crystallization conditions similar to those yielding the a-naphthoflavone 
structure.  The global structure of the mammalian ancestral 1B1 bound to 17b-estradiol was highly 
similar to the structure bound to a-naphthoflavone, with a root-mean-square deviation of 0.57 Å.  
Thus, the 17b-estradiol-bound structure also had a large channel from the active site proper 
extending between the F helix and b4-loop to the protein surface.  However, only one copy of 17b-
estradiol was present, located directly adjacent to the heme in the active site proper (Figure 6.2C).  
Despite the open conformation, density was not observed for ordered water molecules in the 17b-
estradiol structure.  From this we can conclude that the overall open protein conformation observed 
is not dependent on the specific ligand or number of copies of the ligand.  Thus it is likely that the 
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additional three a-naphthoflavone molecules take advantage of the open channel to bind 
fortuitously.  As always, however, one cannot exclude the possibility that multiple protein 
conformations occur and that the specific conformation selected is dependent on its facility to pack 
into crystals for structure determination. 
 Within the active site, the positioning of sidechains is also largely conserved compared to 
the same ancestral enzyme bound to a-naphthoflavone.  17b-Estradiol extends across the heme, 
with its flat, unsubstituted planar a-surface approximately orthogonal to the heme plane and the 
steroidal A and B rings packing against the against the I-helix Gly-329-Ala-330 peptide bond 
(Figure 6.2C).  Because 17b-estradiol is positioned closer to the heme than a-naphthoflavone it 
does not interact with Phe-231 or other F helix residues, but 17b-estradiol does appear to make 
two hydrogen bonds with active site residues.  The 17b-estradiol C3 hydroxyl is a hydrogen bond 
donor to the backbone carbonyl of Leu-509 in the b4 loop, while the C17 hydroxyl hydrogen bonds 
with the side chain of Asp-326 in the I helix.  The overall result is that 17b-estradiol carbons 7 (4.2 
Å), 15 (4.9 Å), and 6 (5.1 Å) are closest to the heme iron (Figure 6.2C). 
6.4.6 Ancestral CYP1B1 Titrations with 17β-Estradiol 
 Titration of the ancestral CYP1B1 protein with 17b-estradiol resulted in monotonic 
decreases in the Soret band at 416 nm, associated with Fe-water coordination, but no increases in 
absorbance at 393 nm corresponding to the high-spin state (Figure 6.2E and 6.2E upper inset).  
Studies clearly indicate that this is a result of ligand binding and not protein instability as the 
reduced, carbon monoxide difference spectra of samples from the end of a titration are the same 
as those at the beginning of the titration (not shown).  Corresponding titrations done in difference 
mode indicate 17b-estradiol binds with a classic type 1 binding mode, but the maximal response 
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is approximately four-fold weaker in comparison to a-naphthoflavone binding.  Overall, however, 
these observations correspond to positioning of 17b-estradiol in the ancestral CYP1B1 structure. 
6.4.7 Ancestral CYP1B1 Metabolism of 17β-Estradiol 
 It has been previously observed that the ancestral CYP1B1 enzyme is ~9-fold less active 
towards 17b-estradiol than human CYP1B1 (24) but also shows differences in the regioselectivity.  
Extant human CYP1B1 produces 4-hydroxy-17b-estradiol as the major metabolite, with smaller 
amounts of 2-hydroxyestradiol and trace amounts of a third hydroxy-17b-estradiol metabolite 
likely to be 15a-hydroxy-17b-estradiol.  The ancestral CYP1B1 enzyme produces these same 
three metabolites but in approximately equimolar amounts (24).  The orientation of 17b-estradiol 
observed in the crystallographic structure is consistent with the formation of 15a-hydroxy-17b-
estradiol, but to form the 2- and 4-hydroxymetabolites, 17b-estradiol would need to reorient in the 
active site so that C2 and C4 were presented to the Fe for catalysis at these positions. 
 The regioselectivity of extant CYP1B1 forms for 4- or 2-hydroxylation is known to vary 
among species:  human, dog, and monkey isoforms preferentially produce 4-hydroxy-17b-
estradiol, while rodent isoforms produce more 2-hydroxy-17b-estradiol (55).  This preference has 
been attributed to the residue at position 395 (55). Forms containing Val at this position produced 
more 4-hydroxy-17b-estradiol, while those containing Leu produced more 2-hydroxy-17b-
estradiol, and exchanging these two residues reversed the regioselectivity. The current results 
suggest that additional factors influence regioselectivity because while the ancestral CYP1B1 has 
Val at position 395 position, it does not exhibit a strong preference for either 2- or 4-hydroxylation.  
In the ancestral CYP1B1 structure with 17b-estradiol, the terminal methyl of Val-395 is 3.6 Å 
from C16. 
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6.4.8 Structural Changes to the Redox Partner Binding Surface 
 One final notable structural difference between the extant and ancestral CYP1B1 structures 
occurs on the opposite side of the heme from the active site, on the proximal surface of the protein 
comprising part of the surface that binds the redox partner NADPH-cytochrome P450 reductase 
required for catalysis.  In particular, the loop between the C and D helices contains three positively-
charged Arg residues that have been implicated in electrostatic interactions with the negatively-
charged surface of the reductase.  This loop has different conformations in all three structures 
(Figure 6.5A).  In the extant human CYP1B1 structure the C/D loop is positioned closer to the H 
helix (Figure 6.5A, green), while in the ancestral CYP1B1 structure with a-naphthoflavone it is 
displaced in the opposite direction, toward the L helix (Figure 6.5A, blue).  In the ancestral 
CYP1B1 structure with 17b-estradiol the C/D loop adopts an intermediate conformation (Figure 
6.5A, purple).  In the ancestral CYP1B1 structures the C/D loop conformations are coincident with 
similar shifting of the H helix on one side and the loop preceding the J' helix on the opposite side.  
As a result, the placement of the positively charged C/D loop guanidine groups is different for all 
three structures.  These differences are reflected in the surface shape and exposed charge for this 
region (Figure 6.5B, 6.5C, and 6.5D), in which the ancestral CYP1B1 structures display a less 
prominent concavity and positive charge.  The C/D loop region in P450 enzymes is thought to be 
a critical binding surface for reductase, so it is possible that changes in the charged features in this 
region affect reductase binding for the ancestral CYP1B1 enzyme.  The ancestral CYP1B1 has 
similar catalytic activity for a-naphthoflavone as the human CYP1B1 enzyme, suggesting that its 
C/D-loop conformation is compatible with reductase binding.  However when the ancestral 
CYP1B1 enzyme is bound to 17b-estradiol, the enzyme has much lower activity towards 
production of all three metabolites than human CYP1B1.  One possible explanation for this is that 
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the conformation of the CD loop observed in this structure prevents effective reductase binding 
and/or electron transfer. 
 
Figure 6.5  Comparison of the proximal surface of extant human CYP1B1 and ancestral CYP1B1.  A) Significant 
conformational differences are observed in the region of the C-D loop region of the human CYP1B1 (green) vs. the ancestral 
CYP1B1 crystallized with a-naphthoflavone (blue) vs. the ancestral CYP1B1 crystallized with estradiol (purple).  As a result three 
positively-charged Arg residues (sticks) are repositioned, some of which have been implicated in binding the negatively-charged 
surface of its redox partner NADPH-cytochrome P450 reductase.  B-D) Electrostatic surfaces (blue, positive; red, negative) for the 
proximal, reductase-binding surfaces of B) extant human CYP1B1 crystallized with a-naphthoflavone, C) the ancestral CYP1B1 
crystallized with a-naphthoflavone, and D) the ancestral CYP1B1 crystallized with estradiol. 
6.4.9 Structural Elements and Interactions Proposed to Confer Thermostability 
 A key consideration in engineering P450 enzymes for biocatalysis is thermostability.  In 
the previous literature, several structural features have been proposed to contribute to 
thermostability, especially when comparing mesophilic and thermophilic P450s.  This information 
is based on a limited dataset of four thermophilic P450 enzymes for which structures are available 
(48,56-58).  A recent meta-analysis of these structures compared to their mesophilic P450 relatives 
(49) concluded that cytochrome P450 thermostability may correlate with: 1) smaller, more 
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compact enzymes, especially due to N-terminal truncation and shorter loops; 2) a preference for 
charged and hydrophobic residues vs. non-charged, polar and Ala residues; 3) increased salt 
bridges, particularly complex, extended salt-bridged networks; and perhaps 4) extended clusters 
of aromatic side chains.  These enzymes were all soluble, microbial cytochrome P450 enzymes. 
 The advantages of using bacterial cytochrome P450 enzymes for biocatalysis often 
includes better stability, but many of them are highly specific for their substrates and the products 
generated.  If a particular soluble P450 can be identified that performs a commercially useful 
transformation (59) or can be engineered to do so (60-63), then this is may be the most 
advantageous route.  However, many of the less stable mammalian cytochrome P450 enzymes 
have evolved to intrinsically bind and metabolize a wide diversity of foreign compounds and may 
be more commercially useful if one could engineer in thermostability. 
 Although the difference in thermostability of the ancestral mammalian CYP1B1 enzyme 
compared to extant human CYP1B1 is not as dramatic as thermophilic vs. mesophilic bacterial 
P450 enzymes, it does provide one of the first real opportunities to determine if some of the same 
four concepts can confer increased thermostability in eukaryotic microsomal P450s. 
 First, the overall protein size and lengths of loops and N- and C-termini were compared.  
The ancestral CYP1B1 and extant human CYP1B1 structures reveal loop regions of similar length 
(Figure 6.1A and 6.1B).  Only small differences are observed in a few of the loops and they are 
not always in the anticipated direction.  The D/E loop is three residues longer in the ancestral 
CYP1B1 enzyme (Figure 6.1B).  Likewise, the H/I loop appears to be six residues longer in the 
ancestral enzyme, a region that is disordered in both enzymes.  A three-residue helical segment 
occurs in the ancestral CYP1B1 enzyme corresponding to the human K''/L loop, while a short, 2-
strand b-sheet (the b-4 sheet) occurs in the human enzyme (Figure 6.1B).  Although both enzymes 
 170 
were truncated to remove the N-terminal transmembrane helix for crystallization, there are obvious 
differences in the remaining N-termini.  In the ancestral CYP1B1 enzyme residues 48-60 could be 
modeled but not residues 61-67 (due to insufficient density to trace the backbone).  By comparison 
the human CYP1B1 structure could only be modeled beginning at residue 68 where the A helix 
begins.  Since they are present in the construct crystallized, the absence of electron density for 
residues 48-60 in the human 1B1 structure must be due to high flexibility.  It is not obvious from 
the primary sequence why this part of the ancestor would be more stable, but this region forms a 
small beta-strand (Phe-55-Trp-57) that interacts with b-sheet 1.  Additionally Trp-57 forms a 
potential face-to-edge aromatic interaction with Phe-74 (A-helix).  At the C-terminal end of the 
protein, the ancestor is sixteen residues shorter, reducing the overall size by 2 kDa.  In human 
CYP1B1 only six residues in the extended C-terminus could be modeled.  However these were 
packing against symmetry related molecules (26) and may be more conformationally flexible in 
solution.  This shorter C-terminus in the ancestral CYP1B1 enzyme is perhaps comparable to the 
shorter N-termini observed in soluble thermophilic P450 enzymes and may reduce conformational 
flexibility. 
 Second, since thermophilic bacterial P450 enzymes seemed to have more charged and 
hydrophobic residues and fewer non-charged, polar and Ala residues than related mesophilic P450 
enzymes, the amino acid compositions of the ancestral CYP1B1 and extant human CYP1B1 were 
compared.  The charged amino acids and non-charged but polar amino acids were very similar 
(£0.5% different).  The more thermostable ancestral CYP1B1 has 2% fewer hydrophobic amino 
acids, which is opposite to the trends in soluble P450 enzymes.  Conversely, the ancestral enzyme 
also had 1% fewer Ala residues, which is consistent with the thermostable bacterial P450 trends.  
Of the twelve times that Ala in human CYP1B1 was replaced by another amino acid in the 
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ancestral CYP1B1, 11 of these substitutions were to non-conserved amino acids (Pro (5), Glu (3), 
Arg (1) or Ser (1)). 
 Third, salt bridge pairs and networks were compared between the two structures.  In the 
extant human CYP1B1 structure thirteen two-residue salt bridges were found, while in the ancestor 
CYP1B1 structure fourteen were present.  Evaluation of salt-bridge networks involving three or 
more residues revealed that human CYP1B1 had six and the ancestral CYP1B1 had eight (Table 
6.2).  It is useful to examine two-residue salt-bridges and networks that are unique to only one of 
the CYP1B1 enzymes (Figure 6.6A and 6.6B, spheres).  In the extant human CYP1B1 five of the 
seven unique two-residue interactions and the one unique network occur within the same structural 
element, generally with residues found in close proximity within the primary sequence (Figure 6.6, 
black text; Table 6.2, red text but not bolded).  Two unique two-residue salt-bridge occur between 
secondary structural elements (Figure 6.6A, colored text; Table 6.2, red and bolded text).  In the 
mammalian ancestor, of the six unique two-residue salt-bridge interactions (Figure 6.6B, grey 
spheres), three of them occur between different secondary structure elements (Figure 6.6B, spheres 
with colored text; Table 6.2, red bolded text).  Additionally, of the three unique networks in the 
ancestor (Figure 6.6B, black spheres), all three occur between secondary structure elements 
(Figure 6.6B, colored text; Table 6.2, red, bold text).  Such interactions likely help stabilize 
multiple regions of the protein, and could be a contributor to the thermostability of the ancestor. 
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Figure 6.6  Analysis of unique salt bridges and aromatic interactions in human CYP1B1 and the ancestral CYP1B1 
structures, both co-crystallized with a-naphthoflavone.  A) Extant human CYP1B1 (green ribbons) and B) ancestral CYP1B1 
(blue ribbons) showing unique two-residue salt bridges (grey spheres) and more extended networks (black spheres).  Not shown 
(for clarity) are instances where a single new amino acid was added to a previously existing network, one for extant CYP1B1 and 
two for the ancestor (see Table 6.2)  C) Extant human CYP1B1 (green ribbons) and D) ancestral CYP1B1 (blue ribbons) showing 
unique aromatic and pi-cation stacking interactions (grey sticks).  In all four images, the text indicates the secondary structure 
element in which the indicated residues belong, with black text indicating that the residues are in the same secondary structure 
element and colored text indicating the pairings of residues that are in distinct secondary structure elements. 
 Finally, soluble thermophilic cytochrome P450 enzymes such as CYP119A1 (56) and 
CYP119A2 (57) from archaea have extended networks of aromatic residues.  Analysis of aromatic 
and/or cation-pi stacking interactions in the human and ancestral CYP1B1 proteins indicated some 
differences (Table 6.3).  Human CYP1B1 contained six two-residue pairs, three of which had 
stacking interactions with a third aromatic residue.  By comparison, the ancestral CYP1B1 
structure had eight two-residue aromatic or pi-cation stacking pairs, with only one stacking pair 
interacting with a third aromatic residue.  Unique aromatic and pi-cation stacking interactions 
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between the two proteins are shown in Figure 6.6C and 6.6D.  Human CYP1B1 contains two 
unique two-residue aromatic interactions (Figure 6.6C, grey sticks; Table 6.3, red) and one three-
residue network (Figure 6.6C, black sticks; Table 6.3, red).  Two of the aromatic/pi-cation stacking 
two-residue pairs are composed of residues that are more distant in the primary sequence and likely 
facilitate interactions between different parts of the tertiary protein structures (Figure 6.6C, colored 
text labels; Table 6.3, red bold).  By comparison, the ancestral structure has five unique two-
residue aromatic interactions (Figure 6.6D).  Four of these interaction pairs occur between residues 
found in distinct secondary structure elements and thus are more likely to contribute to global 
protein structure. 
6.5 Conclusions 
 The first structural evaluation of a reconstructed ancestral cytochrome P450 has reinforced 
several existing concepts about enzyme functionality and stability but also suggested some new 
ones.  The ancestral CYP1B1 enzyme retains most of the active site residues of the extant human 
CYP1B1 enzyme and retains some of the metabolic capabilities and metabolite stoichiometries for 
some substrates (in this case a-naphthoflavone) while showing very different metabolic capacity 
and metabolite ratios for others (e.g. 17b-estradiol).  Subtle amino acid substitutions outside the 
active site seem to control overall protein conformation, in this case restoring the helical nature of 
the entire F helix and opening up a broad channel from the active site to the protein surface.  While 
ideas about shorter loops contributing to thermostability did not appear to apply here, a C-terminal 
truncation may be relevant.  The somewhat more thermostable ancestral enzyme did show a few 
more electrostatic and aromatic interactions that could contribute to thermostability, but the 
locations of such interactions between distinct secondary structure elements, often far apart in the 
 174 
primary sequence, may be more critical.  Additional structures will be required to determine if 
these trends continue in even older reconstructions that have higher stability. 
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Table 6.2  Comparison of salt bridge interactions in extant human CYP1B1 vs. the ancestral CYP1B1 enzyme.  Red text 
indicates interactions that are unique to that protein structure.  These correspond to the residues show in Figures 6.6A and 6.6B, 
with the exception of partials, which are defined as one are two unique residues that interact with a shared network.  Bold indicates 
that an interaction is between two distinct secondary structure elements.  An asterisk indicates that the residue varies between the 




Table 6.3  Comparison of aromatic and pi-cation stacking interactions in extant human CYP1B1 vs. the ancestral CYP1B1 
enzyme.  Red text indicates interactions that are unique to that protein structure.  These correspond to the residues show in Figures 
6.6C and 6.6D, with the exception of partials, which are defined as one are two unique residues that interact with a shared network. 
Bold indicates that an interaction is between two distinct secondary structure elements.  An asterisk indicates that the residue varies 




Table 6.4  MRM transitions used for quantification of a-naphthoflavone, metabolites and internal standard. 
Compound Q1 Q3 CE EP 
a-naphthoflavone 273.1 115.1 55 10 
 273.1 129.1 55 10 
 273.1 143.2 55 10 
 273.1 171.2 55 10 
 273.1 202.3 55 10 
 273.1 226.2 55 10 
Progesterone (IS) 315.2 97.1 28 8 
 315.2 109.1 28 8 
 315.2 297.2 47 8 
OH-a-naphthoflavone 289.09 215.09 55 10 
 289.09 131.05 55 10 
 289.09 115.05 55 10 
 289.09 103.05 55 10 
 289.09 95.05 55 10 





Figure 6.7  Mass fragmentation of a-naphthoflavone metabolites.  Tandem mass spectra and predicted fragmentation patterns 
of (A) a-naphthoflavone, (B) M1, and (C) M2.  The fragmentation patterns of M1 and M2 are consistent with the addition of a 




Figure 6.8  The known metabolic pathways of a-naphthoflavone (ANF) catalyzed by liver microsomes and recombinant 
CYP1A forms.  The known a-naphthoflavone metabolic pathways catalyzed by CYP1 enzymes and rat liver microsomes (RLM) 
induced by either 2,3,7,8-tetrachlorodibenzodioxin (64), 3-methylcholanthrene, b-naphthoflavone or phenobarbital (65) are 
summarized.  The two main products of a-naphthoflavone metabolism by rat (r)CYP1A1 are the 5,6-oxide and 7,8-oxide (64,65).  
These compounds are further metabolized by rat epoxide hydrolase (rEH) to form the respective dihydrodiols.  In the absence of 
rEH, the 5,6-oxide is chiefly observed, as the 7,8-oxide is unstable and will interact with nucleophilic groups on proteins, or 
spontaneously convert to the 7-hydroxy-a-naphthoflavone product (54,66).  Recombinant human (h)CYP1A1, and to a lesser extent 
hCYP1A2, produced the 5,6-oxide as the main product, which was converted to the 5,6-dihydrodiol in the presence of rEH (54).  
The 7,8-dihydrodiol was not observed even in the presence of rEH. Other minor metabolites produced by recombinant rCYP1A1 
or induced RLM are also shown. Earlier studies (67-69) generally agreed with the metabolite assignments shown here, except that 
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Conclusions and Future Directions* 
 
The work in this dissertation has been aimed towards extending our understanding of 
human cytochrome P450 enzyme structure and how modulations to this structure contribute to the 
functional capabilities of these diverse enzymes.  In the course of this dissertation multiple areas 
have been explored to this effect.  The first area addressed was to determine if differences in 
interaction occur between the catalytic modulator protein cytochrome b5 and distinct drug-
metabolizing P450 enzymes.  Second, a P450 involved in detrimental chemical carcinogenesis and 
toxin formation was probed to determine its structural malleability when binding structurally 
diverse ligands.  Lastly, research was directed toward understanding the structural basis of 
increased thermostability in an ancestral-reconstructed P450 enzyme. 
The initial study, presented in Chapter 2, examined the structural interactions of 
cytochrome b5 towards a set of human xenobiotic P450 enzymes via solution NMR.  Titrations of 
the human P450 enzymes CYP2A6, CYP2D6, CYP2E1, and CYP3A4 into 15N-labeled b5 resulted 
in line-broadening, permitting the identification of individual b5 residues involved in the different 
binding interfaces.  Mapping those residues onto the b5 structure revealed that the b5 / P450 
interactions were both distinct and partially conserved among the four P450 enzymes tested.  The 
participation of individual residues was confirmed by mutagenesis.  Clearly electrostatic 
                                               
* The results and discussion of the docking experiments described in this chapter have been submitted for publication 
in the ISSX symposium report: Bart, A.G. & Scott, E. E. Substrate Recognition by Cytochrome P450s: Applying 
Structure to Understand Cytochrome P450 1A1 Metabolism. Drug Metabolism Reviews. 
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interactions play a key role in b5 binding to P450 enzymes.  In addition to distinctions observed in 
binding surfaces, the P450 isoforms also were observed to have differing apparent affinities 
towards b5.  Functionally cytochrome b5 had varied effects on product formation between the P450 
enzymes in this study, where a range of b5 modulatory behavior on P450 activity was observed.  
These included cytochrome b5 enhancing, inhibiting, or having no effect on product formation.  
Furthermore, the research performed in this study showed that b5 had a common propensity 
increase the coupling of P450 reactions, regardless of the effect on product formation. 
Alterations of P450 metabolism by b5 introduces additional complexities in the prediction 
of drug pharmacokinetics, and could be a significant source of interindividual variability seen in 
certain drugs.  Comprehensive understanding of how b5 elicit differential responses in different 
P450 enzymes is currently unknown, however evidence is accumulating which supports allosteric 
mechanisms.  To fully understand the allosteric effects of b5 on P450 enzymes will require high-
resolution structural investigations of these complexes.  The research in chapter 2 provides initial 
steps towards this, however work remains to completely define these complexes, especially the 
residues on the P450 side.  Generation of isotopically-labeled P450 samples for probing both 
interaction interfaces and dynamics will involve circumventing major hurdles such as stability and 
aggregation of human P450 enzymes. 
Research presented in Chapters 3 and 4 were broadly aimed towards understanding the 
extent of conformational flexibility in the human P450 CYP1A1.  This work was prompted by the 
initial CYP1A1 structure, which demonstrates a planar enclosed active site too small to 
accommodate its larger and/or nonplanar substrates.  In Chapter 3 CYP1A1 was successfully co-
crystallized with the structurally diverse substrates bergamottin and erlotinib.  The resulting 
structure with the furanocoumarin bergamottin showed that it was accommodated within the 
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CYP1A1 active site by only small perturbations of sidechains and bound in an orientation 
consistent with non-reactive metabolite formation observed in corresponding catalytic assays.  The 
second new complex was with the tyrosine kinase EGFR inhibitor erlotinib, which is a lung cancer 
drug.  Erlotinib bound to CYP1A1 in an orientation consistent with CYP1A1 oxidation of this drug 
to yield reactive metabolites linked to adverse pharmacological effects.  In both new CYP1A1 
structures, the planar portions of the substrates occupied a similar region of the active site, 
aromatically stacking with a key phenylalanine side chain, similar to the arrangement observed in 
the initial CYP1A1 crystal structure with alpha-naphthoflavone.  Both new compounds perturbed 
residues composing the active site roof, namely F and G helical regions.  While bergamottin only 
somewhat expanded the CYP1A1 active site volume, with erlotinib the changes were more 
substantial, creating a channel to the protein surface through which ligands may access the 
otherwise buried active site. 
 The new structures of CYP1A1 presented in Chapter 3 expanded the known CYP1A1 
active site and conformational landscape.  Ideally one would like to solve a limited number of 
structures to define the range of enzyme flexibility since co-crystallization of human P450 
enzymes is both heavily time and resource consuming.  A question remains whether a sufficient 
range of CYP1A1 conformation has yet been explored to serve as effective start points for 
computational docking.  The goal for docking would be to predict orientation and thus potential 
site of metabolism for other CYP1A1 substrates for which experimental structures are not 
available.  In this pursuit a series of docking runs were initiated first to validate the approach with 
compounds whose orientations are known from solved crystal structures, then to do so for a series 
of CYP1A1 substrates that are clinical tyrosine kinase inhibitors, but for which such structural 
information is not known.  In the initial validation docking runs, the experimental CYP1A1 
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structure determined with bergamottin successfully oriented bergamottin and erlotinib a high 
percentage of the time, but was less successful in yielding the correct orientation of alpha-
naphthoflavone (Figure 7.1B).  However, the CYP1A1 structure experimentally determined with 
erlotinib successfully oriented all three ligands (a-naphthoflavone, bergamottin, and erlotinib) 
with the dominant solution being in the correct orientation.  This suggests that this 
CYP1A1/erlotinib structure might be most useful for docking an even wider range of compounds 
(Figure 7.1B).  Thus, subsequent tests focused on its ability to correctly predict the binding 
orientations of three structurally diverse tyrosine kinase inhibitors also metabolized by CYP1A1: 
sunitinib, gefitinib, and ponatinib (Figure 7.1C).  Sunitinib is approved for renal cell carcinoma 
and gastrointestinal tumors (1) and is primarily N-deethylated to a nontoxic metabolite by 
CYP1A1 (2).  Gefitinib is used in the treatment of non-small cell lung cancer and is defluorinated 
by CYP1A1 to an initial para-hydroxyanaline moiety that can rearrange to a reactive quinone-
imine that forms glutathione (GSH) and protein adducts linked to adverse pulmonary and hepatic 
effects (3).  Finally, ponatinib is a BCR-ABL inhibitor used in the treatment of chronic myeloid 
leukemia that is oxidized by CYP1A1 on the purine, ethynl linkage and methylphenyl group, 
proposed to generate an epoxide also leading to GSH and protein adducts (4).  Only the 
experimental CYP1A1 structure determined with erlotinib was able to correctly dock all three new 
drugs in orientations consistent with the known metabolites (Figure 7.1B&C).  In comparison, the 
CYP1A1/bergamottin structure oriented only sunitinib in an orientation consistent with its known 
metabolite and produced a mix of correct and incorrect orientations of gefitinib (Figure 7.1B).  The 
original CYP1A1/alpha-naphthoflavone structure was unable to accommodate the larger 
compounds sunitinib and ponatinib at all and predicted orientations for gefitinib that were 
inconsistent with its site of metabolism. 
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Figure 7.1  CYP1A1 experimental X-ray structures and docking results.  A.  Comparison of CYP1A1 active site bound to 
alpha-naphthoflavone (ANF) (light grey ribbons) vs. erlotinib (green ribbons), showing expansions in the active site cavity volume 
and shape (grey transparent surface for CYP1A1/ANF and green mesh for CYP1A1/erlotinib).  Green arrows highlight differences 
in secondary structure elements or residues.  B.  Summary of docking results using the three currently available CYP1A1 crystal 
structures with various ligands metabolized by CYP1A1.  The experimental structures and corresponding PDB codes are listed 
across the top and the ligand redocked or docked into each structure is listed on the left side.  The percentage of docking poses that 
successfully recapitulated orientations consistent with the experimental structure (ANF, bergamottin, erlotinib) and/or known 
metabolites (gefitinib, sunitinib, ponatinib) are color coded according to the legend.  C.  Docking into the experimental 
CYP1A1/erlotinib structure was most successful in orienting known sites of metabolism (indicated red dashes) with 6 Å to the 
heme iron. 
The CYP1A1 expanded active site cavity with a channel, identified in the 
CYP1A1/erlotinib structure, performed the best in correctly orienting test compounds with a range 
of sizes and structures.  Other members of the P450 family 1, CYP1A2 and CYP1B1, are similarly 
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represented in the PDB by only one or two structures and may undergo similar conformational 
changes, but this is unknown at present.  Finally, for CYP1A1 this new structural information may 
be useful in the redesign of clinical agents like gefitinib and ponatinib to remove metabolic 
liabilities related to patient toxicities and to better anticipate toxic metabolites for future 
pharmaceutical agents. 
Even further conformational changes of CYP1A1 were observed when binding the 
candidate pan-Pim kinase inhibitor GDC-0339, presented in Chapter 4.  In this structure CYP1A1 
repositions one of the key elements in the active site, Phe224, outside the active site cavity.  This 
side chain normally forms one side of the active site, confining it to a planar topology.  
Repositioning Phe224 serves to both accommodate some of the non-planar features of the ligand, 
as well as potentially priming the CYP1A1 active site for metabolism involving a proposed non-
planar tetrahedral intermediate.  These findings reinforce the concept that P450 enzymes are highly 
flexible and can adapt their active site for diverse substrates and reactions. 
 The work presented in Chapter 5 describes the binding and structural characterization of 
seco-duocarmycin prodrugs with CYP1A1 and CYP2W1.  The question specifically addressed 
was if selectivity between the two P450 enzymes could be achieved by changes in the chirality of 
the analogs.  Spectral binding experiments demonstrated that the seco-duocarmycin analogs 
ICT2700 (bio-activated by CYP1A1 and CYP2W1) and ICT2726 (not bioactivated by the P450 
enzymes), bound CYP1A1 with relatively high affinity, but differed in spectral binding mode 
between ICT2700 and ICT2726.  The change in chirality caused only slight alterations in binding 
affinity and/or mode for CYP1A1.  However these same analogs displayed very distinct binding 
modes for CYP2W1.  Additionally, CYP2W1 appeared to be very sensitive to changes in the 
analog chirality. 
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Moreover, Chapter 5 presents two co-crystal structures of specific enantiomers of ICT2700 
and ICT2726 in complex with CYP1A1.  The orientation of (S)-ICT2700 in the active site 
supported generation of metabolites that would not undergo bio-activation.  This is contrary to 
results of CYP1A1 metabolism of racemic ICT2700, which showed formation of a bio-activated 
metabolite.  This result could indicate CYP1A1 enantiomeric selectivity for bioactivation or the 
crystal structure only captured a predominate pose, since multiple CYP1A1-mediated metabolites 
of the racemic analog have been observed previously.  In the other structure solved, CYP1A1 
bound to (S)-ICT2726, orientation of this compound was not supportive for bio-activation, 
consistent with the absence of an activated metabolite during previous metabolism studies.  Assays 
to test bioactivation of the seco-duocarmycin enantiomers are still ongoing, but the binding and 
structural study presented herein suggests changes in the chirality of the molecules can modulate 
binding and possibly orientations of these compounds.  Ultimately the ongoing goal of this project 
is in the development of selective CYP2W1 seco-duocarmycin prodrugs for specific colon tumor 
bioactivation. 
Finally, in Chapter 6 structural examination of an ancestral-resurrected P450 enzyme was 
reported in order to determine elements that may contribute to its increased thermostability.  The 
structure of the mammalian ancestor CYP1B1 enzyme displayed significant expansions in active 
site cavity compared to human CYP1B1, which allowed the ancestral enzyme to bind multiple 
copies of the ligand alpha-naphthoflavone.  There are multiple structural features that could 
contribute to the increased thermostability of the ancestral 1B1.  These include greater structuring 
of the N-terminal region and increased salt-bridge and aromatic stacking interactions between 
secondary structures composed of residues distant in the primary sequence.  This structure serves 
as a potential starting point for further enzyme engineering, with the eventual goal of producing 
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industrially viable P450 biocatalysts.  Additionally, other ancestral reconstructed forms within 
Family 1, as well as other P450 families, are being pursued in order to determine whether the 
structural alterations we have observed in the N98-1B1-M structure hold true for other 
thermostable ancestors.  Structural trends observed could lead to incorporating structure-based 
rational design to enhance P450 thermostability. 
In summary, the research described herein has improved our structural understanding of 
human P450 enzymes in multiple aspects.  The initial descriptions of the cytochrome b5 complex 
with clinically relevant human P450 enzymes will aid future efforts of high-resolution structures 
of the complexes, with the goal of understanding how b5 differentially effects P450 metabolism.  
Our improved knowledge of CYP1A1 structural flexibility makes it a source for enhancing 
predictions of detrimental metabolite formation and as a tool in further design of selective pro-
duocarmycin cancer drugs.  Lastly the structure of the first reconstructed ancestral P450 lays a 
groundwork in understanding the evolution of P450 structure and development of versatile P450 
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